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HYPERPOLARIZED CARBON-13 MAGNETIC RESONANCE MEASUREMENTS
OF TISSUE PERFUSION AND METABOLISM
Keith Andrew Michel, B.S.
Advisory Professor: James A. Bankson, Ph.D.
Hyperpolarized Magnetic Resonance Imaging (HP MRI) is an emerging modality that
enables non-invasive interrogation of cells and tissues with unprecedented biochemi-
cal detail. This technology provides rapid imaging measurements of the activity of a
small quantity of molecules with a strongly polarized nuclear magnetic moment. This
polarization is created in a polarizer separate from the imaging magnet, and decays
continuously towards a non-detectable thermal equilibrium once the imaging agent
is removed from the polarizer and administered by intravenous injection. Specialized
imaging strategies are therefore needed to extract as much information as possible
from the HP signal during its limited lifetime.
In this work, we present innovative strategies for measurement of tissue perfusion
and metabolism with HP MRI. These techniques include the capacity to sensitize the
imaging signal to the diffusive motion of HP molecules, providing improved accuracy
and reproducibility for assessment of agent uptake in tissue. The proposed methods
were evaluated in numerical simulations, implemented on a preclinical MRI system
and demonstrated in vivo in rodents through imaging of HP 13C urea. Using the sim-
ulation and imaging infrastructure developed in this work, established methods for
encoding HP chemical signals were compared quantitatively. Lastly, our method was
adapted for imaging of [2-13C]dihydroxyacetone, a novel HP agent that probes enzy-
matic flux through multiple biochemical pathways in vivo.
Our results demonstrate the capacity of HP MRI to measure tissue perfusion and
metabolism in ways not possible with the imaging modalities currently available in
the clinic. As the use of HP MRI advances in clinical investigations of human disease,
these imaging measurements can offer real-time and individualized information on
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Chapter 1
Introduction
Cancer is a class of diseases arising from the unrestrained proliferation of a population
of cells [1]. Despite advances in our understanding of these diseases and significant
investments in the development of more effective therapies, cancer remains a lead-
ing cause of mortality in the United States and worldwide [2]. As our comprehension
of cancer biology has grown in the past two decades, it is increasingly understood as
a disease in which the accumulation of genetic mutations drive a phenotypic trans-
formation supported by dysregulation of metabolism and interactions with the tissue
microenvironment [3].
In the progression of tumorigenesis, mutated cells continually reshape their en-
vironment by recruiting new blood vessels, inflammatory immune cells and growth
factors. These environmental changes can in turn promote the genetic instability and
aberrant cellular signaling that drive continued cellular proliferation. Notably, every
cancer is unique in the series of genetic mutations and environmental transformations
it undergoes. Even within a single tumor, expansion of cellular populations accumu-
lating different mutations and subject to disparate environmental signals results in
significant genomic and phenotypic heterogeneity [4]. This heterogeneity represents
a tremendous impediment to the selection of appropriate therapies and to the assess-
ment of their efficacy. In recent years, these considerations have led to a significant
paradigm shift in oncology away from standardized treatments and towards individ-
ualized precision medicine [5].
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The importance of imaging to these precision medicine initiatives cannot be over-
stated. The most widely used clinical imaging methods provide anatomical detail
suitable for assessing tumor size. Treatment response in solid tumors is still most
commonly assessed by tracking this radiological tumor size over time [6]. However,
there is much greater potential for precisely quantifying disease state and treatment
response through functional and molecular imaging modalities [7]. While these molec-
ular imaging methods often lack significant morphological detail, they provide direct
pathophysiological insights into individual tumors that are more sensitive to the di-
versity of cellular conditions present.
New molecular imaging methods that expand the clinical capability to measure
the physiological and biochemical state of tissues in a rapid and reproducible man-
ner will be a critical component of precision medicine for cancer. One such emerging
molecular imaging modality is hyperpolarized (HP) 13C MRI [8]. In this technique,
a small quantity of 13C labeled molecules are subjected to conditions that generate a
large nuclear magnetic polarization. The polarization process takes place in a polar-
izer separate from the MRI system used for imaging. Once removed from the polarizer
the HP agent is quickly administered by intravenous injection, and imaging can pro-
vide direct and quantitative measurements of perfusion, uptake and metabolism in
vivo. Clinical trials are currently underway at several sites worldwide investigating
HP MRI in cancer and other diseases [9, 10].
HP MRI has tremendous potential to detect short-term changes in tumor metabol-
ism and to provide non-invasive measurements of treatment response, but standard-
ized methods for image acquisition and analysis have not been established. Robust HP
MRI acquisition strategies are difficult to formulate due to the transient nature of the
HP signal. Outside of the polarizer the HP agent depolarizes continuously, and a por-
tion of the HP signal is depleted by each imaging measurement. In addition to these
magnetization loss mechanisms, the evolution of HP signals in vivo is further compli-
cated by the effects of capillary delivery of the HP agent to tissues of interest. In most
cases, analysis of HP MRI data is very challenging since a significant but unknown
proportion of the signal arises from blood rather than the cellular and extracellular
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spaces that are often of primary interest. To derive quantitative biomarkers of tissue
function, these effects must be considered in the design of HP imaging experiments
and properly accounted for in the analysis methods, for example via pharmacokinetic
modeling [11] and numerical simulation [12]. Additional challenges arise when formu-
lating imaging strategies for novel HP agents, which can create signals very difficult
to image in vivo due to their very brief lifetimes and the ranges of resonant frequencies
they exhibit.
In this work, we develop a framework for acquisition and analysis of preclinical HP
imaging data. This framework includes extensive infrastructure for numerical simu-
lation of HP imaging experiments, both for the purpose of experimental design and for
pharmacokinetic analysis of HP agent perfusion and uptake in tissue. The acquisition
methods presented here provide a high degree of flexibility in the strategy of chemical
and spatial encoding, and also permit the application of a novel method for preferen-
tially suppressing the vascular component of HP signals in vivo. The feasibility of this
novel HP signal suppression strategy is demonstrated via imaging of HP 13C urea in
rodents. Furthermore, an investigation of the hepatic metabolism of the novel imaging
agent, [2-13C]dihydroxyacetone, exemplifies the flexibility of our imaging framework
and the significant potential of HP MRI to improve our basic understanding of the
biochemical foundations of many diseases.
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1.1 Specific Aims
The overall goal of this work is to improve measurements of the physiological fate
of HP agents in vivo. Such measurements are challenging due to both the transient
nature of HP signals and their dynamic evolution by perfusion, capillary extravasation
and interaction with target biology. If these effects are properly accounted for in the
acquisition and analysis of HP images, quantitative biomarkers of tissue perfusion
and metabolism can be obtained [11]. Such biomarkers hold tremendous potential in
the rapid assessment of disease state, for example in the context of early treatment
response [13–19].
This project has developed an imaging method capable of resolving the signals ob-
served in HP MRI experiments with 13C urea, [1-13C]pyruvate and [2-13C]dihydroxy-
acetone (DHA). Our central hypothesis is that an optimized image acquisition and
analysis protocol will permit characterization of the physiological fate of HP agents with
chemical, spatial and functional resolution. This hypothesis has been tested with the
following aims:
Aim 1: Implement a MR imaging method for flexible dynamic preclinical imaging
of HP agents. We will create a pulse sequence for our preclinical MRI system capable
of implementing multiple methods for encoding k-space and chemical shift. Selectiv-
ity for dynamic imaging of individual chemical shifts will be enabled through two of
the most widely used methods in HP MRI: spectral-spatial excitation pulses [20] and
constrained phase-sensitive decomposition of echo-time shifted readouts (IDEAL) [21,
22]. The SNR performance of chemical shift encoding via spectral-spatial excitation
and IDEAL imaging will be compared in both numerical simulations and 13C-enriched
thermal phantom experiments. For simulations, the pulse sequence parameters us-
able on our preclinical MRI system will be used in order to match the results obtained
in phantom experiments. These results will guide the selection of an acquisition strat-
egy that provides optimal image quality for in vivo HP imaging.
Aim 2: Evaluate perfusion and permeability effects by imaging HP 13C urea in the
rat liver with and without motion sensitization. Dynamic imaging of HP urea will
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probe vascular perfusion in the liver, measuring the representative blood volume frac-
tion for hepatic tissue and the permeability of liver microvasculature to a low molec-
ular weight imaging agent. Diffusion preparation gradients can be applied in an in-
terleaved fashion during the dynamic experiment to suppress moving signals from
flowing blood, preferentially weighting the HP signal to urea within the extravascular
space and improving the accuracy of this measurement. The diffusion gradient mag-
nitude and timing, as well as other sequence parameters such as repetition time and
excitation angle, will be chosen based on simulation experiments quantifying the ac-
curacy and reproducibility of pharmacokinetic modeling of HP urea uptake in tissue.
While urea is not itself a metabolic agent, these results will demonstrate the capabil-
ity of our imaging method to resolve HP signals arising from the metabolically distinct
vascular and tissue spaces.
Aim 3: Acquire spectroscopic images of HP DHA metabolites in vivo. Imaging of
HP DHA and its downstream metabolites in the rat liver will be conducted with the
sequence developed in Aim 1. Since the signal intensities of many of these metabolites
is quite weak in vivo, sequence parameters will be chosen carefully to maximize SNR.
Imaging of these metabolic signals is particularly challenging due to their very wide
chemical shift separation (>150 ppm) and rapid relaxation in tissue. Despite these
obstacles, HP DHA imaging can probe the biochemical flux into multiple metabolic
pathways, including glycolysis, gluconeogenesis and ketogenesis. This agent therefore
provides a wealth of information on the metabolic state of the liver and mammalian
body as a whole.
Chapter 2
MRI Physics
Magnetic Resonance Imaging is unique amongst medical imaging modalities in the
physics of its signal generation and detection. Most medical imaging is based on the
measurement of radiative energy passing through tissue from internal or external
sources. In contrast, MRI maps the volume density and relaxation properties of nu-
clear spins using static and time-varying magnetic fields. The fundamental physics
underpinning MRI are the same as Nuclear Magnetic Resonance (NMR) spectroscopy,
which is widely used in a variety of disciplines including chemistry and materials sci-
ence.
In this chapter we will review the basis of NMR signals, techniques for strength-
ening these signals via hyperpolarization, relaxation and contrast mechanisms, and
Fourier methods for spectroscopy and imaging.
2.1 NMR Signal
In a standard NMR experiment a sample is placed in a strong, uniform magnetic field.
By virtue of the elementary particles that make up individual nuclei, they possess
quantized values of angular momentum called spin. Nuclear spin can take on half-
integer or integer values depending on the number of protons and neutrons a nucleus
contains. The nuclei most commonly used in NMR and MRI, and most relevant to
this work, have a spin quantum number of ½. A nucleus with non-zero spin possesses
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a magnetic moment and experiences a torque given by the cross-product of the indi-
vidual nuclear magnetic moment vector and the magnetic field it experiences. This
torque causes the nuclear moment to precess at the Larmor frequency [23], which is
proportional to the magnetic field strength ( ~B0) and nuclear gyromagnetic ratio (γ):
ω0 = 2πf0 = −γ ~B0 (2.1)
Here the negative sign indicates a left-handed direction of precession relative to the
direction of ~B0. The quantity ω is used throughout this chapter to denote angular
frequency (in radians per unit time), while f denotes cyclic frequency (in cycles per
unit time). A convenient way to express the gyromagnetic ratio in the latter case is γ
2π
,
typically in units of megahertz per Tesla.
A nucleus with a spin of I can inhabit 2I + 1 energy levels within a magnetic field,
referred to as spin states. These nuclear spin states correspond to differing angles
between the precessing nuclear magnetic moment and ~B0. For an isolated spin ½ nu-
cleus, the directional axis of its Larmor precession is either parallel (+) or antiparallel
(-) to ~B0 [24]. At equilibrium, the ratio of the number of nuclei in the antiparallel






Here ~ and k denote the reduced Planck’s constant and Boltzmann constant, respec-
tively, while T is temperature. The number of nuclear moments in the state with
lower potential energy, aligned parallel to ~B0, is greater than the number aligned an-
tiparallel at equilibrium. This excess of nuclei in the lower energy alignment state
gives rise to an aggregate magnetic moment ( ~M ) in the sample. At equilibrium, ~M
is aligned with ~B0 and not detectable. However, when a time-varying magnetic field
( ~B1) is applied to the sample at the Larmor frequency and perpendicular to ~B0, ~M is
progressively nutated out of alignment with ~B0. For the values of ~B0 used in NMR and
MRI, f0 is in the Radio Frequency (RF) range and ~B1 is therefore referred to as a RF
pulse. After the application of this RF pulse, the portion of ~M perpendicular to ~B0 is
transiently detectable in the form of a voltage induced in conductive coils of the NMR
system [26, 27].
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Figure 2.1: For spin ½ nuclides at thermal equilibrium, individual magnetic moments
in an applied magnetic field ( ~B0) precess at the Larmor frequency with the axis of
precession aligned with or against ~B0. A slightly greater number of nuclear moments
align with ~B0, which generates a small net magnetic moment ( ~M ) as shown here in
green. The population difference between spin states in this illustration is much larger
than typically observed in thermally polarized spin systems.
The signal recorded in a MRI examination is therefore an ensemble measurement
arising from the bulk magnetic polarization of a small fraction of the NMR-active nu-
clei present. The most common isotope employed in magnetic resonance experiments
is protium (hydrogen-1, 1H), which is the most abundant isotope in the universe and
ubiquitous in living tissue. Other isotopes of nuclei common in biological systems,
such as carbon-13 (13C), are useful in biochemical and medical research. However,
these applications are often limited by low isotopic abundance and low nuclear gyro-
magnetic ratio, both of which result in poor sensitivity. From equation 2.2, the fraction








A larger NMR signal can therefore be achieved through a greater nuclear polarization
fraction at greater static magnetic field strengths or lower temperatures. However,
neither ~B0 or T can be easily manipulated to directly improve MRI sensitivity in clin-
ical practice. Plots of polarization fraction for the two nuclides of greatest interest in
this work are shown in figure 2.2. Even at 7 T, the strongest ~B0 currently available for
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clinical MRI, the thermal polarization fraction of excess 13C nuclear moments aligned
with ~B0 is approximately 6 ppm at room temperature.
Figure 2.2: The thermal equilibrium spin polarization fractions for 1H and 13C plotted
semi-logarithmically against magnetic field strength (B0 in units of Tesla) and tem-
perature (T on the Kelvin scale) show larger polarizations for lower T or for greater
B0 or γ.
2.2 Hyperpolarization Techniques
A variety of techniques have been developed to transiently overpopulate the nuclear
alignment state parallel to ~B0 and provide dramatic enhancements in NMR detection
sensitivity. The simplest such hyperpolarization method exposes the NMR sample to
a high magnetic field at low temperature [28]. This technique is known as brute-force
polarization, and does not provide as large sample polarizations as other hyperpolar-
ization methods that rely on the transfer of spin state polarization to the NMR-active
nuclei of interest from electrons or molecular hydrogen.
When the NMR nuclei are in the gaseous state, hyperpolarization is most eas-
ily achieved via spin-exchange optical pumping (SEOP). In this technique, most com-
monly used for polarizing xenon-129 (129Xe) and helium-3 (3He), circularly polarized
infrared light is used to polarize the electrons of an alkali metal [29]. The polarized
electrons then transfer their spin polarization to the NMR nuclei via atomic collisions.
Polarization fractions of>50% can be achieved with SEOP for 129Xe [30] and the hyper-
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polarized (HP) gas produced has enabled exciting new MRI methods in vivo, primarily
for imaging lung function. Since SEOP relies on molecular collisions for polarization
transfer it is most feasible in the gaseous state which limits its utility in polarizing
the NMR isotopes and molecules most useful for probing biochemistry in vivo.
Figure 2.3: In spin systems at thermal equilibrium, the number of excess nuclear mo-
ments aligned with ~B0 is very small, which can result in poor detection sensitivity for
the net moment ( ~Meq, left). This poor sensitivity is particularly problematic for NMR
studies of low gyromagnetic ratio nuclei such as 13C. Hyperpolarization techniques cre-
ate spin populations containing a much larger proportion of nuclear moments aligned
with ~B0, producing a greater aggregate magnetic moment ( ~Mhp, right).
In an alternative hyperpolarization method, the spin order of molecular hydrogen
is transferred to molecules of interest through chemical couplings. In the first step
of this process, called parahydrogen induced polarization (PHIP), molecular hydrogen
(H2) is exposed to a catalyst at cryogenic temperatures. These conditions enrich the
parahydrogen isomer (pH2) in which the magnetic moments of the individual 1H nu-
clei are oriented in opposite directions [31]. The pH2-enriched spin system therefore
has a uniformity of 1H spin state that is much greater than a population of thermally
polarized 1H nuclei, and this spin order persists when the H2 is warmed to ambient
temperatures. The spin order can then be transferred to other molecules via chemical
hydrogenation reactions or via simultaneous interaction of both pH2 and the molecule
of interest with a catalyst. Using an appropriate catalyst or polarization transfer
methods in an NMR system, the pH2 spin order can be used ultimately to enrich the
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parallel spin state of 13C or 15N nuclei in organic molecules [32]. Unlike other hyper-
polarization methods, PHIP requires a chemical interaction of H2 with the substrate
that is to be polarized, which is generally a less efficient polarization transfer method
than direct interaction of nuclei with strongly polarized electrons. Additionally, the
catalysts used in this process can be toxic and difficult to remove from solution in the
timeframe necessary to utilize the HP solution in vivo. As a result, PHIP methods
have been limited to in vitro and preclinical applications.
The hyperpolarization technology employed in this work, Dynamic Nuclear Polar-
ization (DNP), differs from the methods described above in that it relies on the transfer
of spin polarization from electron to nucleus in the solid state via hyperfine coupling
[33]. DNP, specifically the more recently developed dissolution DNP method that al-
lows very large polarization fractions to be achieved for 13C in the liquid state, will be
discussed in greater detail in the following chapter.
2.3 Relaxation and Contrast Mechanisms
A distinguishing factor of MRI compared to other medical imaging modalities is the
variety of contrast mechanisms that affect the imaging signal. For the 1H imaging
routinely performed clinically, these mechanisms provide exquisite soft tissue contrast
and permit imaging of tissue function in ways not possible via other modalities. In
HP MRI, they must be accounted for in quantifying imaging signals in order to derive
parameters reflective of tissue function.
Spin-Lattice (T1) Relaxation and Radio Frequency Excitation
Regardless of whether the bulk magnetization is derived from thermal polarization
or hyperpolarization methods, ~M will relax over time towards thermal equilibrium. A
variety of mechanisms contribute to this relaxation process, however they are in gen-
eral mediated by the transfer of energy from individual nuclear magnetic moments to
their surrounding environment. For this reason, this relaxation process is often called
spin-lattice relaxation. By convention, the direction of ~B0 is assigned the longitudinal
2.3. Relaxation and Contrast Mechanisms 12
or z-axis in 3D space, leading to the alternative term, longitudinal relaxation. For a
sample with initial z-axis magnetization Minit, the z-component of ~M will change over
time to approach the thermal equilibrium magnetic moment of M0. The rate of this
change is directly proportional to the displacement of Mz from this equilibrium value,











Note that without application of any RF pulse, Minit will beM0 for HP experiments.
If t = 0 denotes the moment at the end of a RF pulse applied to a thermally polarized
spin system, Minit will be < M0. For a RF pulse that is brief in duration, the nuta-
tion angle (θ) will determine the redistribution of ~M into the x-, y- and z-components
by simple trigonometry. For short RF pulses applied at the Larmor frequency, this
excitation angle can be calculated from the nuclear gyromagnetic ratio and the time





where T is the duration of the RF pulse.
Immediately after a RF pulse, ~M will precess about the z-axis at the Larmor fre-
quency. It is therefore useful to consider a coordinate system, distinct from the true
laboratory reference frame, in which the x-y plane is rotating about the z-axis at this
frequency. In such a rotating frame of reference, ~B1 appears as a vector along a single
direction in the transverse (x’-y’) plane for a simple RF pulse. If an RF pulse is ap-
plied in the x’ direction, ~M is nutated about ~B1 leading to components in the y’ and z
directions. Immediately after the RF pulse is applied to a spin system with ~M initially
along the z-axis these components are determined by the excitation angle [34]:
My′ = M sin θ
Mz = M cos θ
(2.6)
In this case, the quantity My′ represents the detectable component of the aggregate
magnetization at the end of the RF pulse, after which Mz recovers or decays towards
M0 as defined in equation 2.4.
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In studies using thermally polarized spin populations, a shorter T1 is generally fa-
vorable from a signal to noise perspective. A shorter T1 allows the thermal spin system
to return to equilibrium more quickly allowing repeated application of RF pulses and
averaging of multiple measurements in a brief timeframe. For HP spin systems, how-
ever, the level of thermal polarization is typically negligible and undetectable in vivo.
T1 therefore represents a decay process that limits the overall lifetime of the HP signal.
Longer T1 time constants are therefore preferable in HP MRI, particularly when the
HP nuclei rely on relatively slow physiological processes such as systemic blood flow
to enter the tissues of interest. For the same reason, small excitation angles are often
used in HP experiments so as not to deplete the HP magnetization before the nuclei
can experience uptake and/or chemical transformation.
A comprehensive review of the mechanisms contributing to spin-lattice relaxation
is beyond the scope of this discussion, however the most dominant effect in 1H NMR is
dipole-dipole relaxation. In this relaxation mechanism, the translational, rotational
and intramolecular motion of molecules carrying magnetic moments cause them to im-
press time-varying magnetic fields on the detectable nuclear moments. When these
local fields oscillate close to the Larmor frequency, they can cause nutation of nearby
magnetic moments towards the z-axis [36]. Notably, both dipoles in dipole-dipole relax-
ation do not need to be NMR-active nuclei. Paramagnetic electrons — found in (triplet)
molecular oxygen, deoxygenated hemoglobin and gadolinium-based contrast agents —
are also magnetic dipoles that can mediate this form of relaxation. These effects are
fairly well characterized for 1H MRI, however their impact on relaxation of HP 13C
in vivo warrant further study. In particular, the effect of blood oxygenation state on
the T1 of common HP 13C agents has not been as fully characterized at clinical field
strengths, which could be an important consideration since these agents are nearly
always administered intravenously.
One spin-lattice effect, chemical shift anisotropy, is worth special mention because
of its significance in HP 13C imaging and spectroscopy. This effect is most impactful
when the 13C label resides in a molecule with anisotropic molecular structure and
when the labeled molecule is not able to move freely in solution [37]. Both of these
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situations are common for metabolically active HP 13C agents, which are frequently
13C-labeled on highly anisotropic carboxyl groups and bind to proteins that mediate
transport and metabolism in vivo. The strength of this chemical shift anisotropy effect
scales with B20 . This effect can result in a decreasing T1 with increasing magnetic field
strength for many 13C agents, which is the opposite of the trend typically observed in
1H NMR.
Spin-Spin (T2 and T ∗2 ) Relaxation
Prior to application of the RF pulse, ~M is oriented along the z-axis due to the partial
coherence of the individual nuclear magnetic moment vectors in this direction. Upon
being nutated into the transverse plane, ~M maintains this phase coherence in the
direction along which it is oriented at the end of the RF pulse. However, this phase
coherence is not permanently maintained due to variations in the local magnetic field
experienced by the vast number of nuclei in every milliliter of fluid or tissue. As de-
scribed in the previous section, these localized magnetic non-uniformities can result
from the superposition of ~B0 and the magnetic moments of nearby nuclei, electrons
and molecules. The distribution of local magnetic fields experienced by individual nu-
clei causes a matching distribution in precessional frequency, as indicated in equation
2.1. This spread of frequencies in the sample volume appears over time as a progres-
sive loss of phase coherence for the component of ~M in the transverse plane, Mxy. As
individual nuclear magnetic moments fall out of phase with one other, the magnitude
of the detectable signal induced by Mxy in a NMR signal reception coil decreases ex-
ponentially with a time constant T ∗2 [25, 34]. If the component of ~M in the transverse






where T (∗)2 can be either T ∗2 or T2 depending on the type of MR scan used. When viewed
in the rotating frame of reference, Mxy behaves as described in this equation. How-
ever, in the laboratory frame the exponential decay described here corresponds to the
envelope of a damped sinusoid that oscillates at the Larmor frequency. This damped
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sinusoidal signal is the induced voltage directly recorded in a MR study, and is often
called the Free Induction Decay (FID).
Since this relaxation mechanism refers to the loss of partial phase coherence for
the ensemble of spin angular moments that generate detectable magnetization in the
transverse plane, it is often called spin-spin or transverse relaxation. In reality, addi-
tional mechanisms account for the observed Mxy relaxation rate, including chemical
exchange, direct transfer of spin state polarization between pairs of nuclei and the
mechanisms that mediate spin-lattice relaxation [25]. Conservation of angular mo-
mentum dictates that the loss of transverse spin coherence described in equation 2.7
must occur at least as fast as the change in longitudinal spin coherence expressed in
equation 2.4. In other words, T2 ≤ T1. As discussed in the previous paragraph, the
assumption of a perfectly uniform ~B0 field is violated for even small NMR and MRI
sampling volumes. In addition to the microscopic mechanisms described above, ~B0
non-uniformities arise from the presence of paramagnetic substances, mismatches in
magnetic susceptibility at air-tissue interfaces, and both fundamental and practical
limitations in MRI hardware. For the signal recorded immediately following a single
RF pulse, the decay time constant encapsulates all of these effects and is referred to
as T ∗2 . If spins experiencing these inhomogeneities are subjected to two RF pulses in
quick succession, the second pulse will cause a reversal of precessional frequency for
some nuclei and refocus a portion of the dephased Mxy. After a delay equal to the
time separation of the two RF pulses, the maximal amount of refocusing occurs and
a signal called a spin echo is generated [38]. The greatest spin-echo amplitude occurs
for a refocusing RF pulse nutation angle of 180 degrees. Even when a perfect 180 de-
gree refocusing pulse is applied, not all mechanisms of spin-spin relaxation are fully
reversed. The spin echo signal will therefore possess a decreased amplitude relative
to the signal present immediately after the first RF pulse. Multiple spin echoes can
be generated by applying multiple refocusing pulses, and T2 is the time constant in
equation 2.7 describing the decreasing amplitudes of these subsequent spin echoes
with time.
T ∗2 accounts for mechanisms of spin coherence loss that are not captured by T2.
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The rate of T ∗2 decay is therefore always faster than T2 decay, and the T ∗2 rate can be











Small values of T ′2 occur most often in 1H MRI for sampling volumes with poor ~B0
homogeneity or containing paramagnetic molecules, leading to substantial differences
between T2 and T ∗2 . When imaging many of the most commonly used HP 13C substrates,
there is also a large difference between T2 and T ∗2 due in part to the large sampling
volumes in which excellent ~B0 uniformity is difficult to achieve. Although this makes
spin echo experiments appealing for HP 13C MRI from a signal to noise perspective,
the effects of refocusing pulses on HP spin systems need to be handled carefully in
order to avoid extinguishing the large and non-recoverable z-axis magnetization. For
this reason, double spin echo methods with two refocusing pulses have been used for
HP imaging [39]. If both refocusing pulses have a 180° nutation angle and occur close
to one another in time, the second pulse will mostly reverse the effects of the first pulse
on the z-axis magnetization and preserve HP signal for imaging over time.
The Bloch Equations
The Bloch equations are a set of equations describing the behavior of the aggregate
NMR magnetization over time. These equations are named for Felix Bloch, who first
introduced in 1946 such a set of equations accounting for the RF excitation and relax-
ation effect described in the preceding sections. They can be derived as solutions to
the following vector-valued differential equation [25, 34].
d ~M
dt








Here all vector variables are composed of three values describing the corresponding
magnetic fields in each direction. ~B describes all external magnetic fields acting on
the subject, including ~B0, the magnetic component of RF fields ( ~B1), and — as we shall
discuss in section 2.5 — magnetic field gradients. The cross product in the first term
may be conceptualized as a torque applied to ~M when its direction does not coincide
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perfectly with ~B, which contains non-zero values in the x and/or y direction when an
RF pulse is active. When no RF pulse affects the magnetization, solutions to this
differential equation are found in equations 2.4 and 2.7. Following a 90° pulse, the tip
of ~M can be visualized as tracing out a damped helix over time as shown in figure 2.4.
Figure 2.4: After the application of a 90° RF excitation pulse to a thermally polar-
ized spin system at equilibrium, the net magnetization vector ( ~M ) is displaced into
the transverse plane. Without any further perturbation, relaxation effects cause this
vector to follow a damped helical trajectory as it returns to equilibrium (left). The
component of ~M in the transverse plane exhibits sinusoidal oscillation at the Larmor
frequency and decays exponentially over time with a rate of 1
T2
, inducing a character-
istic FID signal in an appropriately positioned receiving coil.
Solving equation 2.9 in a more generalized case is difficult due to the cross product
in the first term. This non-linear differential equation may also be modified to account
for additional effects not described in this form. Some examples of such modifications
are the Bloch-Torrey equations [40], which describe effects of molecular diffusion, and
the Bloch-McConnell equations [41], which describe the effects of chemical exchange.
Application of these equations provide invaluable insight into NMR and MRI exper-
iments, especially for HP MRI in which ~M represents a non-renewable signal source
[12].
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2.4 NMR Fourier Spectroscopy
Chemical Shift
The transient NMR signal provides detailed information on the chemical environment
of the population of polarized nuclei. This effect arises from the diamagnetism of mov-
ing orbital electrons, which create a small local magnetic field that opposes ~B0. Nuclei
in molecular environments with a greater density of orbital electrons therefore ex-
perience a reduced magnetic field due to this diamagnetic shielding. The resulting
difference in the impressed magnetic field results in a proportional shift in the pre-
cessional frequency of the nuclear magnetic moment, called a chemical shift [42]. For
a nucleus experiencing an effective magnetic field ( ~Beff ) that is the combination of ~B0
and the diamagnetic electron field (Be), equation 2.1 can be rewritten:





( ~B0 − ~Be) = fe − f0 (2.10)
Here, fe denotes the relative chemical shift frequency, which is the frequency of the
signal observed upon demodulation of the NMR system frequency, f0, from the directly
measured FID. This relative frequency is typically determined empirically for a given
chemical environment relative to a reference chemical shift that is assigned a chemical
shift of zero for each NMR nucleus. For 1H and 13C spectroscopy this reference shift
corresponds to the resonances of these nuclei in tetramethylsilane [43]. The frequency
of a chemical shift may be expressed relative to the nuclear reference shift in units of
Hz or ppm, with the latter having the advantage of being independent of ~B0. If the
reference chemical shift (in Hz) for a given nuclide is fref , then the chemical shift at





The convention of expressing this quantity in ppm derives from the fact that the nu-
merator of this equation is typically expressed in Hz while the denominator is on the
order of MHz for most modern NMR and MRI systems. By convention, the chemical
shift axis is usually presented with decreasing values from left to right. This orien-
tation places signal from nuclides experiencing less diamagnetic electronic shielding
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on the left side of graphs and those experiencing more shielding on the right side.
Chemical shifts observed in 1H spectroscopy are typically in the 0 to 12 ppm range, or
an approximately 3.6 kHz bandwidth at 7 T. Due to the greater diversity of molecular
bonding for carbon, a much wider range of shifts is observed in 13C spectroscopy that
extends from 0 to >200 ppm (>15 kHz at 7 T).
Since chemical shift is an effect determined by the intramolecular environment of
nuclear magnetic moments, it is distinct from the effects of the distribution of localized
precessional frequencies that mediate the relaxation effects discussed in the previous
sections. For an identical ~Beff , all chemically identical nuclides (e.g. the protiums in
water or in the methyl group of a specific type of fat molecule) would ideally resonate at
precisely the same frequency. In reality, each set of chemically equivalent nuclear mo-
ments is observed to have a distribution of frequencies due to the differing microscopic
magnetic fields produced by molecular moments and local ~B0 inhomogeneities in the
vicinity of the individual nuclides. The width of this frequency distribution observed
for each chemical shift is therefore related directly to the rate of spin-spin relaxation
that determines the lifetime of the FID. If contributions to spin-spin relaxation from
effects other than localized variations in magnetic field are negligible, the width of the







Under ideal conditions, this equation describes the width of a Lorentzian peak for each
chemical shift in a properly processed NMR spectrum.
The FID signal generated by the NMR sample or MRI subject is a time-varying
voltage produced in a conductive coil via electromagnetic induction. This coil is ori-
ented spatially to intercept the component of the aggregate magnetization vector that
lies in the transverse plane, Mxy. In the laboratory reference frame, this voltage mea-
sured from a sample containing a single chemical shift will be observed to oscillate at
the frequency f defined in equation 2.10 and decay over time as specified in equation
2.7. A rough rule of thumb for the lifetime of the FID following an RF pulse is 5× T ∗2 .
When the FID is demodulated by the NMR system frequency, f0, the rate of its oscil-
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lation becomes fe and the signal represents Mxy in the rotating reference frame. In
practice the FID is sampled in quadrature, by mixing the signal from receiving coils
with two sinusoids that oscillate at f0 but possess a 90 degree phase shift relative to
one another. This form of sampling produces two components, referred to as In-phase
(I) and Quadrature (Q), which are conveniently represented as the real and imaginary
parts of a complex-valued signal. If a single chemical shift is present resonating at the
angular frequency ω = 2πf , the observed in-phase, quadrature and complex signals
will be
I(t) = Mx(t) = Mxy(t) sin (ωt)
Q(t) = My(t) = Mxy(t) cos (ωt)
S(t) = I(t) + iQ(t) = Mxy(t)(sin (ωt) + i cos (ωt)) = Mxy(t)e
iωt
(2.13)
where i denotes the imaginary unit and Mxy(t) decays with time constant T ∗2 as de-
scribed in equation 2.7. As indicated in this last equation, the complex signal values
can be represented either as real and imaginary components or as a complex expo-
nential, which is also called phasor notation. In phasor form, each complex value is
specified by its magnitude (Mxy(t)) and a phase (ωt, with units of radians) that is the
product of time and angular frequency. When multiple chemical shifts contribute to
the NMR signal, the FID is — in the simplest case — the sum of the individual time
domain signals across all species present. The fundamental challenge of NMR spec-
troscopy lies in extracting the phasor magnitudes (Mxy(t = 0)) and frequencies (f ) for
these chemical shifts given the observed FID signal (S(t)).
Fourier Spectroscopy
The Fourier Transform (FT) provides the frequency content of a time domain signal by
decomposing it into a series of sinusoids with varying frequency, phase and amplitude.
The FT is defined as the integral of the product of a function, g(t), and a unit phasor
[44].




Just as the human auditory system interprets pressure applied to the eardrum over
time as a series of tones, the FT converts a finite time domain signal into a spectrum
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depicting the amplitudes and phases of its constituent frequencies. Applying the FT
to the FID recorded in a NMR experiment therefore provides a spectrum representing
the magnitudes and precessional frequencies of the aggregate magnetic moments for
the chemical shifts present [45].
In practice, the continuous FT given in equation 2.14 is not directly applicable to the
FID since this signal is sampled digitally at discrete time points. Instead the Discrete
Fourier Transform (DFT) is used, which can be defined for a series of function values
(g(τ)) sampled at N equally spaced points as [44]:







In the context of NMR and MRI studies, an increment of τ represents the time delay
elapsed between subsequent digital samples, called the dwell time (tD). Intuitively,
it is easy to comprehend that high frequency signals must be sampled with a small
tD in order to be measured accurately. After applying of the DFT, a complex-valued
NMR spectrum of N discrete frequencies (denoted by ν) is obtained. The total fre-
quency bandwidth is equal to the FID sampling frequency (1/tD). The FID is typically
band-pass filtered during the data acquisition process so that frequencies outside of
this spectral bandwidth are removed. The RF pulse shape imparts an additional fre-
quency selectivity separate from the bandwidth defined by sampling and the acquisi-
tion filter. For a conventional RF pulse, the excitation profile in the frequency domain
is approximated by the FT of ~B1(t) in the rotating reference frame [35]. Using shaped
RF pulses therefore provides a straightforward way to modulate the frequency content
of the NMR signal, for example in MR Spectroscopic Imaging (MRSI). When a uniform
excitation profile is desirable, as in routine NMR spectroscopy, a very short duration
rectangular pulse is often used.
In NMR spectroscopy, the Fourier transformed spectrum is usually processed so
that the real component depicts the frequency distribution of chemical shifts in the
sample. This is accomplished by applying phase corrections to the complex Fourier
transformed spectrum that compensate for delays between RF excitation and signal
readout, and for variations in effective nutation angle for different chemical shifts
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Figure 2.5: 1H FID (left) and magnitude spectrum (right) of a 1.6 cm slab covering
a healthy rat liver measured at 7 T. Without any signal suppression strategies, the
dominant signals in this spectrum are water and fat at 4.7 and≈ 1.5 ppm, respectively.
[45]. Once phase-corrected, the real NMR spectrum exhibits chemical shift peaks
with linewidths narrower than in a corresponding magnitude spectrum. If relaxation
effects are consistent across all chemical shifts observed in a spectrum, the area under
the curve measured at a specific fractional peak width for each peak provides a quan-
titative measure of the relative number of nuclides in that molecular environment.
Noise in NMR Data
NMR data possess notable noise properties due to the complex values they take and
the physics underlying signal generation. The noise measured from the receiving coils
of a NMR or MRI system in the absence of any RF nutation of the net magnetic moment
is ideally zero-mean white noise, without any correlation between coils or between real
and imaginary components of the complex-valued data. This noise arises both from the
thermal electronic noise in the receiving chain instrumentation and from the motion
of molecular moments and charged particles within the sensitive volume of a NMR
coil [46]. In general noise with greater variance is produced by larger or more elec-
tronically resistive RF coils, or by samples with greater electrical conductivity. Figure
2.6 depicts the distribution of raw (not Fourier transformed) noise acquired using a
13C imaging setup on a preclinical 7 T MRI system, which is employed throughout
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this work. The real and imaginary channels each demonstrate a zero-mean Gaussian
noise distribution.
Figure 2.6: MR data take complex values, which can be represented either as real
and imaginary Cartesian coordinates (red and blue) or as magnitude and phase polar
coordinates (green and brown). The histograms and scatter plot in this figure show
the distribution of raw complex noise acquired on a Bruker 7 T preclinical MRI sys-
tem. These data were measured using a 48 µs dwell time from a 2 cm diameter 13C
surface coil. The real and imaginary components of ideal MR noise follow a zero-mean
bivariate normal distribution.
For phase-corrected real NMR spectra, the noise seen in regions devoid of signal
would ideally exhibit a zero-mean Gaussian distribution similar to that observed in
the raw real and imaginary noise, but with a variance scaled by the number of points
in the applied DFT. Given a real MR signal amplitude S and noise variance σ2, the
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In MRI, however, images are most often viewed and analyzed in magnitude mode,
which presents values corresponding to the radial distance from the origin to a point
in the complex plane. The magnitude of complex valued zero-mean Gaussian noise fol-




times the standard deviation of the underlying complex noise distribution [47, 48].
Accurate estimation of magnitude image SNR therefore requires the application of a











An estimate of σmag can be made by reconstructing a magnitude image acquired with
RF pulse power set to zero, or by specifying a region of a magnitude image that is
devoid of signal [49]. In this latter approach, care must be taken to exclude spurious
signal created by image artifacts.
The Rayleigh distribution describing pure magnitude noise in MR images is a spe-
cial case of the more general Rician distribution that is followed by noisy magnitude
MR data [50]. For complex signal magnitudes above ≈ 3σ, the Rician distribution ex-
hibits a normal probability density function. At the high SNRs routinely seen in 1H
MRI, a Gaussian distribution can therefore be assumed for voxels within a uniform
high-signal region of the image. If such a uniform high-signal region is present, its
standard deviation may be used as an estimate of σ to calculate SNR using equation
2.16. In HP 13C imaging, however, low SNRs are often observed and coarse image
matrices make the calculation of standard deviation within a uniform signal region
very difficult. For these reasons, SNR values reported for 13C images in this work are
calculated using equation 2.17, with σmag measured from an image reconstructed from
pure acquisition noise.
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Figure 2.7: Data from figure 2.6 were used to generate magnitude distributions with
means (µ) of 0, 2 and 4 times the standard deviation of the underlying complex noise
distribution (σ). Magnitude MR data in the presence of ideal noise follows a distri-
bution that is Rician, which is equivalent to the Rayleigh distribution at µ = 0 and
approximately equivalent to a normal distribution for µ > 3σ.
2.5 Magnetic Resonance Imaging
The Fourier transform is the fundamental mathematical transformation that enables
modern NMR spectroscopy. Applying the DFT to a digitized FID provides the signal
frequency content in the form of a NMR spectrum from which the chemical content
of the interrogated sample may be identified. Importantly, the DFT is a linear and
invertible transformation [44]. By applying the inverse DFT (iDFT) to a signal repre-
senting a NMR frequency spectrum, the time domain signal (FID) is obtained. If the
input signal represents spatial rather than temporal frequency, the iDFT provides a
spatial profile of the corresponding subject. Due to the linearity of the iDFT, signals
representing spatial frequencies sampled in two or three orthogonal directions can be
transformed separately in each direction. This process provides a set of images, and
is the mathematical basis for Magnetic Resonance Imaging.
In order to encode spatial frequencies for imaging, linear magnetic field gradients
are typically applied [51]. These gradient fields are magnetic fields directed along the
same axis as ~B0, with amplitudes that vary linearly along each spatial direction. In
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Figure 2.8: The iDFT converts a measured set of spatial frequencies (left) to a spatial
projection along the physical direction of the encoding gradient (right). For clarity,
only the magnitude spatial profile is shown.
MRI systems, gradients in the x, y and z directions can be used in combination to
create an effective linear field gradient in any direction. By applying these gradients
for a brief duration of time following an RF pulse, the precessional frequencies of in-
dividual nuclear magnetic moments are modulated linearly with position along the
corresponding spatial axis.
ω(x) = −γ(B0 +Gxx) (2.18)
Sets of nuclear moments that behave identically when manipulated via RF excitation
and field gradients are often called isochromats. This term refers to the fact that they
precess at the same — or very close to the same — frequency, just as all visible light of
a specific color is electromagnetic radiation with the same frequency. In imaging, this
denotes a group of NMR moments that share the same frequency by virtue of position
and/or chemical shift, depending on the context.
After the application of a gradient field for an increment of time, the isochromats
contributing to the detectable net aggregate magnetization (Mxy) will possess phases
that vary along the gradient axis in direct proportion to the duration of time the gra-
dient is active, the amplitude of the gradient and the nuclear gyromagnetic ratio [52].
Ignoring relaxation effects, the signal observed at any point in time during application
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of a constant amplitude linear field gradient (Gx) is proportional to the volume inte-
gral of the imaged object’s nuclear spin density (ρ), modulated by the spatially varying








Here, ~r denotes position in three dimensional space and we are assuming all spins
are stationary. By sampling this signal in quadrature at the Larmor frequency as de-
scribed in section 2.4, the contribution of ~B0 in the exponential argument is eliminated.
The remaining phase term in equation 2.19 describes a wave of magnetic moment en-
coded in the subject along the gradient direction. This wave may be characterized
by its k-number, which is the wave’s spatial frequency. The k-number is equal to the
reciprocal of the wavelength, often expressed in cycles per centimeter. Note that this
k-number corresponds only to the spatial phase roll imparted by gradients, and not the
wavelength of electromagnetic interactions between the spin system and the receiving
coils. Recording the voltage signal induced in a receive coil by Mxy in the presence of
this wave effectively samples the spatial frequency of isochromats in the subject cor-
responding to this k-number. The spatial frequency domain discretized by k-numbers
sampled in two or three orthogonal directions is called k-space, which is the domain
of direct signal detection in modern MRI. In order to encode signals for which the
iDFT provides three dimensional images, the goal of a MRI experiment is to sample
an extent of k-space uniformly in three directions.




In reality, field gradients cannot be switched on and off instantaneously. Most often
they are ramped up and down linearly with time, resulting in trapezoidal gradient






where ~G is the gradient amplitude. Sampling of k-space in MRI can be performed in
two ways, typically called phase encoding and frequency encoding. Phase encoding
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Figure 2.9: The iDFT converts a measured set of two-dimensional spatial frequencies
(k-space, left) to an image (right). For clarity, only the magnitude data are shown, and
k-space is displayed on a logarithmic scale.
refers to a strategy in which a gradient pulse is applied briefly to encode a single k-
number in a specific direction. By iterating through a series of gradient amplitudes
and directions, k-space can be sampled point-wise in one, two or three dimensions
[53]. Phase encoding alone is a very inefficient method in terms of scan time, since it
records only a single k-space point per gradient pulse amplitude and direction. Fre-
quency encoding, in contrast, encodes k-numbers continuously over time by sampling
Mxy periodically during a gradient pulse. In the case of a constant frequency encoding
gradient amplitude, the product of the sampling dwell time, gradient amplitude and
gyromagnetic ratio determine the increment of k-number between samples.
In most MRI scans, constant amplitude frequency encoding is used in one direction
to acquire rectilinear lines of k-space, and phase encoding is used for encoding one or
two directions orthogonal to the frequency encoded direction [35]. In the simplest
case, a full line of frequency encoded k-numbers at a single phase encoded k-number
is sampled following each RF pulse. In order to sample k-space symmetrically about
the origin, the frequency encoding gradient must be preceded by a preparation gradi-
ent of opposite polarity in the same direction. In this context, as the readout frequency
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gradient progressively unwinds the phase imparted by the preparation gradient, the
recorded signal oscillates with increasing amplitude, reaching a maximum at k = 0
and diminishing thereafter. Since this signal is produced solely by the spatial phase
refocusing influence of the readout gradient, it is called a gradient echo (or, by some
authors, a gradient recalled echo). As described in section 2.3, spin echoes are gen-
erated by the application of two RF pulses with a separation in time that is short
relative to the rate of spin-spin relaxation (T2). These spin echoes may be encoded to
represent image spatial frequencies in the same manner described here for gradient
echoes. Since a spin echo without any spatial gradient encoding evolves over time in a
manner controlled primarily by the chemical shifts present, image artifacts can occur
in spin echo imaging if the centers of the spin and gradient echoes do not coincide.
This chemical shift offset is exploited in some approaches to spin echo chemical shift
imaging [54]. In general, gradient echo imaging methods are more useful for rapid or
dynamic imaging, or for encoding images with signal intensities weighted according
to T ∗2 . Since T2 > T ∗2 , spin echo imaging methods generally offer more time for MR sig-
nal encoding and are typically more useful for higher resolution anatomical imaging,
including T2-weighted imaging.
The composite sequence of RF and gradient pulses arranged in time for MR imaging
and spectroscopy is called a pulse sequence. A very wide variety of pulse sequences are
used to achieve different contrasts and to accelerate the acquisition of k-space data.
Generalizations about MRI methods without exceptions are difficult to make, however
there are a handful of scan parameters that affect all pulse sequences in a mostly
consistent manner. From an image contrast perspective, the three most important
parameters that can be defined for any pulse sequence are the RF pulse excitation
angle (θ), repetition time (TR) and echo time (TE). The RF excitation angle controls the
redistribution of longitudinal and transverse magnetization as described in equation
2.6. The repetition time denotes the time elapsed between subsequent RF excitation
pulses that nutate a given set of isochromats, and therefore in general refers to the
duration of time that is allowed for spin-lattice relaxation. Note that in spin echo type
sequences the RF excitation pulses are distinct from the refocusing pulses, and both
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excitation and refocusing pulses will control the time allowed for T1 relaxation. Most
spin echo sequences use a nominal 90 degree excitation and 180 degree refocusing
pulse since these settings provide the maximum spin echo signal amplitude. For the
purpose of the following discussion of image contrast, the maximum excitation angle
will be considered to be 90 degrees.
Most pulse sequences are designed to operate on a steady-state longitudinal mag-
netization (Mz). This steady-state level is determined for isochromats within the sub-
ject by their spin-lattice relaxation rate, the repetition time and the excitation angle.
In general, greater T1 weighting of MR signals is achieved by using shorter repetition
times or — particularly for gradient echo sequences — larger excitation angles. These
changes to a given pulse sequence will decrease the magnitude of the steady-state
Mz it establishes, allowing isochromats with shorter T1 relaxation times to establish
steady-state levels of Mz that are greater than isochromats with longer T1 relaxation
times. Greater T (∗)2 weighting is achieved for a given pulse sequence by extending the
echo time, which is defined as the time elapsed between RF excitation and the mo-
ment at which k = 0 is sampled (i.e. the peak of the gradient echo). This increase in
TE incurs a reduction in imaging signal magnitude due to the greater amount of T (∗)2
decay occurring before signal readout, however the image contrast that is attained is
often very useful for differentiating diseased tissues in vivo [55]. When neither T1 nor
T
(∗)
2 contrast is desirable, spin-density weighted imaging signals can be encoded using
a short TE and long TR to minimize spin-spin signal decay and maximize spin-lattice
recovery.
For routine MRI sequences that operate on thermally polarized spin systems, the
choice of image weighting depends on the desired visibility and contrast of tissues
in the resulting images. Special considerations must be given to a pulse sequence
used for HP imaging. As discussed in section 2.3, for the HP case T1 is the time con-
stant of Mz decay, usually towards an undetectable equilibrium value. Furthermore,
each RF pulse depletes a portion of the non-recoverable Mz. If a conventional gradi-
ent echo imaging method were used for HP MRI, apodization of the encoded spatial
frequency signals over time would impart a filtering effect that can lead to severely
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blurred and non-quantifiable images. This effect is simulated in figure 2.10 by ap-
plying an HP signal apodization filter to the raw 1H MR imaging data of a lemon.
Also, since the nuclear moments that provide the HP signal are exogenous and typ-
ically delivered by perfusion, the dynamics of signal evolution in vivo complicate HP
imaging experiments. Imaging approaches for HP MRI are generally designed either
to sample the temporal dynamics of the HP imaging signal or to encode high quality
spectroscopic images of a specific set of chemical shifts that are averaged over time.
For the latter approach, precise timing can be difficult since many HP agents depolar-
ize completely within a few minutes of being removed from the polarizer. These single
time point data can also only be quantified with simple frequency integration or ra-
tiometric approaches. Imaging data acquired dynamically over time can be expected
to exhibit lower image quality — either in terms of SNR, spatial resolution or both —
but are required in some form for pharmacokinetic modeling of HP agent uptake and
metabolism.
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Figure 2.10: In conventional gradient echo imaging of thermally polarized subjects,
the periodic application of RF pulses establishes a steady-state level of longitudinal
magnetization (Mz) determined by the pulse nutation angle and the rate of Mz recov-
ery ( 1
T1
). Once established, this steady-stateMz produces a consistent amount of trans-
verse magnetization (Mxy) with each excitation prior to encoding of the image spatial
frequencies. In HP imaging, each RF pulse depletes a portion of the non-recoverable
HP MZ , which also decays continuously with time constant T1. If the same gradient
echo imaging method were applied to a HP spin system, the depletion of MZ would
have an undesirable filtering effect on the encoded image spatial frequencies, result-
ing in severe image blurring. Because of this filtering effect, as well as the effects of
vascular delivery for HP 13C agents in vivo (not accounted for in this figure), special-
ized imaging techniques are needed for HP MRI.
Chapter 3
Hyperpolarized 13C MRI
In its most basic sense, NMR hyperpolarization is the production of a sample con-
taining a net nuclear moment much greater than would occur at thermal equilibrium.
Such a technique was theorized by Felix Bloch in the same 1946 paper in which he
introduced his eponymous equations.
As to the nuclear induction effect, there exists the interesting possibility
of first establishing the equilibrium in a strong magnetic field under con-
ditions of relatively short relaxation time (by evaporation into an oxygen
atmosphere, addition of a paramagnetic catalyst, heating, etc.), thereupon
considerably lengthening the relaxation time (by recondensation, removal
of the catalyst, cooling, etc.), and thus preserving the high field polariza-
tion for a considerable time, even when the sample is removed from the
high field. A subsequent nuclear induction experiment, carried out under
suitable conditions, can then exhibit either a moment, pertaining to the
field in which it was originally established, or indicate that the relaxation
time was comparable or short, compared to the time which has elapsed since
removal. [34]
Although these precise physical methods for polarizing nuclear spins better describe
brute-force polarization, temporarily establishing a large aggregate magnetic moment
in conditions separate from those in which the MR experiment is carried out is the fun-
damental idea underlying the hyperpolarization method discussed in this chapter. As
reviewed briefly in section 2.2, methods by which high nuclear spin polarizations may
be attained include polarization transfer from metal electrons via optical pumping and
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from parahydrogen via chemical interactions. A more recently developed hyperpolar-
ization method, dissolution dynamic nuclear polarization (dDNP), is the focus of this
work.
In this chapter, the process and implementation of hyperpolarization by dDNP will
be reviewed. This discussion will cover the production of the HP sample, its use in
spectroscopic and imaging experiments with living systems, and an overview of some
important 13C labeled HP agents. At the close of this chapter, a recent study applying
this method to the measurement of the effect of a metabolic intervention in a mouse
model of brain cancer is presented.
3.1 Dissolution Dynamic Nuclear Polarization
Dissolution DNP was demonstrated first in the seminal work of Jan Henrik Ardenkjær-
Larsen [56]. This technology can produce biocompatible solutions containing 13C la-
beled molecules with spin polarizations far exceeding what had been reported previ-
ously in the liquid state.
DNP refers to a class of hyperpolarization techniques that exploit electron para-
magnetic resonance (EPR) effects to create large nuclear spin polarization fractions.
This process is most efficient at high magnetic field and low temperature (typically
~B0 > 3 T and T < 2 K) in the solid state. In these conditions, the paramagnetic elec-
trons achieve a spin polarization fraction that approaches 100% due to their large
gyromagnetic ratio ( γe
2π
= -28,025 MHz/T), while the equilibrium nuclear polarization
remains <1%. The transfer of electron spin polarization to nuclei can be accomplished
in a variety of ways that will not be fully covered here, including magic angle spinning
[57] and photochemical reactions [58]. For the purpose of dDNP, polarization transfer
is induced by narrow-band saturation of an EPR line using a time-varying magnetic
field with a frequency that is the difference between the EPR and NMR Larmor fre-
quencies. At the field strengths used in DNP, this saturation frequency usually falls
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within the microwave range of the electromagnetic spectrum. In an amorphous solid
irradiated at the appropriate microwave frequency, hyperfine coupling and thermal
mixing of the electron and nuclear spins permit cross-relaxation mechanisms that
strongly favor the accumulation of nuclear moment alignment in the direction of ~B0.
This DNP process is a well-established NMR technique used in high energy physics
research and for the investigation of solid state molecular structures, having been first
proposed theoretically [33] and demonstrated experimentally [59] in the 1950s. The
pivotal innovation in Ardenkjær-Larsen’s work was the rapid dissolution of the solid
DNP sample in a superheated solution, yielding HP solutions that are useful for in-
terrogation of biochemistry and physiology in vivo. Using a suitable radical, DNP can
be used to attain large solid state polarization fractions for any NMR nuclide, however
dDNP has been applied primarily to 13C labeled molecules.
The dDNP process is usually performed on a highly 13C-enriched solution. A high
concentration of 13C nuclei not only increases the absolute level of net magnetic mo-
ment attainable, but also enhances the efficiency of the DNP process, which depends
on physical proximity of nuclear and radical electron magnetic moments. This solution
is prepared with a glassing agent and a triarylmethyl (trityl) radical, then loaded into
a specially-built dDNP polarizer. The polarizer consists of a superconducting magnet
equipped with a specialized insert designed to provide an extremely low temperature
and pressure environment using a vacuum-pumped liquid helium bath. Once loaded
into this insert within the polarizer, the DNP sample is cooled to <2 K. Microwave
irradiation at a narrow frequency band catalyzes polarization transfer from electrons
to 13C nuclei, however this build up of solid state polarization proceeds slowly due to
several factors, including the relatively low likelihood of cross-relaxation mechanisms
in the solid state [60]. The electron T1 is relatively short in the solid state (≈1 s), but at
a lower polarizer field strength (e.g. 3.35 T) it can be reduced significantly via doping
with small quantities of gadolinium or other lanthanide ions [61]. In these conditions,
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the doped DNP sample polarizes more quickly and attains a greater maximum level
of polarization [62]. A NMR coil tuned to the 13C frequency may be used to monitor
the build-up of the solid state nuclear polarization via low excitation angle RF pulses.
This build-up curve follows the same shape as a traditional T1 exponential recovery
curve in MRI, due to solid state spin-lattice effects in the coupled electron and 13C
spin systems. Depending on the polarizer field strength and the chemical properties
of both the radical and the 13C molecule being polarized, continuous microwave irra-
diation must be applied for an hour or more to attain maximal nuclear polarization
levels.
In order to facilitate transfer of polarization from radical electrons to 13C nuclei,
the molecules in the DNP sample must form an amorphous glass matrix when rapidly
chilled to cryogenic temperatures. The crystalline lattice formed by most aqueous so-
lutions when frozen inhibits thermal mixing of the radical electrons and 13C nuclei,
which is a critical mechanism of angular momentum transfer in the solid state [60].
With some notable exceptions, a glassing agent must be added to the DNP sample to
prevent crystal formation and allow thermal mixing at low temperature. The DNP
solution described in Ardenkjær-Larsen’s initial publication consisted of 13C urea dis-
solved in glycerol, which functioned as a glassing agent. For aqueous dDNP solutions,
common glassing agents include dimethyl sulfoxide (DMSO), dimethyl acetamide and
ethanol. The amount of glassing agent used represents a trade-off between the effi-
cacy of glass formation and the dilution of 13C nuclei, which impart competing effects
for the DNP process. Additionally, the presence of the glassing agent in the final HP
solution can pose an added impediment to its use in vivo. If a pharmaceutical grade
glassing agent cannot be employed, or the glassing agent concentration after dissolu-
tion is too high, the HP solution cannot be administered in human subjects and may
not be usable in animal studies.
Once sufficiently high spin polarization is achieved for 13C nuclei in the solid state,
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a dissolution is performed. A dissolution buffer is loaded into a heating chamber out-
side of the DNP insert. Within this chamber, the liquid buffer is heated to≈200° C and
pressurized to ≈10 bar using helium gas. The DNP sample is then raised out of the
liquid helium bath and the superheated buffer is forced through the sample chamber
by the pressurized helium gas, melting the sample and ejecting it from the polarizer in
liquid form within seconds. The polarization of the 13C compound is retained through
this dissolution process, providing a HP solution with a transient NMR signal four
orders of magnitude greater than the equilibrium conditions attainable in a typical
MRI or NMR instrument. The dissolution buffer is typically formulated chemically
and heated to an appropriate temperature such that it produces a biocompatible solu-
tion when combined with the frozen DNP sample. This is critical for studies in living
systems, both in vitro and in vivo, since a non-physiological pH and temperature in the
HP solution could significantly perturb the biological processes under investigation.
Currently, the most widely used preclinical polarizer is the Oxford Instruments
HyperSense, which is largely based on Ardenkjær-Larsen’s original design. This po-
larizer operates at 3.35 T using an open and reusable sample cup that is loaded with
a DNP sample and inserted directly into the liquid helium bath. Upon dissolution,
the buffer is forced through the sample cup via a stick that lowers into the DNP insert
and connects tightly around the cup opening, preventing direct contact between the
superheated liquid and cryogenic helium. This design is advantageous in that samples
are easy to prepare and it uses no disposable parts, however there is a risk that a cup
could be displaced in the DNP insert. If a dissolution is attempted with a displaced
sample cup, superheated buffer is sprayed directly into the liquid helium bath and
flash frozen. This catastrophic event results in significant downtime for the polarizer
as the DNP insert must be warmed and flushed with helium gas to clear away the
frozen buffer.
Apart from this risk of a major dissolution failure, the reusable nature of the Hy-
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perSense cups and fluid lines that carry liquid into and out of the DNP insert mostly
preclude the possibility of producing the sterile solutions necessary for HP studies
in human subjects. Additionally, this system can only polarize a single sample at a
time, which limits system throughput due to the long solid state polarization build-up
time. These issues were addressed in the design of the GE SPINlab. This polarizer
was designed for clinical use and consists of a 5 T magnet and a multichannel DNP
insert that can polarize up to 4 samples simultaneously [63]. Each sample must be
prepared in a fully enclosed fluid path that can be assembled in a clean environment.
This fluid path consists of a sample cup and three syringes connected with durable
plastic tubing. Two syringes are loaded with components of the dissolution buffer and
the third is kept empty to receive the HP solution upon dissolution. End stage steril-
ization is performed by forcing the HP solution through a sterile filter at the end of the
fluid path connected to the receiving syringe. The sample cup is loaded with the DNP
sample, sealed to the fluid path with a laser welder and the entire fluid path assem-
bly is pressure tested before insertion into the polarizer. While this reduces the risk
of a catastrophic dissolution failure, there are several epoxy and glue joints in these
fluid paths that can fail. In the worst case scenario, such a failure can introduce the
heated dissolution buffer into the cryogenic environment of the DNP insert, requiring
polarizer downtime as described in the previous paragraph.
In addition to sterility concerns, the temperature, chemical content and polariza-
tion level of the HP solution must be verified before it is cleared by a pharmacist for
administration in human subjects. For these purposes, the SPINlab can be interfaced
with a Quality Control (QC) module that rapidly analyzes the concentration and pH
of a small quantity of the HP agent spectrophotometrically. Additionally, the trityl
radical does not have regulatory approval for injection in humans. For clinical use,
the radical is therefore removed from the HP solution by forcing it through a filter
integrated into the fluid line, and the residual trityl concentration is measured op-
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Figure 3.1: The original dDNP system created by Ardenkjær-Larsen, et al. consists
of a 3.35 T magnet interfaced with a vacuum pump and DNP insert (A). Individual
samples are prepared in open cups inserted manually into the DNP insert and irra-
diated with microwaves for ≈1 hour before dissolution. This same design was used
in the Oxford Instruments HyperSense (B), with the addition of an automated dis-
solution system. The GE Healthcare SPINlab (C) offers an improved design, with a
cryogen-free 5 T magnet and DNP insert that can polarize up to four samples simulta-
neously in fully enclosed fluid paths. The SPINlab can be equipped with a QC module
(black cylinder below the LCD screen) for rapid analysis of the HP solution prior to
administering in human subjects.
Figure reprinted from Jan Henrik Ardenkjær-Larsen. On the present and
future of dissolution-DNP. Journal of Magnetic Resonance 2016; 264: 3-12.
doi:10.1016/j.jmr.2016.01.015. with permission from Elsevier (License Number
4865461302802).
tically. The QC module also contains an infrared temperature probe and a compact
NMR system for verifying the sample temperature and percent polarization. Due to
the possibility of the HP product failing any of these various QC checks — or of fluid
path failure — multiple fluid lines are typically loaded into the SPINlab for human
studies. In the event of a dissolution or QC failure, a second dissolution can be at-
tempted within minutes using a backup fluid path.
Upon dissolution of the DNP sample, the HP signal decays with at a rate deter-
mined by the T1 time constant of the 13C labeled molecule in the liquid state. This
spin-lattice decay of the HP 13C signal limits the time available for imaging to within
a few minutes of dissolution. For studies in human subjects, the QC process entails
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an unavoidable added delay — typically around 30 to 60 seconds — between dissolu-
tion and HP signal readout during which some polarization loss occurs. Due to these
constraints, the dDNP system must be installed in close proximity to the NMR or
MRI systems on which the HP agent will be used. An interesting possibility is to per-
form the polarization and dissolution process in separate systems. If the frozen DNP
sample is extracted from the polarizer and kept in a high magnetic field and low tem-
perature environment, polarization loss would occur at a rate determined by the 13C
T1 in the solid state. This solid state T1 is typically two orders of magnitude longer
than the corresponding liquid state T1, which could allow sufficient time for transport
to a dissolution system that is sited distant from the polarizer but near a magnet pre-
pared for HP signal readout. However, maintaining such a low temperature outside of
the DNP system is extremely difficult, and the separation of the DNP and dissolution
systems is currently an active area of research [64].
3.2 Hyperpolarized Imaging Agents
The capability to produce HP 13C labeled solutions has opened new avenues of chemi-
cal interrogation in biology and medicine. Unlike the most commonly used gadolinium
and iodine based contrast agents, the HP agent is itself a signal source for imaging that
decays over time. In these respects, HP MRI is very similar to rapid dynamic imaging
of short-lived radionuclides that is sometimes performed in nuclear medicine. With
current instrumentation, nuclear medicine imaging is sensitive to concentrations of
radionuclide with a lower bound in the nanomolar to picomolar range [65] while HP
agents must be present in millimolar or micromolar concentrations for reliable de-
tection [66]. Although inferior in sensitivity, HP MRI can provide real-time insight
into biochemical reactions in ways not possible via positron or single photon emis-
sion imaging. The emission events that underlie all nuclear medicine modalities oc-
cur with equal probability over time in all nuclei of a given radioisotope. A nuclear
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medicine study cannot directly distinguish the chemical environment of a radionu-
clide and seeks to quantify the delivery, uptake and/or retention of the radionuclide in
a tissue of interest to provide insight into a physiological or biochemical process solely
through the number of nuclear decay events occurring within an imaging volume over
time.
While in nuclear medicine imaging discrete decay events are registered in detectors
with precisely known positions and mapped to image space, the signal source in MR
imaging is the net magnetization induced in a subject by an external magnetic field.
As discussed in the previous chapter, this magnetization arises from a population of
NMR active nuclei due to an excess of nuclei with spin state aligned parallel rather
than anti-parallel to the direction of an external magnetic field. Although the signal
detected in MRI always represents a large population of nuclei, sub-populations can be
distinguished by virtue of slight differences in the local magnetic field they experience.
As outlined in section 2.4, an important determinant of this local magnetic field is
the configuration of the orbital electrons surrounding a given nucleus, which shield
the nucleus from external fields and impart a resonant frequency shift specific to the
chemical environment of the nuclear magnetic moment. NMR active nuclei present
in different molecules therefore experience unique chemical shifts, and through this
effect the precursors and products of specific chemical reactions can be distinguished.
To date, dozens of HP compounds have been developed as agents for imaging and
basic science research. Many of these agents have demonstrated the capacity to resolve
metabolism, perfusion and other biological functions. There are several practical con-
siderations that affect the usability of a HP 13C agent. Perhaps the most important
property of these agents from a physics perspective is a slow spin-lattice relaxation
rate of the 13C spin system, which impacts both the ability to generate large nuclear
spin polarization fractions in the solid state and the lifetime of the HP signal following
dissolution. When bound directly to other NMR-active nuclei such as 1H, heteronu-
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clear coupling (J-coupling) of the spin system results in splitting of the 13C resonance
lines and rapid spin-lattice relaxation. For molecules in which undesirable heteronu-
clear coupling is unavoidable, isomeric substitution of the 13C-bound nuclei (e.g. 2H
for 1H, or 15N for 14N) can significantly prolong the lifetime of the HP signals of in-
terest [67]. From a biological perspective, HP agents for metabolic applications must
undergo rapid cellular uptake and chemical conversion in order to allow observation
of the metabolic products of interest during the HP signal lifetime.
As is the case for radiopharmaceutical imaging agents, the chemical structure of
a HP agent impacts the evolution of the imaging signals it creates in vivo and re-
lates directly to the biological process that is to be measured. The dDNP agents that
have been most thoroughly investigated are 13C labeled on carbonyl functional groups,
which consist of a carbon-oxygen double bond. Carbonyl groups are present in a wide
variety of organic molecules that are the reactive substrates for many vital enzymes
that exploit the asymmetric electronegativity of the carbon-oxygen bond. Measure-
ment of the molecular flux through these enzymatic reactions in tissue is typically the
putative goal of MR studies using metabolic HP agents. Several HP agents have also
been developed for the disparate purpose of measuring perfusion and capillary per-
meability in vivo. In these agents, a molecular structure that is biochemically stable
in tissue within the time frame of the HP measurement is needed, and the dispersion
of the HP agent in tissue is controlled in part by the ability of the agent to cross cap-
illary and other biological membranes. Apart from measurement of metabolism and
perfusion, a third class of HP agents is intended for probing the chemical conditions of
the extracellular space. These agents undergo chemical reactions that are dependent
on the pH of the interstitium or the extracellular presence of enzymes which indicate
necrotic cell death. In the following subsections, the HP agents most relevant to this
work are introduced.
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[1-13C]Pyruvate
[1-13C]Pyruvate is by far the most widely studied HP 13C agent, to the extent that in
some contexts the term hyperpolarized MRI is considered synonymous with imaging
studies of this agent. Pyruvate sits at a crucial branching point in cellular metabolism,
and has several biochemical properties that make it an excellent HP imaging agent
[68–70]. Pyruvate is the conjugate base of pyruvic acid, a simple organic acid consist-
ing of carboxyl, ketone and methyl groups. Neat pyruvic acid glasses when brought to
cryogenic temperatures, and therefore a high purity solution for DNP can be formu-
lated with just the addition of a suitable radical. Most often pyruvic acid for dDNP
is 13C labeled in the C-1 position, which corresponds to the carboxyl carbon. The 13C
MR signal that results is characterized by a long T1 of around 60 seconds in solu-
tion, which allows time for QC and transport into a nearby MRI system before the HP
signal fully relaxes [63]. The metabolic products observed following administration
of [1-13C]pyruvate in living systems create well-resolved spectral signals spanning a
chemical shift range of around 24 ppm, with a minimum separation for neighboring
peaks of around 2.5 ppm. At typical MRI field strengths this 13C spectrum is suffi-
ciently compact for broadband excitation and has adequate chemical shift separation
for resolving the distinct metabolic signals in vivo. These spectral characteristics per-
mit the application of a variety of different strategies for imaging the chemical shifts
of interest.
Pyruvate is generated as the final product of glycolysis, the series of enzymatic re-
actions that produce the primary intermediate of cellular energy, adenosine triphos-
phate (ATP). When administered intravenously, pyruvate rapidly distributes in tissue
and is transported into cells through monocarboxylate transporters (MCTs). In the
cytosol, pyruvate may be reduced to form lactate, transaminated to form alanine, or
transported into the mitochondrion where it may provide carbon fuel to the tricar-
boxylic acid (TCA) cycle in two ways: via decarboxylation to form acetyl coenzyme
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A (acetyl-CoA) or via carboxylation to form oxaloacetate. Importantly, each of these
reactions proceeds rapidly, and the corresponding enzymatic fluxes can therefore be
measured via MR studies of HP pyruvate in vivo.
The overall reaction of glycolysis breaks the six carbon monosaccharide, glucose,
into two pyruvate molecules, producing two ATP molecules and two reduced nicoti-
namide adenine dinucleotide (NADH) cofactors. In most eukaryotic cells pyruvate is
typically present in very low concentrations since it is quickly shuttled into various di-
vergent biochemical pathways. For differentiated mammalian cells in an adequately
oxygenated environment, pyruvate is primarily imported into the mitochondria where
it is decarboxylated in a reaction that produces one NADH cofactor, donates the ke-
tone and methyl carbons to the TCA cycle through acetyl-CoA, and releases the car-
boxyl group as carbon dioxide (CO2). The TCA cycle is a series of reactions that oc-
cur within the mitochondrial matrix, involving the progressive oxidation of carboxylic
acids and reduction of enzymatic cofactors. These reduced cofactors, which include
NADH, in turn participate in redox reactions with enzymatic complexes embedded in
the mitochondrial inner membrane that pump hydrogen cations (H+) out of the mito-
chondrial matrix into the intermembrane space. The resulting electrochemical gra-
dient across the inner membrane powers ATP production via H+ transport down the
gradient through the transmembrane enzyme ATP synthase. This process is called
oxidative phosphorylation, since it depends on the presence of molecular oxygen (O2)
as the terminal electron acceptor in the chain of redox reactions driving H+ transport.
The theoretical energetic yield of glycolysis, the TCA cycle and oxidative phosphoryla-
tion for a single glucose molecule is about 30 ATP, compared to the net production of
2 ATP through glycolysis alone [71].
In the absence of the oxygen necessary to drive oxidative phosphorylation, cells
must rely on the relatively inefficient ATP yield of glycolysis to meet their energetic
needs. Under these hypoxic conditions, the oxidized form of nicotinamide adenine din-
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Figure 3.2: HP [1-13C]pyruvate can undergo rapid enzymatic conversion in vivo via lac-
tate dehydrogenase (LDH), alanine transaminase (ALT) or pyruvate dehydrogenase
(PDH), as shown in diagram (A). In the decarboxylation reaction catalyzed by mito-
chondrial PDH, the 13C label is released in carbon dioxide (CO2), which is in rapid
enzymatic equilibrium with bicarbonate (HCO3-) via carbonic anhydrase (CA). Mea-
surement of H13CO3- therefore provides a marker of pyruvate flux into the TCA cycle.
These metabolites are shown in a HP 13C NMR spectrum of an isolated perfused rat
heart (B). Apart from the metabolites labeled in this figure, HP pyruvate hydrate is
observed at approximately 179 ppm. This signal arises from the spontaneous and re-
versible formation of a geminal diol via hydration of the ketone carbon of pyruvate.
Pyruvate hydrate is not metabolically active, and therefore represents a signal that
may need to be accounted for in spectroscopic imaging so as to not interfere with the
metabolic signals of interest. Because of the dramatic increase in sensitivity provided
by dDNP, metabolic signals can be measured over time with temporal resolution on
the order of 1 second (C). Note that the data shown in this figure were acquired from
an isolated organ in a high resolution NMR system, which provides spectroscopic de-
tail difficult to match in intact animals. In particular, 13CO2 is typically not observed
for HP [1-13C]pyruvate experiments in vivo, due in part to rapid T1 relaxation of this
resonance.
Figure reprinted from John Kurhanewicz, et al. Analysis of Cancer Metabolism by
Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research. Neo-
plasia 2011; 13(2): 81-97. doi:10.1593/neo.101102. with permission from Elsevier
(License Number 4865081446783).
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ucleotide (NAD+) needed to drive glycolysis would become rapidly depleted if it could
not be restored from NADH. Without oxidative phosphorylation, pyruvate flux into the
TCA cycle provides no energetic output, and the reoxidation of NADH to NAD+ neces-
sary to sustain continual glycolytic flux can be realized in mammalian cells through
reduction of pyruvate to lactate. This redox reaction is catalyzed by the enzyme lac-
tate dehydrogenase (LDH), which exists in several different isoforms with differing
propensities for the forward and reverse reactions. The lactate produced in cells rely-
ing on anaerobic metabolism can be exported by MCTs, then subsequently imported
through MCTs into cells with adequate oxygen to metabolize lactate aerobically [72].
It is important to note that none of these metabolic pathways occur in isolation. Within
any eukaryotic cell, the flux of carbon skeletons through glycolysis and the TCA cycle
are linked at various points to many other biochemical pathways through which or-
ganic molecules may be siphoned off for anabolic synthesis or donated for catabolic
ATP production. In order to provide the necessary biomolecular building blocks, tis-
sues undergoing rapid cellular growth therefore exhibit a high rate of glycolytic flux,
a metabolic phenotype that is similar to tissues lacking adequate oxygen for oxidative
phosphorylation [73].
This observation that proliferative tissues always rely predominantly on glycoly-
sis, even in aerobic conditions, was first observed by Otto Warburg in the 1950s and is
called the Warburg effect. Warburg further hypothesized that this effect resulted from
dysfunctional mitochondria and was the etiological cause of malignant cellular growth
[74], however these malignancies are now understood to result from genetic mutations.
The Warburg effect has profound implications in the context of cancer metabolism. A
variety of therapeutic strategies have been devised targeting the aberrant metabolism
of cancer[75], and diagnostic evaluation of neoplastic growths on the basis of their
metabolic activity is routinely performed using 18F-fluorodeoxyglucose (FDG). FDG is
a radiolabeled glucose analog that is imported into the cell in the same manner as glu-
3.2. Hyperpolarized Imaging Agents 47
cose, but undergoes only the initial reaction of glycolysis and becomes trapped in the
cytosol [65]. Highly glycolytic tissues thereby accumulate a large amount of the 18F
radionuclide, which can be detected with exquisite sensitivity by positron emission to-
mographic (PET) imaging. However, due to the lack of insight into chemical endpoints,
a strong FDG-PET imaging signal is open to multiple interpretations. Such signals
could be observed, for example, in tissues that rely on glycolysis due to hypoxic condi-
tions rather than abnormal proliferation. Furthermore, FDG-PET measurements are
not well suited for detecting neoplastic growths in tissues with high baseline glycolytic
activity, such as the brain, or in physical proximity to organs with large FDG-PET sig-
nals, such as in the prostate which neighbors the urinary bladder. HP pyruvate can
therefore provide an alternative method of metabolic imaging in these cases, as well
as metabolic measurements that are complimentary to FDG-PET in other organs [9].
To date, HP pyruvate imaging has been investigated in the human prostate, heart,
brain, liver, kidney, pancreas, breast and breast [10], in addition to a plethora of
preclinical disease models in small and large animals. The rapid readout of tissue
metabolic state provided by pyruvate imaging is particularly well suited to detecting
early responses to treatments, as has been demonstrated in androgen ablation ther-
apy for patients with prostate cancer [13] and will be shown for a glycolytic inhibitor in
a mouse model of brain cancer at the end of this chapter [76]. The capability to detect
non-response early and adjust the treatment a patient receives is of great importance
in oncology, both in terms of limiting unnecessary toxicities and providing optimal
personalized therapies. HP pyruvate imaging may also be very useful for guidance of
certain biopsies in a manner that spares damage to healthy tissue, e.g. in the prostate.
It should be noted that the dosage of intravenous HP pyruvate used for these mea-
surements is quite large compared to the trace amounts of metabolic agents used
in FDG-PET and other nuclear medicine studies. This is an unavoidable aspect of
these imaging studies due to the inherently low sensitivity of MR signals, even for HP
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agents. At very high doses, there is a risk that the enzymatic transport or metabolic
conversion reactions probed by the HP agent could be saturated as the agent concen-
tration reaches its peak level in tissues of interest. The precise level at which these
saturation effects occur is difficult to predict, and is highly dependent on the organ un-
der investigation. Partial saturation of the conversion of HP pyruvate to lactate and
bicarbonate has been observed in the heart, liver and kidney of healthy rats at injected
doses as low as 0.1 mmol/kg [66]. This pyruvate dosage matches that typically used
in patient studies [77–79], however these saturation effects could be expected to have
less impact in human subjects due to the longer injection times and much slower blood
velocities. Additionally, the observation of saturation effects in healthy tissues cannot
be generalized to HP pyruvate measurements in cancer, where increased expression
of MCT and LDH permit a much greater rate of pyruvate uptake and turnover [72].
13C Urea
Among HP agents used for measurement of tissue perfusion, urea is unique in that
it is an endogenous molecule with a well-established safety profile in vivo. Pharma-
ceutical grade 13C urea with near unity isotopic enrichment is widely available and
inexpensive due in part to its use in routine breath tests for common bacterial infec-
tions of the gastrointestinal tract [80]. Urea is present in mammalian blood and tissue
at millimolar concentrations as a waste product of amino acid metabolism and is fil-
tered out of the blood by the kidneys to form the primary solute constituent of urine.
Large doses of urea have historically been administered intravenously as a treatment
for hyponatremia without any adverse effects [81].
13C urea was the first dDNP agent used in Ardenkjær-Larsen’s 2003 publication in-
troducing the technique [56], and was utilized for angiographic imaging in rodents in
the same year [82]. Since it undergoes no significant chemical transformations in vivo,
HP 13C urea imaging provides a measurement of blood flow and capillary permeabil-
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ity. Compared to the most commonly used gadolinium chelate MRI contrast agents,
urea is a much smaller molecule and could therefore be expected to more accurately
represent the delivery of vital molecular components of blood such as O2 and glucose.
Additionally, the safety profile of urea is favorable for intravenous administration in
patients for whom gadolinium agents are contraindicated, e.g. due to compromised
kidney function. In fact, direct measurement of HP 13C urea transport in the kidney
is a particular interesting application, which can provide spatially resolved and quan-
titative assessments of glomerular filtration rate [83]. In most tissues with continuous
capillaries, HP 13C urea has not been observed to collect outside of the capillary space
in a significant amount [84]. However, solid tumors, as well as certain organs such as
the liver and spleen, are characterized by highly permeable capillaries through which
urea passes easily. Measurement of tissue perfusion and capillary permeability for
these tissues using HP 13C urea will be discussed further in the next chapter.
[2-13C]Pyruvate
As discussed in section 3.2, the 13C-labeled carboxyl carbon of [1-13C]pyruvate is most
often released as 13CO2 when this substrate enters the TCA cycle. The resulting gen-
eration of H13CO3- is sometimes detectable in vivo, providing a measurement of flux
through PDH into the TCA cycle. However, this H13CO3- signal provides no insight into
the ultimate chemical fate of the ketone and methyl carbons of pyruvate. For this pur-
pose an alternate isotopologue, [2-13C]pyruvic acid, may be used. With the 13C label
residing on the ketone carbon, HP signals can be observed from metabolites associ-
ated with the TCA cycle, such as citrate, glutamate, acetoacetate and acetylcarnitine,
in addition to lactate and alanine [85]. This provides much greater detail into oxida-
tive metabolism than can be had through [1-13C]pyruvate, however the many chemical
shifts that result span a very wide frequency range of >150 ppm, with some of these
peaks resonating at close to the same frequency. These spectroscopic features, as well
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as the relatively rapid T1 relaxation of many of these signals, make imaging of these
metabolites very difficult in vivo. Nevertheless, the broader insight into metabolism
provided by [2-13C]pyruvate may prove very useful for improving our understanding
of metabolism in healthy and diseased tissues. The application of [2-13C]pyruvate is
particularly interesting in tissues that rely on oxidative metabolism such as the heart
[86] and the brain, with a recently published work demonstrating imaging and spec-
troscopic data from the brains of healthy human volunteers [87].
[1,4-13C]Fumarate
Fumarate is a four-carbon TCA cycle intermediate with a safety profile compatible
with intravenous administration. The two carboxyl carbons on either end of the molecule
are chemically equivalent and may be polarized by DNP in the conjugate acid form,
[1,4-13C]fumaric acid. The HP fumarate that is obtained following dissolution dis-
tributes rapidly in tissue when introduced into the blood, however cellular uptake of
fumarate is slow relative to the lifetime of the HP signal. Endogenous fumarate is
converted to malate in a hydration reaction catalyzed by the enzyme fumarase, which
occurs both in the cytosol and the mitochondrion. Due to the slow rate of fumarate
transport across the plasma membrane, interaction of HP fumarate with fumarase
mainly occurs when this membrane is compromised due to necrotic cell death. The
observation of fumarase activity on HP fumarate in tumors has been shown to be a
sensitive indicator of necrosis occurring with 24 to 72 hours after chemotherapeutic
[88] and anti-angiogenic treatment [89]. Similar to the metabolic measurements ob-
tained through [1-13C]pyruvate, necrosis imaging via [1,4-13C]fumarate has great po-
tential to evaluate early treatment efficacy in cancer, permitting changes to ineffective
therapies much sooner than would be possible with established diagnostic methods.
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[2-13C]Dihydroxyacetone
Dihydroxyacetone (DHA) is a three-carbon ketose, the phosphate ester of which is an
important glycolytic intermediate (dihydroxyacetone phosphate). Like [2-13C]pyruvate,
HP [2-13C]dihydroxyacetone has been demonstrated to probe multiple biochemical
pathways in preclinical studies, and there are similar challenges associated with imag-
ing the diverse metabolic signals generated by DHA metabolism in vivo due to their
wide chemical shifts and rapid relaxation rates [90]. In addition to measurements of
glycolytic and TCA cycle activity, HP DHA has been used to measure hepatic glyc-
erol metabolism and gluconeogenesis in isolated perfused mouse livers [91]. This
study of isolated livers demonstrated that several of the downstream metabolic sig-
nals are sensitive to nutritional state. The spectroscopic measurement of specific
metabolic products of HP DHA has more recently been shown to reflect acute changes
in metabolism induced by infusion of fructose (but not glucose) in the livers of fasted
rats [92]. In chapter 6, we will present the results of experiments measuring the hep-
atic metabolism of HP DHA in vivo, including the previously unreported observation
of ketogenic metabolism.
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3.3 Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic
Inhibition in a Mouse Model of Glioma
Introduction
Glioblastoma (GBM) is the most commonly diagnosed primary brain tumor in adults,
and has a very poor prognosis with deterioration of cognitive function and quality of
life [93]. Despite considerable research investment in improved therapies, the median
survival remains 12-14 months [94]. Treatment for GBM and most other gliomas typ-
ically consists of surgical resection with subsequent chemotherapy and radiotherapy.
During and after therapy, most patients undergo serial MRI scans to assess treat-
ment response and disease recurrence. Enhancement in T1-weighted post-contrast
images remains the reference standard for identification of high grade malignant tis-
sue in the brain, but these images often depict misleading changes in patients receiv-
ing chemotherapy, radiotherapy or symptomatic therapies [93]. There is therefore a
need for imaging methods capable of accurately and quantitatively measuring treat-
ment response in glioma. As new therapies for glioma are developed to exploit the
propensity of tumors to utilize glycolysis [95], new imaging approaches for monitoring
the efficacy of these treatments will also be needed.
Dissolution dynamic nuclear polarization (dDNP) can enhance the MR signal of [1-
13C]pyruvate more than 10,000-fold compared to thermal equilibrium, enabling new
insights into tumor metabolism in vivo [56]. Previous work in rodent models of glioma
has demonstrated that hyperpolarized (HP) [1-13C]pyruvate MR spectroscopy detects
decreases in tumor lactate metabolism caused by radiation [14] and chemotherapies
[16, 18, 19, 96] within a few days of treatment. Recent advances in HP 13C MRI have
This subchapter is reproduced with permission from Keith A Michel, Rafal Zieliński, Christopher
M Walker, Lucia Le Roux, Waldemar Priebe, James A Bankson, Dawid Schellingerhout. Hyperpolar-
ized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology
2019; 293(1): 168-173. doi:10.1148/radiol.2019182919.
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enabled the real-time measurement of glycolytic metabolism in patients with brain
cancer [78, 97]. The hypothesis of the present study was that dynamic HP MR spec-
troscopy could be used in mouse models to detect an acute decrease in aerobic glycolysis
following treatment with the glycolytic inhibitor, WP1122. Our purpose was to investi-
gate the feasibility of using HP [1-13C]pyruvate to probe the metabolic state of glioma
as a direct readout of treatment effect with a glycolytic inhibitor.
Materials and Methods
Animals
Thirteen 6-10 weeks old female Athymic Nude mice were implanted with 5 x 105
U87MG cells (ATCC, Manassas, VA) expressing firefly luciferase. We administered
cells by stereotactic injection into the right caudate nucleus through a transcranial
plastic guide screw [98]. Five female Athymic Nude mice served as experimental
healthy controls. We monitored initial tumor engraftment and early growth by bio-
luminescent imaging. Our Institutional Animal Care and Use Committee approved
all animal experiment procedures, which were performed between October 2016 and
March 2017.
Experimental Drug
2-Deoxy-D-glucose (2-DG) is a widely studied inhibitor of glycolysis; however, its ther-
apeutic use in vivo is limited due to its rapid metabolism. WP1122 (3,6-di-O-acetyl-
2-deoxy-D-glucose) is a prodrug of 2-DG that improves biodistribution and prolongs
exposure. Increased levels of 2-DG were observed in the murine brain when WP1122
was used instead of 2-DG itself [99]. WP1122 was therefore expected to lead to en-
hanced metabolic effects in brain tumors.
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MRI protocol
Approximately 40 days after implantation, mice were scanned using a 7 T small an-
imal MRI system running ParaVision 6 and equipped with BGA-12SHP gradients
and a 72 mm inner diameter 1H/13C volume resonator (Bruker Biospin MRI, Billerica,
MA). We anesthetized each mouse using 2% isoflurane, inserted a catheter into the
tail vein and secured the animal on the MRI bed with a heating pad and respiratory
monitoring pillow. A 20 mm mini-flex coil (Rapid MR International, Columbus, OH)
placed on the cranium was used for HP 13C signal reception. [1-13C]pyruvate was hy-
perpolarized using a HyperSense dDNP system (Oxford Instruments, Abingdon, UK),
as described previously [11, 15]. 200 µL of 80 mM HP [1-13C]pyruvate (approximately
60 mg/kg) was injected into the tail vein during dynamic 13C MR spectroscopy. We per-
formed baseline scans around 40 days post-implantation and repeated all MRI scans
the following day, 30 minutes after administering 2.5 g/kg WP1122 by oral gavage.
In each MRI session the following scans were acquired: axial and coronal T2-weight-
ed RARE (TE/TR = 57/3000 ms), axial T1-weighted RARE (TE/TR = 7.25/1000 ms), and
axial slice-selective dynamic 13C spectroscopy (90 repetitions, TR = 2000 ms, 20° exci-
tation angle, 10 mm slice, 2048 complex points over 5000 Hz spectral width). The
slice position for 13C MR spectroscopy was centered on the tumor as visualized in
T2-weighted coronal images. T1-weighted axial images were acquired before and af-
ter administration of 0.2 mmol/kg of gadopentetate dimeglumine (Magnevist, Bayer
Healthcare, Berlin, Germany) via tail vein catheter.
Histology
After the final imaging session, the brain of each mouse was immediately excised,
frozen over liquid nitrogen and stored at -80°C. Frozen sections were cut at a thickness
of 10 µm, fixed with 4% paraformaldehyde and stained with hematoxylin and eosin
(H&E) using standard methods [100].
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Data Analysis
Dynamic HP 13C spectra were analyzed using code written in-house in MATLAB R2016a
(Mathworks, Natick, MA). Spectral peaks corresponding to [1-13C]pyruvate and [1-
13C]lactate were fit with Lorentzian line shapes to obtain relative metabolite ampli-
tudes for each time point. A simple precursor-product model of HP lactate production
was fit to these metabolite time curves in order to estimate the rate of pyruvate to
lactate conversion in tissue, kPL. This model-based analysis assumes that all of the
observed HP pyruvate is in contact with the enzymes that mediate conversion to lac-
tate. A longitudinal relaxation time constant of 30 s was assumed for [1-13C]lactate in
vivo [101]. In addition, the normalized lactate ratio (nLac) was calculated as the sum
of lactate amplitudes over time divided by the sum of pyruvate and lactate amplitudes
over time.
Statistical Analysis
We made statistical comparisons of lactate metrics between mice bearing gliomas and
healthy controls using the one-tailed Wilcoxon rank-sum test. Using the one-tailed
Wilcoxon signed-rank test, we compared paired measurements obtained on subse-
quent days from the same mice before and after WP1122 treatment. We used built-in
functions in MATLAB R2016a to perform all statistical tests. Differences were con-
sidered statistically significant for p-values less than 0.05.
Results
Representative MRI and H&E-stained images from a mouse bearing an orthotopic
glioma are shown in Figure 3.3. Tumor volumes of 53.76 ± 36.01 mm3 were observed
on T2-weighted imaging at the second (final) scan time point. H&E staining confirmed
the presence of tumors in the right deep gray matter of mice implanted with U87MG
cells.
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Figure 3.3: Representative images of a mouse with orthotopic glioma. Large well-
vascularized tumors were present 40 days after implantation of U87MG glioma cells,
as shown by the hyperintense lesion on T2-weighted (A) and gadolinium-enhanced T1-
weighted (B) axial MRI. The corresponding slice from hematoxylin and eosin (H&E)
staining (C) demonstrates a large infiltrative tumor centered in the right sided deep
gray matter.
Figure 3.4A shows the typical location of the 1 cm slice used for 13C MR spec-
troscopy. Representative 13C dynamic spectra from the animal depicted in Figure 3.4A
are shown as waterfall plots in Figure 3.4B and 3.4C. HP pyruvate and lactate signals
were observed with high SNR following the pyruvate injection, and a reduction in the
relative amount of lactate was usually seen after treatment with WP1122 for mice
with orthotopic gliomas.
Table 3.1 and Figure 3.5 summarize the quantification of HP lactate from dynamic
13C spectroscopy. At baseline, mice with orthotopic gliomas exhibited mean kPL and
nLac values of 0.027 sec-1 and 0.28, respectively, which were greater than those ob-
served in healthy control mice (mean kPL=0.011 sec-1, nLac=0.16; p=0.001 for both).
Following treatment with the glycolytic inhibitor WP1122, a decrease in kPL and nLac
was observed for mice bearing glioma (from baseline mean kPL=0.027 sec-1 to post-
treatment kPL=0.018 sec-1, p=0.01; from baseline mean nLac=0.28 to post-treatment
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Figure 3.4: Representative hyperpolarized (HP) MR spectroscopic data from a mouse
with orthotopic glioma. Pulse-acquire spectroscopy was performed for a 1 cm axial
slice centered on the tumor as visualized in coronal T2-weighted images (A) during in-
jection of HP pyruvate through a tail-vein catheter. Waterfall plots show more lactate
signal at baseline (B) than 30 minutes after treatment with the glycolytic inhibitor
WP1122 (C).
nLac=0.22, p=0.01). In healthy control mice, no decrease in HP lactate was seen after
WP1122 treatment (baseline mean kPL=0.011 sec-1 to post-treatment kPL=0.017 sec-1,
p=0.91; baseline mean nLac=0.16 to post-treatment nLac=0.21, p=0.84).
Discussion
In this study, we investigated the use of dynamic HP pyruvate MR spectroscopy to
assess changes in tumor metabolism after administration of the glycolytic inhibitor
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Figure 3.5: Apparent conversion rate of pyruvate to lactate (kPL, left) and lactate sig-
nal normalized to sum of lactate and pyruvate signals (nLac, right) were greater in
mice bearing orthotopic glioma than in healthy controls (p=0.001 for both kPL and
nLac, One-tailed Wilcoxon rank-sum test). After treatment with the glycolytic in-
hibitor WP1122, a decrease in lactate was observed for mice with glioma (p=0.01 for
kPL both and nLac, One-tailed paired Wilcoxon signed-rank test), but no significant
decrease was seen for healthy controls (p=0.91 for kPL and p=0.84 for nLac, One-tailed
paired Wilcoxon signed-rank test). *, statistical significance with p<0.05; **, statisti-




kPL (sec-1) nLac kPL (sec-1) nLac
Brain with
Glioma (n=13) 0.027 ± 0.015 0.28 ± 0.094 0.018 ± 0.0077 0.22 ± 0.069
Healthy
Brain (n=5) 0.011 ± 0.0029 0.16 ± 0.031 0.017 ± 0.0046 0.21 ± 0.041
Table 3.1: Hyperpolarized lactate quantifications in diseased and healthy mouse
brains. Values are given as means ± standard deviations of the apparent rate con-
stants of pyruvate to lactate conversion (kPL) and normalized lactate (nLac), the time-
integrated ratio of lactate to combined pyruvate and lactate.
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WP1122. HP lactate production was quantified at baseline and 30 minutes after oral
administration of WP1122 in mice with gliomas and healthy controls, as both an ap-
parent reaction rate (kPL) and normalized lactate ratio (nLac). Both metrics of HP
lactate decreased after WP1122 treatment in mice with gliomas, while no significant
change was seen in healthy controls.
HP [1-13C]pyruvate MR spectroscopy delivers valuable insights into tumor metabol-
ism that are not directly obtainable through other imaging modalities. Lactate dehy-
drogenase A (LDHA) expression is upregulated in glioma cells, resulting in higher
lactate production and maintaining the cellular reducing potential necessary to sus-
tain glycolysis [102, 103]. Measurements of HP pyruvate and lactate specifically probe
the reaction catalyzed by LDHA, delivering information on enzymatic flux that can
assess treatment response and disease state in various models of malignant disease
[11]. Importantly, the changes in cancer metabolism detectable by HP pyruvate MR
spectroscopy reflect the real-time glycolytic state of tumors and precede morpholog-
ical changes seen in T2-weighted imaging [15, 18]. This technology therefore holds
great promise to provide early indications of response in glioma [17] following treat-
ment with radiation [14], chemotherapy [16, 19] and immunotherapy. HP pyruvate
MR spectroscopy measurements are particularly well-suited for assessing the effects
of emerging metabolic therapies for glioma, such as inhibitors of glycolytic and mito-
chondrial metabolism [104].
Recent studies have established the safety and feasibility of HP pyruvate MR in pa-
tients with brain tumors, and demonstrated higher lactate production in some tumors
relative to background brain metabolism [78, 97]. The unique information offered by
HP pyruvate imaging complements the advanced MRI methods often used in patients
with brain tumors. Proton spectroscopy and recently introduced methods for deu-
terium spectroscopy [105] can interrogate the quantities of key metabolites including
lactate in normal and diseased tissues; however, these are steady-state measurements
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of metabolite pool size and not the direct assessments of enzymatic flux provided by
HP MR spectroscopy. The combination of more established advanced MRI methods
and real-time metabolic imaging with HP MR spectroscopic imaging could offer dras-
tic improvements in evaluating glioma disease state and treatment response.
While providing detailed dynamic spectroscopic data, the acquisition method used
in our study is limited by its lack of spatial resolution. Our data were acquired from the
region of the brain containing the tumor, weighted by proximity to the 13C surface coil
used for HP signal reception. The tumors interrogated in our study were implanted
at a relatively superficial depth. They were large and well-vascularized at the time
of HP pyruvate MR spectroscopy. Therefore, despite the contribution of signal from
normal tissue, the significant decrease in lactate in tumor-bearing animals following
administration of WP1122 was greater than the modest increase in lactate observed
in normal matched brain anatomy (Figure 3.5) and can be considered representative
of tumor metabolism. While there are imaging methods capable of discriminating
HP signals in tumors from other tissues, the application of these methods would in-
cur diminished signal to noise ratio relative to slice selective spectroscopy [106], and
with relatively coarse spatial resolution, would not eliminate partial volume averag-
ing effects. Because of the heterogeneous distribution of tissues measured with HP
MR spectroscopy and the non-uniform signal reception profile, we chose to quantify
our data with a precursor-product model and an area under the curve method. More
complicated and physiologically accurate models account for the transport of HP sub-
strates between metabolically distinct physical compartments; however, they require
estimation of a vascular input function and fitting of several additional unknown pa-
rameters [11]. The quantification methods used here are a compromise given the lim-
ited HP signal available from the small quantity of pyruvate that can be administered
in a mouse.
Further research is needed to establish the utility of HP pyruvate measurements
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in clinical decision making for patients with glioma. HP pyruvate imaging in human
subjects has resolved differences in metabolism between regions within healthy brains
[107], between normal brain tissue and tumor, and between subregions of large tumors
[78, 97]. More thorough clinical trials must be completed to quantify the variability
in standardized acquisition and analysis methods before this technology can guide
treatment decisions.
Our results show that hyperpolarized MR spectroscopy with [1-13C]pyruvate can
assess both baseline metabolism and treatment effects, with promise for rapidly and
non-invasively quantifying the metabolic state of gliomas.
Chapter 4
Quantitative Analysis of Hyperpolarized MRI
Hyperpolarized agents must be delivered quickly to the tissues of interest in order to
interrogate tissue function within their signal lifetime. In most cases, HP 13C agents
are introduced directly to the blood via intravenous injection, although direct intra-
arterial infusion may enhance agent delivery and allow HP studies of certain organs
with reduced doses or short T1 agents [108]. Once in the blood stream, the HP agent
traverses the vascular tree and extravasates from downstream capillary blood into
tissue. In studies using HP agents intended to measure perfusion and permeability,
these rates of blood flow and capillary extravasation are of primary interest. For stud-
ies of metabolism, the rate of HP agent delivery through the blood controls the amount
of agent available to undergo metabolic conversion in tissues of interest. Accounting
for the delivery of the administered agent by vascular perfusion is therefore a critical
factor in nearly any HP study.
In this chapter, methods for quantification of HP agent perfusion and metabolism
are presented. First, a pharmacokinetic model of vascular delivery and extravasa-
tion for HP agents is presented. We then address metabolism of HP agents in ex-
tended physiological models and in quantification approaches that are not model-
based. Lastly, we present novel strategies for dynamic acquisition and analysis of
HP perfusion data that are designed to improve measures of vascular volume and
permeability.
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4.1 Perfusion Modeling
The amount of HP agent delivered to a given tissue is determined by the quantity of
agent injected and the rate of delivery via perfusion. When administered to a rodent, a
HP solution is typically delivered via tail vein injection and passes through the inferior
vena cava into the right atrium of the heart. In human patients injection into a vein
in the arm delivers the agent to the heart via the superior vena cava. After being
delivered to the right atrium, the HP agent passes through the right ventricle, lungs,
left atrium and left ventricle before entering systemic circulation. While the delivery
of HP agent to the tip of a thin catheter placed in a vein could be modeled as a boxcar
function, at each step of the vascular tree resistance to flow and mixing of the HP
solution with blood smooths out the leading edge of the HP agent bolus.
VIF Modeling
When the bolus reaches the smaller arteries and arterioles supplying most tissues of
the body it can often be modeled accurately as a gamma variate function. The gamma
variate function is often used in nuclear medicine and dynamic susceptibility contrast
(DSC) MRI, and can be derived mathematically from the dilution of a short-lived tracer
via flow through multiple well-mixed chambers [109]. This function can be expressed
as a function of time and two shape parameters (α, β) as
y(t) = Atα exp (−t/β) (4.1)
In this form, A scales the output while α and β affect both the shape and scale of
the function, making least-squares curve fitting difficult. A simplified version of the
gamma variate function derived by Madsen is parameterized instead by three param-















Fitting equation 4.2 to data is much simpler since the three parameters are not coupled
in any way. The parameter α controls the shape of the curve, with a larger value
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corresponding to a sharper rise and fall. Both tmax and ymax are easily estimated for
data with reasonable SNR and affect only the location and magnitude of the function
maximum. If a voxel is present in an HP imaging dataset with predominantly vascular
signal that could reasonably be expected to represent the delivery of the agent to the
tissue of interest, equation 4.2 can be fit to the time curve of this voxel to obtain the
shape of the vascular input function (VIF).1 Alternatives for VIF measurement for HP
MRI that have been demonstrated in small animals include monitoring the signal in
the left ventricle of the heart [11] and invasive sampling of blood via arterial cannula
[111], however these techniques are more difficult to implement in clinical imaging.
In either form, the gamma variate function describes the concentration of HP agent
in blood delivered to the capillaries of a tissue of interest over time. The inner surface
of most capillaries consist of a continuous tube of endothelial cells held together in a
single layer by tight junctions. Oxygen, glucose and small molecules can pass through
the small gaps present at the intercellular junctions of the endothelium, and can also
be transported across endothelial cells in pinocytic vesicles [71]. The outer surface
of this endothelial cell layer is anchored to a thin basement membrane of connective
tissue that supports the blood vessel. In the brain the outer surface of this basement
membrane is tightly surrounded by the processes of astrocytes, forming the blood-
brain barrier that restricts the transport of blood solutes into the brain parenchyma.
Certain organs such as kidney and small intestine have fenestrated capillaries with
an intact basement membrane, and are more permeable due to small openings in
the endothelial cell lining of the vessels. Sinusoidal capillaries present in the liver,
bone marrow and spleen are even more permeable than fenestrated capillaries due to
larger openings in both the endothelium and basement membrane. In tumors, disreg-
ulation of angiogenic signaling results in leaky capillaries that are malformed with a
non-uniform and porous endothelial lining that is not tightly bound to its basement
membrane [112, 113]. Unlike capillaries in most normal tissues, tumor vasculature is
1In many contexts the function describing the rate of imaging contrast agent delivery to tissue is
called the arterial input function, or AIF. Throughout this chapter we use the more general term, VIF,
in part to reflect its use in organs with partially non-arterial blood supply (e.g. liver) and in small
animal studies for which the low temporal resolution of dynamic HP imaging relative to the rate of
blood circulation permits VIF measurement in either arterial or venous blood.
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also characterized by vessels that are tortuous and highly variable in size, shape and
branching. As a result, solid tumors often possess regions that are strongly perfused
in addition to regions that are hypoxic or even necrotic due to inadequate perfusion.
Two-Compartment Perfusion Model
For the purposes of pharmacokinetic modeling, a volume of tissue is assumed to con-
tain one or more compartments in which the concentration of HP agent is uniform.
Most widely used HP agents are small molecules that are present natively in tissue
and can pass out of the capillaries into the interstitial space. The rate of this imaging
agent extravasation into the extravascular extracellular space depends on the perme-
ability of the capillaries, the biochemical properties of the HP agent and the concen-
tration gradient across the capillary membrane. For this discussion of perfusion and
permeability modeling, we will consider the case of a HP agent that is biochemically
inert and predominantly extracellular within the time frame of the imaging experi-
ment such as 13C urea [84].
In the case of such an extracellular HP perfusion agent, a convenient pharmacoki-
netic model for describing signal evolution in vivo consists of two physical compart-
ments corresponding to the vascular and extravascular spaces with volume fractions
vb and ve, respectively. The total HP magnetization within a voxel will be proportional
to the sum of the HP agent concentrations in each compartment weighted by their
corresponding volume fractions.
Mz(t) ∝ vbCb(t) + veCe(t) (4.3)
The VIF is denoted by Cb(t)2. As discussed above, the VIF describing the delivery of a
HP perfusion agent to tissue capillaries can be modeled using a gamma variate func-
tion fit to a voxel containing predominantly vascular signal. This approach estimates
the shape of the VIF, however its absolute magnitude requires special consideration
in HP MRI due to partial volume effects and non-uniformities in RF excitation and
signal reception sensitivity. The currently available RF coil hardware is limited in
2Throughout this chapter, quantities describing concentrations of HP agent are shown in bold font.
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its anatomical coverage, especially for body imaging on clinical MRI systems. As a
result, corrections for non-uniformities in coil receptivity (B−1 ) and often transmission
field (B+1 ) may be necessary to obtain a suitable estimate of the VIF amplitude. Al-
ternatively, the VIF amplitude may be fit to signal time curves alongside the other
pharmacokinetic model parameters, however this approach can suffer from coupling
of VIF amplitude with other parameters, particularly vb.
For a brief duration of time in which the HP agent is present in tissue capillaries,
molecular flux of the agent across the capillary endothelium can be described using
Fick’s first law. This law states that the molar flux (J , e.g. with units of mol/m2/s) in
a given direction is equal to the inverse of the concentration gradient in that direction




Concretely, this law means that in the absence of any other effects stochastic molecular
motion will act to reduce the concentration gradient of a solute. If we model the barrier
separating our two compartments as a single thin membrane of thickness ∆x, the
concentration within this membrane space can be assumed to change linearly as a
function of position.




The molecular flux through the membrane can then be calculated by combining equa-





(Ce −Cb) = P (Cb −Ce) (4.6)
Here we have collected the constants into a single coefficient, P , which describes the
permeability of the capillary barrier. This permeability coefficient takes a value (e.g.
with units of m/s) that depends on the characteristics of the capillaries, the imaging
agent and the flow driving the agent through the vascular space.
Since the VIF is assumed to describe Cb(t), we must formulate an equation describ-
ing how the imaging agent concentration in the extravascular compartment changes
with time. If the change in extravascular concentration can be assumed to occur only
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due to the transcapillary flux described in the previous paragraph, it will have a value
equal to this flux (e.g. units of mol/m2/s) times the capillary surface area (A, e.g. with
units of m2) divided by the total volume of the extravascular compartment within the













Here, we have collected all constants apart from the extravascular volume fraction into
the volume transfer rate constant kve. This quantity effectively describes the propor-
tion of imaging agent in the vascular space that is transferred into the extravascular
space in a given amount of time (e.g. with units of 1/s), and therefore is considered to
quantify the permeability of the microvasculature to the imaging agent.
Equation 4.7 is very similar to the differential equation that forms the basis of
the extended Tofts model [114], which is widely used for analysis of dynamic contrast
enhancement (DCE) MRI data. In DCE analysis, the concentration of a gadolinium
chelate contrast agent measured from rapidly acquired T1-weighted images is used
to obtain volume fraction and capillary permeability measures from a pharmacoki-
netic model similar to our two-compartment model for HP perfusion agents. However,
an important distinction is that the gadolinium chelate collects in tissue over time,
accelerating spin-lattice relaxation in proportion to its concentration. HP agents, in
contrast, provide a direct source of signal with an intensity proportional to the amount
of HP agent in the imaging volume.
We have so far only considered the change in the extravascular concentration of a
HP perfusion agent within a brief period of time during which T1 decay of the HP agent

















Cb − αCe (4.8)
Here we have collected the effects of reverse capillary transport (i.e. washout, which
is assumed to occur at the same rate as forward capillary transport) and spin-lattice
decay into a single coefficient, α. Note that T1 in this equation refers to the apparent
relaxation rate of the HP signal in vivo, which is usually significantly shorter than
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the T1 measured in solution and may include loss mechanisms other than true spin-
lattice relaxation. Just as in the solution for the extended Tofts model, a solution to the
differential equation 4.8 can be found by applying an integrating factor that describes
the system response to a unit impulse of HP agent in the blood.








By combination of equations 4.3 and 4.9, an equation describing the longitudinal
HP magnetization over time can be derived. However, such an equation is not very
useful in itself sinceMz is not observed directly. We must therefore consider the effects
of RF excitation on the HP spin system. If the method used for HP imaging is a spoiled
gradient echo pulse sequence, the transverse magnetization (Mxy) can be assumed to
be negligible when each RF pulse is applied. Most often this assumption is met by
using a repetition time for dynamic HP 13C imaging that is of sufficient length that a
negligible amount of transverse magnetization persists across excitations of the same
set of isochromats due to spin-spin decay (TR > 5T ∗2 ). However, even if this is not the
case, spoiled gradient echo sequences vary the phase of RF excitation pulses and the
amplitude of gradient pulses applied after data readout to suppress the contribution of
coherent transverse signal from separate excitation cycles [35]. Even when spectrally
selective pulses of relatively long duration (e.g. 10 ms or more) are used, this RF pulse
duration is typically very short relative to the repetition time that elapses between
pulses. In this case, the effect of the RF pulse can be modeled as an instantaneous
redistribution of the longitudinal and transverse net magnetic moment.
Mz(TRF ) = Mz(Tpre) cos (θ) (4.10)
Here, Tpre and TRF denote the moments in time at the start and end of the RF pulse,
respectively. The longitudinal HP magnetization in the TR interval elapsed between
pulses (TRF ≤ t ≤ TRF + TR) can be described as:





The observed imaging signal is derived from the transverse magnetization, with some
amount of spin-spin relaxation occurring during the encoding of k-space and/or chem-
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ical shift.
Mxy(TRF + TE) = Mz(Tpre) sin (θ)e
−TE
T∗2 (4.12)
Equations 4.10-4.12 describe the behavior of the HP magnetization in the context
of our two-compartment model of perfusion agent behavior in tissue. The evolution
of longitudinal magnetization is modeled continuously in the TR interval using equa-
tion 4.11, with RF losses depicted discretely in time using equation 4.10. The volume
transfer coefficient and the compartment volume fractions constitute the three pri-
mary physiological parameters (kve, vb, ve) describing the evolution of the HP signal.
Given values for these model parameters, as well as a VIF and the effective relax-
ation time constants, simulated signal curves can be generated for any set of spoiled
gradient echo imaging parameters.
As noted in the first paragraph of this section, we are assuming our imaging agent
does not enter extravascular cells during the HP signal lifetime. It will therefore be
the case that the two individual compartment volumes account for less than the total
imaging volume (vb + ve < 1). Since the compartment volume fractions most often
are unknown parameters that must be estimated via least squares curve fitting ap-
proaches, it is useful to parameterize these quantities in a way that is more amenable
to this process. This can be done by describing the extravascular volume into which
the HP agent can distribute as a fraction of the total extravascular volume.
ve = vei(1− vb) (4.13)
An optimization strategy that constrains both vb and vei to within the open interval
(0, 1) can therefore provide realistic volume fractions. Apart from the cellular space,
the large voxel sizes generally used in HP MRI often include subvolumes that are in-
accessible to any HP agent, such as air or cortical bone, which effectively reduces ve.
Therefore, even for agents that readily diffuse into cells, this manner of formulating
the volume fractions may be useful. However, the fitting of the model parameter vei in
many cases would not be expected to provide much value in itself and is only necessary
to precisely account for the concentration of the HP agent within the extravascular
compartment. Since estimation of an additional parameter in data fitting increases
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the variance of all parameters derived from this process, a common simplifying as-
sumption when applying two-compartment modeling to real data is that ve = 1 − vb
(i.e. vei = 1).
In addition to the sub-compartmentalization of the extravascular space, the cellu-
lar component of blood also deserves consideration. By far the largest cellular com-
ponent of whole blood is made up of erythrocytes, which typically constitute a volume
fraction (hematocrit) of 40-50% [71]. If the HP agent is not able to enter this volume,
the modeled vascular concentration must be corrected for the fact that this signal rep-
resents the imaging agent in the plasma volume rather than the whole blood volume,
as is done for modeling of DCE-MRI data with gadolinium chelates [114]. In the case of
urea [115] and pyruvate [116], the erythrocyte plasma membrane contains transport
proteins that quickly equilibrate the intracellular and blood plasma concentrations,
and we therefore assume a uniform HP agent concentration in the blood for the model
formulated in this section. However other HP agents might need special consideration
in this regard, particularly if pharmacokinetic modeling is applied to HP images in sit-
uations where the imaging subject may have an abnormally high or low hematocrit.
4.2 Metabolic Quantification of HP Pyruvate
The two-compartment pharmacokinetic model derived in the previous section is useful
for modeling the evolution of HP signal in tissue for perfusion agents such as urea, but
requires modification to account for the behavior of biochemically active HP agents.
Such agents are primarily metabolized by enzymes present within cells, so the labeled
molecules must additionally cross the plasma membrane and in some cases the mito-
chondrial membrane before the downstream metabolites of interest are observed. A
more physiologically accurate three compartment model of vascular delivery, uptake
and conversion would therefore account for each of these processes with rate constants
for capillary transport, plasma membrane transport and enzymatic activity [11]. How-
ever, the use of such intricate pharmacokinetic models in the analysis of HP MRI data
can be very difficult. In general, a pharmacokinetic model with more parameters may
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more faithfully represent the physiological processes of interest, however when ap-
plied to a given dataset a larger number of unknowns results in greater variances for
the parameter estimates derived from the data fitting process. Compared to our two-
compartment perfusion model, a three-compartment metabolic model entails — at the
very least — an additional volume fraction, an additional volume transfer coefficient
and a rate constant describing intracellular metabolic conversion. Further complexity
could be added if disparate cellular populations in the tissue microenvironment are
taken into account.
These considerations highlight the fundamental motivation of pharmacokinetic
modeling, which is to provide quantitative metrics of tissue function that are useful
in practice. While such metrics ideally represent a physiological process as accurately
as possible, the high complexity of biological systems will always require trade-offs to
strike a balance between physiological accuracy and practical utility. The more pa-
rameters a pharmacokinetic model contains, the greater the difficulty in applying it
to a given dataset due to both increased computational overhead and greater uncer-
tainty in the derived model parameters. With this in mind, it is worth reviewing anal-
ysis methods — including those that are not model-based — to evaluate their practical
utility in the context of the most widely used metabolic HP agent, [1-13C]pyruvate.
Non Model-Based Metabolic Analysis
The simplest analysis method for a metabolic agent is a ratiometric approach. Unlike
the HP perfusion agent described in the previous section, metabolic agents like HP
pyruvate generate multiple chemical signals in vivo, and their relative amplitudes
can be easily quantified. This method was shown in practice in section 3.3 for HP
pyruvate measurements as the normalized lactate ratio (nLac). nLac was calculated
for this application as the ratio of the time-integrated area under the curve (AUC) for
lactate to the sum of pyruvate and lactate AUCs.
nLac =
AUC lac
AUCpyr + AUC lac
(4.14)
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In many cases, alternate ratiometric analyses are performed by calculating the time-
integrated ratio of lactate relative to pyruvate or relative to the sum of all HP 13C
signals. For experiments with very limited temporal and spatial resolution, these ra-
tiometric approaches may be the only viable method of data quantification. Due to the
simplicity of these precursor-product ratios in quantifying the activity of metabolic
agents, they are used in some form in nearly all studies of HP pyruvate metabolism.
Even when data is intended for more complex pharmacokinetic analysis, the calcu-
lation of HP signal ratios often serves as a first-pass evaluation for the purpose of
obtaining preliminary descriptive statistics. If the effects of HP agent delivery to
the compartment in which chemical conversion takes place are consistent, ratiometric
quantities can be shown to be directly proportional to the apparent rate constants of
chemical conversion obtained via pharmacokinetic modeling [117].
The AUC ratios described above quantify the relative lactate signal accumulated
over time. Another class of non model-based methods for HP pyruvate data anal-
ysis depends on measurements made at the precise moment of peak lactate signal.
The lactate signal amplitude at this moment of peak intensity — typically normalized
to the pyruvate signal at the same time point — is often used as a non model-based
quantity descriptive of chemical conversion. Such a peak normalized lactate metric de-
rived from time-resolved imaging was employed in a recently published clinical study
of prostate cancer and shown to correlate with Gleason score [79]. Alternatively, the
time elapsed from onset of HP lactate signal to the moment of peak lactate intensity
has been proposed for model-free analysis, and was shown to correlate well with phar-
macokinetic analysis in vitro and in tumor models in rodents [118]. These maximum
lactate analyses are generally extremely sensitive to the precise timing of data acqui-
sition. In some cases, the start of the imaging acquisition is delayed relative to the
injection time in order to attempt to acquire images with greater lactate SNR due to
the lesser RF depletion of the HP pyruvate precursor before it can undergo metabolic
conversion. In this context, bolus tracking of HP pyruvate using very low excitation an-
gle RF pulses can help ensure efficient use of the HP magnetization and reproducible
timing of lactate imaging [119–121]. However, when initiating imaging after the HP
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bolus arrival the initial portion of the HP signal time curves is lost, which complicates
the use of pharmacokinetic modeling approaches for these data. Even when sampling
of the peak lactate signal is timed perfectly, the lactate signal may have very poor
SNR due to either the experimental setup or the physiological state of the tissue of
interest. These types of peak lactate metrics are therefore better suited for studies in
which strong HP lactate signal is always present.
Pharmacokinetic Metabolic Modeling
While the non model-based methods described in the preceding paragraphs permit
rapid and straightforward quantification of HP pyruvate metabolism, they are sensi-
tive to differences in physiological state apart from true variation in enzymatic flux.
For example, the same nLac value could be measured in tissue with high LDH activity
and low uptake of pyruvate as in tissue with low LDH flux and high pyruvate uptake.
In such situations, pharmacokinetic modeling of HP signals provides a method for
distinguishing tissues on the basis of the shape of the HP pyruvate and lactate signal
curves over time, differentiating the disparate effects of HP agent uptake and chemi-
cal conversion. The solutions to these pharmacokinetic models permit the calculation
of HP pyruvate and lactate signals at any point in time, allowing the non model-based
metrics described above to be derived even for datasets for which they cannot be cal-
culated directly. The primary drawbacks of pharmacokinetic analysis relative to non
model-based analyses are that it can entail a computationally intensive optimization
process, and that it often requires manual user input that could lead to erroneous
results (e.g. the definition of a VIF or of assumed model parameters).
A set of three pharmacokinetic models describing HP pyruvate uptake and con-
version to lactate was introduced by Bankson, et al. in 2015, and evaluated in the
context of constrained reconstruction of HP images for small animal models of cancer
[11]. These models account for two chemical pools of HP magnetization representing
pyruvate and lactate, with chemical interconversion described as a first order process.
In all cases, the parameter kPL is the forward rate constant of this chemical conver-
sion and is nominally indicative of metabolic flux. Typically the reverse reaction rate,
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kLP , is assumed to be negligible, which is often a reasonable assumption given the
low concentration of endogenous pyruvate in tissue relative to lactate. For the sake
of generalizability, kLP terms are included in the equations presented here. Losses
of longitudinal HP magnetization for pyruvate and lactate occur continuously in time
with individual relaxation time constants that are often given as estimated values
and held constant during the data fitting process. The VIF driving signal evolution in
these models is assumed to deliver only HP pyruvate (not HP lactate) to the imaging
volume, and the observed HP lactate is therefore assumed to be the product of local
metabolism. This assumption is consistent with measurements of HP pyruvate ac-
tivity in whole blood [122] and with spin-echo measurement of HP labeling in small
animal models [123], which indicate negligible vascular HP lactate signal.
In the following paragraphs each of these three models will be described. In the
original presentation of these models, losses due to RF pulses were modeled as con-
tinuous Mz decay at a rate of 1−cos θTR . However, in the equations below RF excitation
effects are excluded since they can be modeled more accurately for spoiled gradient
echo imaging as discrete losses with equations 4.10 and 4.12. Differential equations
are provided for each model below, and account for the remaining effects occurring in
the delay between RF pulses, as in equation 4.11 (TRF ≤ t ≤ TRF + TR, where TRF
denotes the moment at the end of the RF pulse).
One-Compartment Model In the simplest pharmacokinetic model, all pyruvate is
assumed to be in direct exchange with lactate in a single spatial compartment. The
differential equations describing inter-pulse evolution of HP longitudinal magnetiza-




















where P and L denote pyruvate and lactate, respectively. With a single spatial com-
partment, there is no explicitly defined VIF in this model. For in vivo data, the pyru-
vate and lactate signal curves are typically fit with the observed pyruvate signal serv-
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Figure 4.1: Candidate kinetic models to describe dynamic signal evolution of HP pyru-
vate and lactate in vivo. All models include two chemical pools and one spatial com-
partment (A), two spatial compartments (intravascular and extravascular) with ex-
change limited to extravascular region (B), or three spatial compartments (intravas-
cular, extravascular/extracellular, and intracellular) with exchange restricted to the
intracellular region (C).
Figure reprinted from James A Bankson, et al. Kinetic Modeling and Constrained Re-
construction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging
of Tumors. Cancer Res 2015; 75(22): 4708-15. doi:10.1158/0008-5472.CAN-15-0171.
with permission from the American Academy for Cancer Research (License Number
4856260086289).
ing as the “effective VIF” driving the model. In this approach, the first row of equation
4.15 is disregarded since changes in P are not considered to occur due to chemical
conversion and T1 relaxation. Instead, the empirically measured HP pyruvate signal
is assumed to reflect P and drive the production of HP lactate subject to kPL and T1,L.
Some authors [124] refer to this type of analysis as “inputless fitting”. For in vitro
experiments, however, it is common for HP pyruvate to be injected rapidly into a cell
suspension that is prepared in an enclosed chamber, e.g. a NMR tube. In such studies,
the evolution of HP signals within a closed system can be modeled using the full set
of differential equations 4.15.
Compared to a fully time-integrated lactate ratio, the kPL derived from this model
offers only marginal added benefits as a summary metric of metabolism. One such
benefit is the ability to model relaxation losses of lactate, which are not accounted
for systematically in non model-based metrics. The one-compartment kPL is sensitive
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to variations in pyruvate delivery to the site of metabolism much in the same way as
nLac. If pyruvate is highly compartmentalized in tissue, for example due to slow trans-
port across the capillary membranes, a one-compartment model may not be able to
accurately represent the observed HP signal curves. Nevertheless, one-compartment
modeling can be useful for in vivo HP experiments that provide dynamic spectroscopic
information but lack the spatial resolution necessary to resolve signal arising from
blood vessels and tissues (e.g. the slice-selective spectroscopy used in section 3.3).
Due to the difficulty of measuring a VIF from the relatively large voxels typically used
for clinical HP imaging, one-compartment modeling is the most widespread method
for obtaining a kPL value in human studies to date [107, 124–126].
Two-Compartment Model The second model for HP pyruvate metabolism accounts
for signals arising in vascular and extravascular spaces, similar to the two-compartment
perfusion model derived in section 4.1. As in that case, signal evolution of the ad-
ministered HP agent in the vascular compartment is described by the VIF (Pb). If
that perfusion model is expanded to include pyruvate and lactate pools with chemi-
cal exchange and T1 losses occurring in the extravascular space, the following set of



























This two-compartment model provides a more realistic depiction of the physiological
process of HP agent delivery than the one-compartment model. However, if chemi-
cal conversion of HP pyruvate occurs only in the intracellular space the implicit as-
sumption underlying this two-compartment model is that pyruvate transit across the
plasma membrane is rapid. When a significant HP pyruvate concentration gradient
is present between the extravascular/extracellular and intracellular spaces, this as-
sumption is violated.
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Three-Compartment Model The third model presented by Bankson, et al. ac-
counts for HP pyruvate and lactate within three spatial compartments corresponding
to the vascular, extravascular/extracellular and intracellular spaces. Chemical ex-
change of HP agent occurs only in the intracellular compartment, resulting in the



































































Here the subscripts ee and ic indicate extravascular/extracellular and intracellular sig-
nals or volume fractions, respectively. As in equation 4.16, kve denotes the rate of capil-
lary transport, while the additional volume transfer coefficient, kec, describes the rate
of HP agent transport across the cellular membrane.
When applying these models to in vivo imaging data for estimation of kPL (where
kLP is assumed to be negligible), the one-, two- and three-compartment models require
some combination of joint estimation or prior assumption for 1, 5 and 7 additional
physiological parameters, respectively. Given this added complexity, the capability of
established 1H MRI methods to inform the quantitative analysis of HP 13C MRI data
is an important consideration. For example, anatomical and angiographic imaging
can provide guidance on the spatial localization of HP signals and on the estimation
of VIFs, while DCE and diffusion weighted imaging could provide spatially resolved
estimation of tissue volume fractions and volume transfer rates. HP pyruvate imag-
ing therefore provides a metabolic measurement that is particularly well suited as an
addition to multiparametric MRI examinations that are being conducted with increas-
ing frequency in diagnosing and staging pathologies of the brain [127], prostate [128],
liver [129], kidney [130] and breast [131], as well as other organs.
The utility of a given quantitative analysis approach in HP MRI is very depen-
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dent on the HP acquisition methods used, the biology of interest and the availability
of prior information to inform this analysis. In the constrained reconstruction ap-
proach implemented by Bankson, et al. a HP pyruvate VIF was measured from the
left ventricle of the rodent heart and image reconstruction was constrained to map
HP signals to voxels containing tissue as visualized in anatomic 1H imaging. Com-
paring the three pharmacokinetic models through these imaging methods, Bankson
et al. demonstrated that the two-compartment model provided the optimal balance
of quantitative accuracy and model complexity [11]. In a more recent study, Larson,
et al. evaluated several lactate quantification approaches in the context of clinical
HP MRI of the prostate using a variable excitation angle dynamic compressed sens-
ing imaging method [124]. This study compared a simple ratiometric analysis, a time
to peak lactate metric, the “inputless fitting” one-compartment kPL described above
(4.2), and kPL from an extended one-compartment model that includes an unobserved
VIF driving accumulation of HP pyruvate in the imaging volume. Unlike the multi-
compartment models described here, this extended one-compartment model allows for
only unidirectional flux of HP pyruvate from the VIF into the imaging voxel. In this
application three VIF parameters describing the time of HP agent arrival, duration
of the VIF and rate constant of HP pyruvate transfer from the unobserved VIF to the
single modeled compartment were fit, with the prior assumption of a fixed VIF shape.
Assessing these analysis methods for their clinical data and in numerical simulation,
the authors found that the time to peak lactate performed very poorly at the SNRs
observed in vivo. Additionally, both the ratiometric lactate measurement and the “in-
putless fitting” kPL were more reproducible than the extended one-compartment kPL
that was obtained with joint estimation of VIF parameters.
Overall, quantification and modeling of HP MRI data remains a very active area of
research, and results of these analyses must always be considered in the context of the
specific biological and technical factors for a given study. Recent data reported in pre-
clinical HP pyruvate imaging of colon and breast cancer [132] and in clinical imaging
of the prostate [79] indicate that HP lactate production positively correlates with the
expression of the MCT proteins responsible for plasma membrane transport. These
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observations suggest that the cellular uptake of pyruvate is an important factor deter-
mining the evolution of HP signals in vivo, however the rate of such transport is only
accounted for systematically in more complex kinetic modeling approaches that are dif-
ficult to implement in practice. Additionally, in vitro experiments have demonstrated
that T1 relaxation of carboxyl 13C signals occurs much more rapidly in the cytosol than
in the extracellular space [133]. While these studies and others are indicative of effects
impacting the apparent chemical exchange rate of pyruvate and lactate in vivo, further
work is required to quantitatively evaluate the impacts of plasma membrane transport
and shorter intracellular T1 relaxation time constants on kPL values obtained through
specific pharmacokinetic models.
4.3 Numerical Simulations of HP Perfusion Imaging
Pharmacokinetic models of HP agent behavior in vivo allow for both the quantitative
analysis of experimental data and the numerical simulation of these experiments. In
the latter application, synthetic HP signal curves are generated for a set of model and
acquisition parameters, and the model is subsequently fit to this synthetic data with
the addition of random noise. By repeating this curve fitting process with fresh noise
multiple times, the accuracy and reproducibility of different sets of acquisition param-
eters can be compared for any set of physiological model parameters. These simulation
experiments can therefore guide the selection of optimal imaging strategies by sam-
pling the overall pharmacokinetic model and acquisition parameter space in a much
more complete fashion than is possible through empirical experimentation. Addition-
ally, by applying intentional errors to parameters that are assumed to be known in the
curve fitting process, the sensitivity of the pharmacokinetic model to such inaccuracies
may be systematically evaluated [101].
Numerical simulations of HP urea signal evolution were performed using the phar-
macokinetic model derived in section 4.1. In these simulations, a conventional spoiled
gradient-echo imaging approach was compared to two alternative approaches described
in the following subsections. The ranges of acquisition parameter, standardized peak
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Figure 4.2: Least-squares curve fitting metrics for simulated HP perfusion imaging
with conventional spoiled gradient-echo acquisitions. All curve fitting was performed
in MATLAB using the lsqcurvefit function with a trust region reflective algorithm.
The normalized 2-norm of the residuals provides a metric of the overall numerical
accuracy of the fit. The exit flag indicates the termination condition of the fitting algo-
rithm, with values of 2 and 3 indicating that the change in the fit parameters and in
the residuals were less than a specified tolerance, respectively. For consistent simu-
lation results, the optimization function should reach similar termination conditions
indicative of the solver approaching a convergent solution, as shown here.












Value [0.1:0.1:4] [2:2:90] [5:5:50] 0.09 0.3 0.02 20
Table 4.1: Parameter ranges used for simulation of proposed HP urea acquisition
methods are shown. Values in square brackets indicate ranges tested, using MAT-
LAB notation (low : increment : high). Parameter values for kve and vb correspond to
those observed in two-compartment modeling of HP pyruvate [101], while the T1 cor-
responds to the apparent in vivo relaxation time for HP urea [82]. Tissue cellularity
can vary tremendously in tumors and other organs, but an extravascular distribution
volume fraction (vei) was chosen based on DCE-MRI results from small animal tumor
models. The peak SNR value corresponds to the variance of added Gaussian noise
that would result in that SNR for a TR of 2 s and θ of 20 deg. Note that this value does
not translate to the specified peak SNR for other TR and θ values due to variations
in HP signal amplitude, however it provides a consistent parameterization of noise
across these simulations.
SNR, and ground-truth physiological parameter values tested are provided in table
4.1. A gamma-variate VIF shape corresponding to that previously measured from HP
urea imaging in mice was used, with α = 0.8 and tmax = 8.1 s (equation 4.2). Although
many noise levels were assessed, in the figures summarizing these experiments only
the results for the noise variance that corresponds to a peak SNR of 20 in a 2 s TR, 20
deg excitation angle conventional imaging experiment are shown. At each combina-
tion of parameter values, fitting of synthetic signal curves was repeated 100 times with
fresh noise using a nonlinear least-squares trust region reflective algorithm [134]. The
accuracy of fitted pharmacokinetic model parameters was summarized as the mean
error relative to the true values, and their reproducibility was assessed through the
coefficient of variation. The figures in the following subsections comparing acquisi-
tion strategy performance on the basis of these numerical simulations present con-
tour plots summarizing the mean relative error and coefficient of variation across the
ranges of repetition times and excitation angles listed in table 4.1. Simulated acqui-
sitions that result in better accuracy and reproducibility are always shown as lighter
colors for each estimated physiological parameter.
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Perfusion Imaging with Periodic Saturation
Large excitation angles are usually avoided in dynamic imaging of HP substrates to
avoid saturating the non-renewable signal, however their careful use offer interesting
possibilities particularly in the context of perfusion imaging. When a perfect 90 de-
gree pulse is applied, the HP longitudinal magnetization in the imaging volume can
be assumed to be fully expunged. If such a saturation pulse is applied at an appropri-
ate time and location in the middle of a dynamic HP experiment, some HP signal will
subsequently reperfuse the RF saturated tissue volume by vascular delivery. In the
context of pharmacokinetic modeling of the HP signal, this greatly reduces the fun-
damental uncertainty which this analysis approach seeks to address — namely, the
compartmentalization of the imaging agent in vivo.
We assessed a HP imaging technique in which 90 degree saturation pulses are used
every 10 seconds in the dynamic imaging experiment, as depicted in figure 4.3. We
refer to this method as “periodic saturation” and the contour plots that follow com-
pare such a technique to the equivalent “conventional” spoiled gradient-echo imaging
method with matching TR and excitation angle (at imaging time points not correspond-
ing to the application of a saturation pulse).
From the results of these simulations, it is evident that the periodic application
of saturation pulses primarily improves measurement of vascular volume (vb, figure
4.5), at the expense of somewhat degraded performance in estimating capillary per-
meability (kve, figure 4.4) and particularly poor accuracy and reproducibility of the
tissue distribution volume (vei, figure 4.6). In order to obtain estimates of kve and vei
with reasonable accuracy and precision using the periodic saturation method, these
simulations indicate that a narrow range of short repetition times and low excitation
angles must be used. Depending on the capabilities of the MRI system on which the
HP experiments are conducted, the use of such short TR values and low excitation
angles may not be feasible due to gradient limitations or due to the SNR levels at-
tainable with a given RF coil setup. Because of these practical considerations, it may
not always be appropriate to assess the comparative performance of these imaging
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Figure 4.3: Simulated Mz and Mxy time curves are shown for HP urea imaging using
conventional (left) and periodically saturated (right) spoiled gradient-echo imaging.
Time curves of the conventional imaging method are plotted as dashed lines on the
right. The application of 90 degree excitations every 10 seconds expunges HP magne-
tization in the extravascular space, allowing perfusion and permeability effects to be
assessed multiple times in a single experiment through reperfusion of the HP agent.
However, this comes at a cost as the overall HP signal is reduced significantly through
the application of 90 degree pulses, as illustrated by these Mz and Mxy curves of the
periodic saturation method relative to conventional imaging.
techniques on the basis of a single optimal set of acquisition parameters. In general,
a more comprehensive comparison of the ranges of acquisition parameter values that
provide accurate and reproducible results would be indicated to evaluate the utility of
proposed imaging strategies in the face of these technical factors.
The results summarized in figures 4.4-4.6 agree with an intuitive interpretation
of the periodic saturation method in the context of our two-compartment pharmacoki-
netic model. Through a 90 degree excitation that removes all previously accrued ex-
travascular signal, the observed HP time intensity curves contain a greater proportion
of vascular signal and therefore can provide less insight into the transit of HP agent
into the tissue space. While these results may be true for the physiological parameters
and specific model used in these simulations, the use of 90 degree pulses for dynamic
HP imaging could prove useful in other contexts. When using modeling approaches
that seek to quantify the rate of blood flow and vascular transit time in tissue (such as
the modeling that is typically employed in DSC-MRI), the use of saturation pulses for
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Figure 4.4: Accuracy and reproducibility plots of kve fits for conventional and peri-
odically saturated acquisitions. Relative to the equivalent conventional metronomic
acquisitions, the application of a 90 degree saturation pulse every 10 seconds gener-
ally tends to increase both the absolute mean error and the coefficient of variation for
estimates of capillary permeability obtained through our pharmacokinetic model of
HP perfusion agent signal evolution.
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Figure 4.5: Accuracy and reproducibility plots of vb fits for conventional and periodi-
cally saturated acquisitions. Relative to the equivalent conventional metronomic ac-
quisitions, the application of a 90 degree saturation pulse every 10 seconds generally
tends to decrease both the absolute mean error and the coefficient of variation for
estimates of vascular volume obtained through our pharmacokinetic model of HP per-
fusion agent signal evolution.
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Figure 4.6: Accuracy and reproducibility plots of vei fits for conventional and peri-
odically saturated acquisitions. Relative to the equivalent conventional metronomic
acquisitions, the application of a 90 degree saturation pulse every 10 seconds greatly
increases both the absolute mean error and the coefficient of variation for estimates of
extravascular volume obtained through our pharmacokinetic model of HP perfusion
agent signal evolution.
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HP imaging can be of much greater benefit. In these cases, the retention of imaging
agent outside of the vascular volume is not of interest and is in fact an impediment to
kinetic modeling. The exclusive use of 90 degree pulses for dynamic HP imaging was
proposed in the context of this type of perfusion modeling early in the development of
HP MRI, and was referred to as “bolus differentiation” [135]. Additionally, the use of
chemically selective pulses for saturating the biochemical products of metabolic HP
agents has been proposed as a method for improving quantitative modeling of these
substrates in vivo [136, 137].
In any case, extreme care must be taken when saturating HP signals in vivo. Im-
perfections in the calibration of RF power and slice profile effects will result in incom-
plete saturation that could negatively impact quantitative modeling. Slices should
generally be positioned precisely to avoid depleting signal in organs and vessels (not
of primary interest) containing a large proportion of the blood, such as the heart, liver,
lungs or (for coronal and sagittal slices) the abdominal aorta. Because of these many
technical difficulties that impact the application of saturation pulses to dynamic stud-
ies of HP agents, we chose not to further investigate this imaging approach in vivo for
this work.
Perfusion Imaging with Interleaved Motion Suppression
The spatially dependent phase imparted by magnetic gradients can be used to encode
not only position, but also motion. Isochromats that move during a gradient pulse
accrue phase in proportion to their position, but at a rate that changes over time due
to their change in position. These effects are used in several MRI techniques for en-
coding flow and diffusion. For the purpose of diffusion encoding, bipolar gradients are
typically used to rewind positional phase in isochromats that are stationary, providing
a signal in which mobile isochromats are selectively suppressed. Such diffusion en-
coding gradients are characterized by their b-value, which describes the exponential
signal loss of isochromats due to their apparent diffusive motion during the bipolar
gradient [138]. In this context, the MR signal as described in equation 4.12 can be
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rewritten to account for the motion sensitizing gradient.
SMS(t+ TE) ∝Mxy(t+ TE) ≈Mz(t) sin (θ)e
−TE
T∗2 e−bDapp (4.18)
The gradient pulses used for encoding diffusion are traditionally applied in the same
direction on opposite sides of a refocusing pulse for spin echo measurements, or (some-
what less traditionally) multiple pulses for stimulated echo measurements. These
approaches have been used in various preclinical applications for HP imaging and
spectroscopy to measure signal compartmentalization in tissue statically [123, 139],
to quantify changes in the diffusion of HP urea in the liver due to fibrosis [140], and
to separate intra- and extracellular HP signals for in vitro NMR [141].
The apparent diffusive motion sensitized by bipolar gradients encompasses effects
other than true diffusive (i.e. Brownian) motion in vivo. In many tissues the ran-
dom orientation of the microvasculature causes blood flow through this space to be
indistinguishable from rapid diffusive motion [142]. This effect, known as intravoxel
incoherent motion (IVIM), is particularly interesting for pharmacokinetic modeling
of HP MRI since diffusion gradients can be used to selectively suppress signal from
the vascular space. This approach has been used previously in preclinical HP stud-
ies to suppress blood signal in the chambers of the heart [143] and in large abdominal
vessels [144]. Here, we will extend this approach to use bipolar motion sensitizing gra-
dients in an interleaved fashion for every other repetition of the dynamic HP imaging
experiment, as shown in figure 4.7. Compared to the conventional spoiled gradient-
echo imaging method, simulation of these effects requires us to account for apparent
diffusion rates in the vascular and extravascular compartments separately.









In the simulations summarized in figures 4.8-4.10, the apparent diffusion coeffi-
cient describing exponential signal loss in the vascular compartment was assumed
to be 30 times the corresponding diffusion coefficient in the interstitial space. This
factor is based on the apparent diffusion coefficients measured in human abdominal
1H IVIM imaging [145]. A value of 0.75 x 10-3 mm2/s was chosen for this apparent
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Figure 4.7: Simulated Mz and Mxy time curves are shown for HP urea imaging using
conventional (left) and interleaved motion suppressed (right) spoiled gradient-echo
imaging. The Mxy time curve of the conventional imaging method is plotted as a
dashed line on the right. The application of diffusion gradients every other time point
reduces signal predominantly from vascular compartment.
diffusion coefficient in the extravascular/extracellular space, based on previously re-
ported diffusion measurement of HP urea in the healthy rat liver [140]. A b-value
of 30 s/mm2 and duration of 11 ms was modeled for the motion sensitizing gradient,
roughly matching the diffusion weighting and duration of the gradient waveform used
for mouse imaging described in the following section.
These numerical simulations suggest that the selective suppression of moving sig-
nals provides substantial benefits in the context of our two-compartment model of HP
perfusion agent imaging. Unlike RF saturation of the HP system, the use of gradient
encoding has no effect on the finite longitudinal magnetization and therefore preserves
imaging signal for interrogation at subsequent time points. The improvements in the
accuracy and reproducibility of vascular volume measurement (vb, figure 4.9) across
a very wide range of acquisition repetition times and excitation angles are particu-
larly striking. However superior performance in measuring capillary permeability
(kve, figure 4.8) and tissue distribution volume (vei, figure 4.10) is also evident. The
stark benefit for vb measurement matches an intuitive interpretation of this acquisi-
tion strategy. Through the selective suppression of the vascular component of the HP
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Figure 4.8: Accuracy and reproducibility plots of kve fits for conventional and inter-
leaved motion suppressed acquisitions. Relative to the equivalent conventional metro-
nomic acquisitions, the application of motion suppression gradients every other rep-
etition generally tends to decrease both the absolute mean error and the coefficient
of variation for estimates of capillary permeability obtained through our pharmacoki-
netic model of HP perfusion agent signal evolution.
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Figure 4.9: Accuracy and reproducibility plots of vb fits for conventional and inter-
leaved motion suppressed acquisitions. Relative to the equivalent conventional metro-
nomic acquisitions, the application of motion suppression gradients every other rep-
etition generally tends to decrease both the absolute mean error and the coefficient
of variation for estimates of vascular volume obtained through our pharmacokinetic
model of HP perfusion agent signal evolution.
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Figure 4.10: Accuracy and reproducibility plots of vei fits for conventional and inter-
leaved motion suppressed acquisitions. Relative to the equivalent conventional metro-
nomic acquisitions, the application of motion suppression gradients every other repe-
tition generally tends to decrease both the absolute mean error and the coefficient of
variation for estimates of extravascular volume obtained through our pharmacokinetic
model of HP perfusion agent signal evolution.
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signal represented in this volume, we are effectively measuring it more directly by
negative contrast.
Just as in the case of the periodic saturation method, the results summarized in
figures 4.8-4.10 should be considered in the context of the practical considerations of
applying the interleaved motion suppressed imaging method. In general, the com-
paratively wider ranges of acquisition settings that provide accurate and reproducible
measurement of the physiological model parameters could result in much more flex-
ibility in setting up a dynamic HP urea imaging experiment on a given MRI system.
However — unlike the conventional and periodic saturation imaging strategies — the
simulations of the interleaved motion suppression strategy presented in this section
were in many ways customized to the capabilities of our preclinical 7 T MRI system.
Specifically, the simulated b-value and encoding time in dynamic gradient-echo imag-
ing (30 s/mm2 in 11 ms) requires high-power gradients to achieve for 13C imaging, and
would not be realizable on clinical MRI systems. One method for attaining sufficiently
large b-values for suppression of flowing HP signals on clinical hardware is through
the use of double spin-echo imaging [146], however kinetic simulation and modeling
of this imaging approach would also require consideration of the effects of refocusing
pulses on the HP magnetization.
Lastly, it should be noted that all of the numerical simulation results in this sec-
tion are derived from the ground-truth physiological parameters outlined in table 4.1.
These specific values were chosen as representative based on previous measurements
in small animals. However, there is tremendous variation in the actual quantities
these physiological parameters represent in tissue, and evaluations of the proposed
HP urea imaging strategies across the wide ranges of values possible in vivo quickly
become very computationally expensive. There may therefore be many circumstances
in which the conclusions drawn from figures 4.4-4.6 and 4.8-4.10 fail to reflect the
actual utility of in vivo HP urea imaging using the proposed strategies.
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4.4 In Vivo 13C Urea Imaging Experiments
While the simulation results illustrated in figures 4.8-4.10 make a strong claim for the
benefit of using motion suppression gradients to improve measurement of HP agent
uptake, the use of these gradient waveforms in the fashion described here has not
been demonstrated in vivo. Therefore, we chose to test the feasibility of this imaging
approach in small animal experiments. The proposed interleaved motion suppressed
imaging method was applied to small animal HP urea imaging of thyroid tumors and
healthy livers.
When implemented in practice, this motion suppression strategy is sensitive to the
direction of the diffusion encoding gradient. As illustrated in figure 4.11, applying
bipolar gradients in two directions simultaneously results in a rotation of the direc-
tion along which motion is suppressed. If isotropic suppression of diffusive motion is
desired, the gradients sensitizing to motion in each direction must be offset in time.
Figure 4.11: Sensitivity of motion suppression to gradient direction
In the context of diffusion imaging, the amplitude of a magnetic gradient over time
defines a trajectory in q-space, which describes the spatial distribution of diffusion
displacement sensitization [147]. The calculation of q-values in three dimensional
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space is identical to the quantification of k-space, the only difference being that the









In this multi-dimensional context, the b-value describing the weight of diffusion en-










Individual elements of the b-matrix denote the magnitude of motion sensitization in
that direction, with the off-diagonal elements describing sensitivity to motion that
is correlated in two directions. Note that through this calculation, b-values can be
seen to be proportional to γ2. This is an important consideration in the use of motion
sensitizing gradients for 13C MRI. Since the gyromagnetic ratio of 13C is approximately
1/4 of 1H, diffusion gradients designed for 1H imaging will only provide around 1/16
the b-value in 13C imaging.
For nearly isotropic motion sensitization in our small animal studies, we designed
preparation gradients consisting of three bipolar pulses applied to each direction. Si-
nusoidal bipolar gradients were used to reduce the impact of eddy current effects from
fast gradient switching. As a compromise between total preparation gradient dura-
tion and isotropic encoding, the sinusoidal bipolar gradient pulses are offset in time
relative to one another with a 90 degree phase offset (1/4 the duration of each individ-
ual sinusoidal pulse). The single b-value reported for each preparation gradient is the
unique value in the diagonal elements of the b-tensor (equation 4.21), and therefore
do not account for sensitivity to motion correlated in two-directions. These three-
dimensional motion sensitization gradients were played out between HP signal exci-
tation and readout for single-shot EPI-encoded spoiled gradient-echo imaging using
the pulse sequence described in chapter 5.
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Orthotopic Thyroid Tumor
HP urea imaging was performed on a mouse bearing an orthotopic thyroid tumor us-
ing the interleaved motion suppression method. The preparation gradient applied at
every other repetition is shown in figure 4.12. It has a total duration of 11 ms, an
effective isotropic b-value of 28 s/mm2 and a first gradient moment in each direction of
0.37 s/mm. A 4 x 4 cm2 FOV flyback EPI trajectory was used to spatially encode a 16 x
16 image matrix with an echo time of 18.54 ms. A 20 degree pulse was applied with a
1 cm axial slice width and a 1 s repetition time, and an 11 ms delay between excitation
and readout occurred in repetitions without motion suppression to provide consistent
T ∗2 decay in the dynamically acquired images. 200 µL of 100 mM HP 13C urea was
produced using a HyperSense DNP system and injected via tail vein manually, with
the acquisition starting at the moment of dissolution and continuing through the ob-
servable lifetime of the HP signal in vivo. Anesthesia was induced and maintained
through 2-4% isoflurane delivered via nose cone.
Separate time-averaged images of HP urea in this mouse are shown for the time
points acquired with and without motion suppression in figure 4.13, along with a nor-
malized time intensity curve for the ROI outlining the thyroid tumor. As shown in
the image acquired without motion suppression, intense vascular signals originating
from major blood vessels in the neck obscured the ability to assess the signal from
the neighboring tumor. The application of diffusion preparation gradients suppressed
these strong vascular signals, resulting in more uniform HP urea signal within the tu-
mor and decreased signal intensities for the tumor ROI. At certain time points of this
dynamic imaging experiment, the motion suppressed signal in the tumor ROI dropped
below the baseline level present prior to the HP urea injection. While the precise rea-
son for this non-physical level of signal reduction cannot be determined from these
data, we suspect that it was due to bulk respiratory motion occurring during the ap-
plication of preparation and readout gradients. Since the preparation gradients are
designed to sensitize imaging signal to microscopic motion, such macroscopic respi-
ratory motion would have a large effect on these HP images. Additionally, due to the
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Figure 4.12: The diffusion preparation gradient waveform that was used for inter-
leaved motion suppressed imaging of HP urea in a mouse model of orthotopic thyroid
cancer. The gradient waveform is 11 ms in duration with a maximum amplitude of
640 mT/m. At the end of this preparation period, a first gradient moment of 0.37 s/mm
and b-value of 28 s/mm2 is imparted for 13C in each principal direction.
significant partial volume averaging within the tumor ROI, the signal reduction effect
observed in this animal corresponds to a suppression of more than just the microvas-
cular signal within capillaries that is modeled in equation 4.18. Because of both these
artifactual signal reductions and partial volume effects, we chose not to fit a kinetic
model to these data. However, these observations informed our imaging methods when
applying interleaved motion suppression to HP urea imaging of the rat liver.
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Figure 4.13: HP 13C urea imaging of orthotopic thyroid tumor using interleaved mo-
tion suppression gradients. In the time-averaged images shown here, the application
of motion suppression gradients eliminates the strong HP signals arising from large
blood vessels in the neck (yellow arrows), resulting in a more uniform HP signal in
the tumor. When the intensity of HP signal from a ROI containing the tumor (includ-
ing partial volume contribution from blood vessels) is plotted over time, the effect of
vascular signal dephasing is evident.
Normal Rat Liver
Dynamic HP urea imaging with and without interleaved motion suppression was also
performed of the livers of healthy Sprague-Dawley rats. Three rats were imaged with
the conventional spoiled gradient-echo method (without interleaved motion encoding)
and the minimum achievable TE of 11.9 ms was used for these scans. One of these
animals was rescanned at a later date using the interleaved motion encoding method
with a TE of 19.1 ms and using a 7.2 ms preparation gradient waveform with an effec-
tive isotropic b-value of 6.8 s/mm2 and a first gradient moment in each direction of 0.15
s/mm. The diffusion preparation gradient waveform used in imaging this rat is shown
in figure 4.14. Due to the high sensitivity to physiological motion observed when us-
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ing motion sensitization in mice, both conventional and interleaved motion suppressed
scans were performed with respiratory gating to ensure gradient encoding occurred
when the liver was stationary. The effective repetition time therefore varied within
and between dynamic HP scans due to variations in the rats’ respiratory rates, how-
ever in most cases a repetition time of 2 to 3 s was maintained. An excitation angle
of 30 degrees was used with a 1 cm axial slice width, followed by a symmetric EPI
readout encoding a 6 x 6 cm2 FOV and 24 x 24 image matrix. For the interleaved mo-
tion suppression scan, a 7.2 ms delay provided consistent T ∗2 image weighting when
the preparation gradient was absent. 100 mM HP [13C,15N2]urea (Sigma Aldrich, St.
Louis, MO) was produced using a HyperSense polarizer and 2.5 mL of this HP solu-
tion was injected over 20 s via a tail vein catheter using an infusion pump (PHD 2000,
Harvard Apparatus, Holliston, MA).
Dynamic images of HP urea in the rat liver acquired with interleaved motion sup-
pression are shown in figure 4.15. As in the mouse imaging shown in the previous
subsection, a marked reduction in signal from the region of large blood vessels is ob-
served for time points at which diffusion preparation is applied. In contrast to imaging
of the mouse thyroid, this intense vascular signal is located in a region of the image
distant from the tissue of interest which allows the effect of motion suppression gra-
dients on the microvascular signal in the tissue voxel to be measured.
For each dynamic HP scan in rats, a VIF estimate was obtained by fitting equation
4.2 to the time intensity curve of a voxel displaying intense HP urea signal from a voxel
in the region of the large hepatic blood vessels (e.g. the voxel highlighted in green in
figure 4.15). For the interleaved motion suppressed scan, this VIF fit only considered
time points without motion sensitization. A separate artifact-free voxel representing
normal parenchyma in the anterior liver near the 13C receive surface coil was selected
for fitting using the two-compartment perfusion model (e.g. the voxel highlighted in
purple in figure 4.15). The estimated VIF was scaled relative to the tissue time in-
tensity curve based on its position in the modeled B1 profile of the 13C receive surface
coil, which is shown in figure 4.16. Fitting of the two compartment perfusion model
to the tissue time intensity curve acquired with the conventional imaging method was
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Figure 4.14: The diffusion preparation gradient waveform that was used for inter-
leaved motion suppressed imaging of HP urea in the rat liver. The gradient waveform
is 7.2 ms in duration with a maximum amplitude of 600 mT/m. At the end of this
preparation period, a first gradient moment of 0.15 s/mm and b-value of 6.8 s/mm2 is
imparted for 13C in each principal direction.
completed using equations 4.10-4.12 with kve and vb as the two free parameters, and
with the simplifying assumption of ve = 1 − vb (i.e. vei = 1). Fitting of the time inten-
sity curve acquired with interleaved motion suppression assumed that the preparation
gradients fully eliminated vascular signal at the time points when they were applied.
When fitting the two-compartment model to tissue voxel time intensity curves se-
lected from the three HP urea datasets acquired with conventional spoiled gradient-
echo imaging, kve values of 0.016, 0.072 and 0.013 s-1, and vb values of 18.8, 37.3 and
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Figure 4.15: HP 13C urea imaging of the healthy rat liver using interleaved motion
suppression gradients. HP images are overlaid on both T2-weighted anatomical (top)
and time of flight angiographic images (below). Dynamic images acquired with mo-
tion suppression are shown in orange, while those without are blue. Note that 13C
image overlays are not corrected for the sensitivity profile of the receive surface coil.
The effect of the preparation gradients is most pronounced for the voxels with intense
vascular signals (green), however some suppression of the vascular signal is evident in
the liver parenchyma (purple). The shaded region of the time intensity curves shown
on the right indicate the twelve imaging time points depicted in the 13C image overlays
on the left.
Figure 4.16: Relative B1 profile of a 2 cm circular coil in a medium of uniform permit-
tivity. Values shown in this figure were used to estimate the positional dependence of
VIF scaling relative to the HP urea signal measured in liver tissue for the purpose of
fitting a pharmacokinetic model to the observed HP time intensity curves.
Adapted from a script obtained from the MATLAB file exchange [148].
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35.4% were obtained. Lower kve and vb values of 0.012 s-1 and 18.3%, respectively,
were measured for the hepatic tissue voxel interrogated with interleaved motion sup-
pressed imaging. Without a greater sample size no firm conclusions can be drawn
from these data, however it is instructive to consider these values in the context of
previously reported measurements of these physiological quantities. Measurements
of the permeability of hepatic capillaries to an agent with the biochemical proper-
ties of urea are not readily available, however mean Ktrans values of 0.003 min-1 (5 ×
10-5 s-1) have been measured in the normal liver parenchyma in DCE-MRI of rabbits
using extended Tofts modeling of clinical gadolinium chelate contrast agent uptake
[149]. This capillary transfer rate of gadolinium agents is three orders of magnitude
smaller than the values derived from our modeling of HP urea images, which could
result from the smaller molecular size of urea and its much greater mobility in liver
tissue. The hepatic blood volume fraction of normal liver tissue has been measured in
many different ways, with a very wide range of values reported in the literature. The
suggested reference range of the normal hepatic blood volume fraction in humans for
radionuclide dosimetry is 18 to 30% [150], and imaging measurement of this quantity
in humans through PET detection of inhaled C15O has demonstrated regional values
of 18 to 22% in normal livers (assuming a tissue density of 1 g/mL) [151]. Local tissue
blood volume fractions of normal liver ranging from 28 to 31% in rabbits [152] and
11 to 18% in rats [153] have been reported using MRI measurements of macromolec-
ular gadolinium agents. In this context, the lower vb (18.3%) measured from our HP
urea images acquired with interleaved diffusion preparation is in better agreement
with published values than the blood volumes estimated from conventional spoiled
gradient-echo imaging.
If microvascular signal is efficiently suppressed at the interleaved time points of the
animal scanned with diffusion preparation, a lower capillary exchange rate and hep-
atic blood volume could generally be expected from this measurement when compared
to conventional spoiled gradient-echo imaging. The velocity of blood varies greatly
throughout the vascular tree, and this variation is particularly significant in the liver.
A large portion (≈25%) of the cardiac output is delivered to the liver through both ar-
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terial and venous sources, and the hepatic capillaries have a wider diameter and are
more permeable than capillaries in most other tissues [71]. Two-compartment mod-
eling of HP agent delivery to the hepatic interstitium is therefore a very simplified
representation. Signal in slow-moving capillary blood and in the extravascular space
may be indistinguishable in modeling of conventional imaging data, which could be
interpreted as more rapid transfer of HP agent into the extravascular compartment.
This overestimation of kve for a given VIF and tissue time intensity curve could in turn
result in underestimation of ve (i.e. overestimation of vb, particularly when assuming
vei = 1) to scale the modeled extravascular signal in a manner that matches the ob-
served data. In modeling of images acquired with interleaved suppression of vascular
signals, the improved discrimination of true extravascular signal would be expected to
reduce this overestimation of kve and vb, however more in vivo data will be necessary
to confirm this interpretation of our preliminary results. Note that in the numerical
simulations outlined in section 4.3, these effects would not be observed since the time
intensity curves were generated using the same kinetic model that was used for data
fitting.
Further extension of dynamic HP imaging with motion suppression to kinetic mod-
eling of in vivo data will require further research. Since the diffusion gradients impart
negative contrast, the utility of this method depends strongly on the HP image SNR
attainable without any suppression of moving signals, so a more robust evaluation of
the effect of noise on analysis of these imaging data is called for. Unlike the somewhat
simple accounting of flow effects in our simulations, the rates and directions of blood
flow in tissue cannot be fully described as a uniform and isotropic diffusive motion that
is accounted for via a single exponential signal weighting factor. However, as in any
model-based analysis of in vivo data, these motion suppression effects only need to be
represented with sufficient complexity to provide robust measurements that are sensi-
tive to the physiological processes of interest. More experimentation will be necessary
to define the appropriate levels of diffusion weighting when applying this method to
specific in vivo applications. Overall, our results demonstrate the great potential of
this technique to provide added insight into the physiological context of HP signals.
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4.5 Conclusion
In this chapter, we have reviewed existing methods and introduced new strategies for
quantitative analysis of HP MRI data with a specific focus on pharmacokinetic model-
ing of HP urea. A two-compartment kinetic model of HP urea signal evolution in tis-
sue was derived from first principles and applied in numerical simulation of dynamic
spoiled gradient-echo imaging. These simulations evaluated the relative performance
of HP urea imaging using a conventional imaging method and two alternative dynamic
imaging strategies that could provide additional insight into the physical compartmen-
talization of HP signals in tissue. Based on the results of these numerical simulations,
the feasibility of one of these HP imaging strategies — which uses diffusion gradient
encoding to preferentially suppress vascular signals — was evaluated in vivo.
These small animal experiments demonstrate the viability of our proposed method
for interleaved motion encoding of dynamically sampled HP data. In both the mouse
imaging illustrated in figure 4.13 and the rat liver imaging shown in figure 4.15, the
application of our interleaved motion suppression method to HP urea imaging illus-
trates a marked reduction of strong vascular signals while preserving detectable signal
from tissue. Notably, some signal suppression is observed even for the relatively slow
rate of blood flow in the rat liver parenchyma when using preparation gradients that
impart a much lower b-value than that used in mouse imaging. While data from only
a single animal was analyzed through kinetic modeling, it is notable that the values
derived from this HP imaging dataset provided a hepatic blood volume fraction that
is in better agreement with published values than the blood volumes estimated from
conventional spoiled gradient-echo imaging.
When extending this imaging approach to human and large animal imaging, sim-
ilar microvascular flow suppression effects can be expected for similar b-values. Al-
though blood flow occurs at slower velocities in larger animals, 1H IVIM experiments
have demonstrated that this is typically compensated by a proportional increase in
the characteristic length of blood vessels resulting in microvascular flow suppression
effects that are consistent across animals of varying size [154]. However, using even
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the relatively low b-value employed here for rat liver imaging will be very difficult for
dynamic gradient-echo 13C imaging on clinical systems due to the limited gradient ca-
pabilities. As discussed at the end of section 4.3, the use of a double spin-echo imaging
method could provide the additional encoding time necessary to impart b-values large
enough to achieve the desired vascular dephasing effects on clinical MRI hardware.
However, kinetic modeling of these data could be more complicated due to the inver-
sion of HP magnetization by the refocusing pulses. In order to optimally exploit the
vascular dephasing effect, future implementations of this HP imaging technique — on
both preclinical and clinical MRI systems — could utilize numerically optimized diffu-
sion gradient waveforms [155] and physiologically gate data acquisition so that images
are acquired during systole, when blood velocities are at their maximum.
Overall, any quantitative analysis of HP MRI data must account for the evolution
of signals in tissue due to substrate delivery, relaxation and utilization by the imaging
sequence itself. Through numerical simulation, these effects can be evaluated to de-
vise acquisition methods for optimal measurement of the specific physiological process
of interest in a given HP imaging study.
Chapter 5
Hyperpolarized Chemical Shift Imaging
Imaging methods for hyperpolarized (HP) 13C agents often must sample the evolution
of multiple chemical shifts within a very brief timeframe, which is challenging using
conventional imaging methods. Given the variety of HP agents available, flexibility in
the choice of spatial and spectral encoding strategy is desirable.
Each HP agent produces a distinct set of chemical signals in tissue, requiring spe-
cialized MR methods to spectrally encode the corresponding chemical shifts that dis-
tinguish the biochemical fates of the HP 13C labels. Imaging of these signals com-
plicates the MR methods needed in HP experiments, as the sequence must encode 3
spatial dimensions in addition to chemical shift. Further technical complexity is in-
troduced by the dynamic evolution of HP signals over time. As discussed in chapter
4, this temporal evolution is vital to quantitative modeling of HP substrate delivery
and metabolism in vivo. Flexibility in the methods of spatial and spectral encoding
is therefore critical when imaging HP agents, particularly for studies using novel HP
preparations.
Various techniques for dynamic and single time point spectroscopic imaging of HP
13C substrates have been developed. These include, among others, traditional phase-
encoded CSI [68], echo-planar spectroscopic imaging (EPSI) [39], balanced steady-
state imaging [156, 157], IDEAL [21, 22] and spectral-spatial excitations coupled with
spiral [136], EPI [158] or EPSI readouts [159]. The IDEAL technique is appealing for
HP MRSI since it constrains chemical shift encoding in a way that is optimized for the
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specific set of chemical shifts that are known to be present in a given HP experiment
[21]. However, there are limitations to the IDEAL method when the range of chemical
shifts occur over a very wide range of frequencies. In these cases, limited slice gradi-
ent amplitude and RF bandwidth can result in large slice offsets for different chemical
shifts. Additionally, the large excitation bandwidths necessary to cover a wide spectral
range can require short RF pulses that exceed B1 limitations. Alternatively, spectral-
spatial RF pulses can accomplish the task of spectral encoding during excitation if the
pulses are appropriately designed to excite only a single metabolite at a time [20]. This
imaging strategy decouples encoding of k-space and chemical shift, greatly simplifying
the HP imaging experiment and allowing excitation angle schemes that are tailored
to the dynamic evolution of individual HP metabolites in vivo [160, 161]. However,
design of these spectral-spatial pulses requires consideration of the specific gradient
and RF capabilities of the MRI hardware on which they are to be implemented [159,
162]. Additionally, design of spectral-spatial pulses for selective excitation of individ-
ual metabolites within a wide range of chemical shifts is particularly difficult due to
spectral aliasing and slice position shifts [90].
While multiple studies have quantitatively compared the performance of various
HP imaging methods, published reports have provided such comparisons primarily for
different spectroscopic imaging readouts on 3 T clinical MRI systems [106, 163]. Only
one study has included a limited comparison of IDEAL spectroscopic imaging read-
outs to chemically selective excitations for HP pyruvate imaging in rodents [136]. In
this report, differences in effective HP magnetization usage, sample polarization lev-
els and rates of vascular delivery effects prevent these data from serving as a robust
quantitative comparison of IDEAL and spectral-spatial imaging. On the GE clini-
cal MRI platform that is most widely used for HP imaging, pulse sequences that can
realize various encoding methods for spectroscopic 13C imaging are provided by the
vendor for systems equipped with multinuclear imaging capablities. In contrast, HP
imaging on preclinical MRI systems typically requires the composition of custom pulse
sequences by the end user, which is time consuming and introduces the possibility of
errors due to the significant complexity inherent in dynamic chemical shift imaging
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of HP substrates.
In this chapter, we will review and compare imaging methods for a typical HP [1-
13C]pyruvate experiment with chemical shift encoding through the frequency response
either of the RF excitation pulse or of a multi-echo acquisition strategy (IDEAL). The
pulse sequence that we have written to enable both of these forms of chemical shift
imaging on our preclinical Bruker 7 T MRI system will be described, as well as quan-
titative numerical simulations and phantom experiments comparing the SNR perfor-
mance of HP pyruvate and lactate imaging on this system with single band spectral-
spatial excitation and IDEAL encoding. Lastly, we demonstrate the applicability of
both of these imaging methods through dynamic HP imaging of pyruvate and lactate
in a LDH phantom and in the murine kidney.
5.1 Imaging Instrumentation and Chemical Shifts
All imaging experiments were performed on a 7 T small animal MRI system (Biospec
70/30 USR, Bruker Biospin MRI, Billerica, MA) running ParaVision 6.0.1 and equipped
with a 72 mm inner diameter 1H/13C volume resonator (Bruker Biospin MRI) and
BGA-12SHP gradients capable of a maximum gradient of 660 mT/m and a maximum
slew rate of 4570 T/m/s. Unless otherwise noted, a 20 mm diameter miniflex coil (Rapid
MRI International, Columbus, OH) was used for 13C signal reception with RF excita-
tion from the volume resonator.
As described in section 2.4, SNR values in MR images require special consideration,
particularly for low SNR magnitude images. In both numerical simulations and real
imaging experiments, SNR values were calculated from magnitude image data and
the standard deviation of an inverse Fourier transformed magnitude noise image, with
correction for the Rayleigh distribution of magnitude noise (equation 2.17). In actual
imaging experiments this noise image was obtained by acquiring a scan equivalent to
the experimental scan but with negligible RF power [49]. In the special case of IDEAL
imaging, this raw acquired noise was first processed through IDEAL decomposition
in the same manner as the experimental imaging data. For display, 13C images are
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bilinearly interpolated to a resolution similar to the matching 1H image data, typically
with resampling factors of 8-16.
The numerical simulation and phantom experiments described in this chapter quan-
tify the performance of different chemical shift encoding methods for a typical HP [1-
13C]pyruvate imaging experiment at 7 T, in which the chemical shifts listed in table
5.1 are present. Note that in our case, 13C urea is present in the form of a phantom
placed within the imaging volume for the purpose of calibrating the 13C frequency and





Hydrate Urea Alanine Bicarbonate
Chemical
Shift (ppm) 171 183.2 179.5 164 177 161
Frequency
Offset
at 7 T (Hz)
0 +921 +642 -566 +453 -755
Table 5.1: Chemical shifts present in a typical [1-13C]pyruvate imaging experiment at
7 T.
5.2 Multi-Echo Chemical Shift Encoding (IDEAL)
For gradient echo imaging, the MR signal with a volume containing K chemical shifts









Here, ρk is the relative complex amplitude of the signal arising from an individual
chemical species, ∆fk is its chemical shift frequency offset (expressed in cyclic fre-
quency, e.g. units of Hz), and R∗2 is the effective rate of spin-spin relaxation (R∗2 = 1T ∗2 ).
The additional spatially-dependent phase shift ψ (~r) accounts for relative ~B0 field shift
present in the imaging voxel (e.g. due to shimming or variations in material sus-
ceptibility). Assuming that these field inhomogeneities can be demodulated from the
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measured imaging signals (e.g. by applying fieldmap corrections), the complex signal
values for a sequence that captures N gradient echoes for K species can be written in
matrix form as:
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Here H denotes the Hermitian transpose of a complex matrix. Note that at least K
echoes are required to decomposeK chemical shifts, but the acquisition of more echoes
may improve noise performance in the decomposed images for individual resonances.
The careful selection of echo times is critical for this approach to chemical shift en-
coding, since together with the known chemical shifts these echo times provide the
basis for sampling the phase evolution of the aggregate signal. The prior knowledge of
chemical shifts present should be used to select echo times for which the phase angles
of the individual chemical shift signals are — at the very least — not static. In this sit-
uation, the condition number of Ā peaks and the system of equations described above
are ill-posed.
This approach to chemical shift imaging is a generalization of the Dixon method
for phase-sensitive separation of fat and water [166]. Throughout this work this type
of chemical shift encoding will be referred to using the acronym IDEAL, which is short
for iterative decomposition of chemical shifts with echo asymmetry and least squares
estimation. Strictly speaking, IDEAL refers to a reconstruction approach in which
the chemical shift images are estimated iteratively from multi-echo MRI data, usually
with joint estimation of the fieldmap (ψ (~r)). All applications of this imaging method
shown here will directly solve for ~ρ using equation 5.3, which provides the theoretical
SNR performance of IDEAL imaging in the absence of any B0 inhomogeneity [167].
5.2. Multi-Echo Chemical Shift Encoding (IDEAL) 111
Selection of IDEAL Echo Times
The performance of IDEAL reconstruction for a given set of echo times and chem-
ical shifts can be quantified through the condition number of Ā or through the ef-
fective number of signal averages (NSA) of individual chemical shifts [21]. While
the condition number provides a summary metric of IDEAL performance for all reso-
nances, it is often the case that specific 13C chemical shifts are of interest while others
may be present but optimizing the SNR of their corresponding images is not a pri-
ority. For example, in HP pyruvate imaging maximizing the SNR for products of in
vivo metabolism such as lactate, alanine and bicarbonate is vital, whereas pyruvate-
hydrate is often present from the moment of dissolution but is not metabolically ac-
tive and provides little additional information [68]. The effective NSA can be used
in such cases to assess noise performance for the specific chemical shifts of interest.
This quantity is calculated as the reciprocal of the diagonal element of the covariance







Without fieldmap demodulation, the application of IDEAL decomposition for a given
set of chemical shifts is a linear transformation with a frequency response fully defined
by the number of echoes used and their relative spacing in time [167]. The magnitude
and phase response of a unit signal at a specific frequency can easily be evaluated
through equation 5.3. From the standpoint of IDEAL decomposition, there is no re-
quirement that the echoes be spaced evenly in time. However, equal echo spacing is
most often used and can greatly simplify the pulse sequence used for data acquisition.
In this work, uniform echo spacing is used.
In the context of HP [1-13C]pyruvate imaging, it is instructive to consider situations
in which some of the chemical shifts listed in table 5.1 are not accounted for in the
IDEAL decomposition process. Bicarbonate, for example, may be difficult to reliably
observe in some in vivo HP pyruvate studies, so there could be some theoretical benefit
to disregarding this and other weak signals in the choice of echo spacing. In order to
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evaluate these considerations systematically, five IDEAL experiments were simulated
in which the numbers of echoes (4-8) acquired were two greater than the numbers of
chemical shifts decomposed (2-6). Decomposed chemical shifts were added in each
successive experiment in the order in which they are listed in table 5.1 (pyruvate,
lactate, pyruvate hydrate, urea, alanine and bicarbonate), since this order typically
corresponds to decreasing maximum signal magnitude in a preclinical HP pyruvate
imaging experiment.
For each simulated IDEAL experiment, the condition number of the coefficient ma-
trix (Ā) and the NSA values for decomposed chemical shifts were calculated for echo
spacings ranging from 1 µs to 1 ms at 1 µs increments. The shortest echo spacing in
this range for which the condition number is minimized was used for evaluation of the
frequency response. T ∗2 decay was not simulated in these calculations (R∗2 = 0). The
frequency response was calculated for each chemical shift as the magnitude and phase
of the corresponding IDEAL decomposition output (ρk) for simulated time-domain in-
put signals of unit magnitude with frequencies ranging from -1 kHz to +1 kHz at 1 Hz
increments. In the magnitude and phase frequency response plots shown below in the
lower panes of figures 5.1-5.5, the discrete offset frequencies of each chemical shift in
table 5.1 are indicated as dashed vertical lines and a synthetic magnitude spectrum
similar to that typically observed in slice-selective preclinical imaging of HP pyruvate
is shown.
As figures 5.1-5.5 illustrate, the decomposition of additional chemical shifts using
additional echoes results in modulations of the IDEAL frequency responses that map
the added shifts to their own output with unit magnitude and zero phase, and that
suppress the contribution of these signals in other outputs. For the IDEAL exper-
iments simulated here, pyruvate and lactate are always decomposed since they are
typically the HP signals of greatest interest in HP imaging of cancer. We chose to ac-
count for bicarbonate signal last since this resonance is typically the weakest product
of HP pyruvate in small animal experiments. However, due to the spectral location of
the bicarbonate signal relative to other chemical shifts, its magnitude is misregistered
predominantly to lactate as additional shifts are added to the decomposition process.
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Therefore if bicarbonate signal is present in IDEAL imaging data acquired using the
encoding strategy shown in figures 5.3 or 5.4 it will produce a significant artifact in
lactate images.
Figure 5.1: IDEAL imaging at 7 T with 4 echoes decomposing 2 chemical shifts: pyru-
vate and lactate. The frequency response for an echo spacing of 0.27 ms is shown as
solid colored lines in the two lower plots. Note how pyruvate hydrate, alanine, urea and
bicarbonate signals are mapped to the decomposed images with varying magnitudes
and phases.
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Figure 5.2: IDEAL imaging at 7 T with 5 echoes decomposing 3 chemical shifts: pyru-
vate, lactate and pyruvate hydrate. The frequency response for an echo spacing of 0.66
ms is shown as solid colored lines in the two lower plots. Note how alanine, urea and
bicarbonate signals are mapped to the decomposed images with varying magnitudes
and phases.
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Figure 5.3: IDEAL imaging at 7 T with 6 echoes decomposing 4 chemical shifts: pyru-
vate, lactate, pyruvate hydrate and urea. The frequency response for an echo spacing
of 0.57 ms is shown as solid colored lines in the two lower plots. Note how alanine and
bicarbonate signals are mapped to the decomposed images with varying magnitudes
and phases.
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Figure 5.4: IDEAL imaging at 7 T with 7 echoes decomposing 5 chemical shifts: pyru-
vate, lactate, pyruvate hydrate, urea and alanine. The frequency response for an echo
spacing of 0.59 ms is shown as solid colored lines in the two lower plots. Note how
bicarbonate signal is mapped to the decomposed images, particularly lactate, with
varying magnitudes and phases.
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Figure 5.5: IDEAL imaging at 7 T with 8 echoes decomposing all 6 chemical shifts
listed in table 5.1. The frequency response for an echo spacing of 0.52 ms is shown as
solid colored lines in the two lower plots. Note how each resonance is properly mapped
to the decomposed images with uniform magnitude and no phase shift.
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Figure 5.6: Effective number of signal averages and condition number for IDEAL
imaging with 4-8 echoes and optimal echo spacing. A slight degradation in noise per-
formance (<5%) is seen with increasing number of echoes and chemical shifts, however
this is most often necessary to prevent misregistrations of chemical signals in the im-
ages of interest. For clarity, the relative NSA is shown only for pyruvate and lactate,
the two shifts most relevant to HP imaging in cancer that are decomposed in all sim-
ulations in figures 5.1-5.5.
The theoretical benefit of these IDEAL encoding strategies that account for fewer
chemical shifts than may be present in HP imaging can be quantified by the effective
NSA of the chemical shifts of primary interest (normalized to the number of echoes),
and by the IDEAL matrix condition number. These quantities are summarized in fig-
ure 5.6, with the normalized effective NSA shown for pyruvate and lactate. While
some very slight degradation in noise performance for pyruvate and lactate occurs for
IDEAL encoding of additional chemical shifts, this change in SNR performance is very
small for the optimal echo spacings illustrated in figures 5.1-5.5. For this very minor
gain in SNR, decomposing fewer shifts using fewer echoes can result in the chemical
misregistration of signals that are not accounted for in IDEAL decomposition, as de-
scribed above for bicarbonate. Given the small differences in normalized effective NSA
and IDEAL matrix condition number, the primary benefit of using any of the IDEAL
encoding strategies decomposing fewer shifts (figures 5.1-5.4) would be the shorter
overall image encoding time that can be realized in acquiring fewer echoes.
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Figure 5.7: Heatmaps of individual chemical shift magnitude responses in IDEAL
pyruvate and lactate output images for each input chemical shift listed in table 5.1.
Each heatmap displays the percentage of each chemical shift magnitude that is passed
through into decomposed pyruvate or lactate images by the IDEAL reconstruction us-
ing the optimal echo spacings shown in figures 5.1-5.5. For example, when 4 IDEAL
echoes with the TE spacing shown in figure 5.1 are used for decomposition of only pyru-
vate and lactate, 39.1 and 86.3% of the pyruvate-hydrate signal magnitude present is
mapped to the pyruvate and lactate output images, respectively. In addition being
misregistered chemically, signals in the final IDEAL images originating from incor-
rect chemical shifts will be shifted spatially in a manner dependent on the method of
spatial encoding, which can lead to severe image artifacts.
This chemical misregisration effect occurs to some degree in each output image,
with contributions from each chemical shift that is not modeled in the IDEAL decom-
position process. Figure 5.7 summarizes the percentage of each chemical shift magni-
tude that is mapped into the pyruvate and lactate IDEAL output images, as calculated
from the magnitude frequency responses depicted in figures 5.1-5.5. Chemical signals
that are mapped erroneously in this manner will also possess frequency shifts that
result in spatial misregistrations dependent on the method of spatial encoding. While
it may be feasible in certain situations to decompose fewer chemical shifts than may be
present in a given HP pyruvate imaging experiment (e.g. using the four-shift IDEAL
encoding depicted in figure 5.3 if alanine and bicarbonate are not of direct interest
and can be expected to be virtually undetectable), doing so can result in artifacts in
the IDEAL images due to these chemical and spatial misregistrations.
For these reasons, the IDEAL encoding strategy used throughout this chapter em-
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ploys eight echoes to decompose all six chemical shifts listed in table 5.1. The echo
spacing of this IDEAL strategy is 0.52 ms, which corresponds to the IDEAL experi-
ment illustrated in figure 5.5.
5.3 Spectral-Spatial RF Pulses
Spectral-spatial pulses consist of multiple short RF pulses with consistent shape but
variable amplitude applied synchronously with an oscillating slice selection gradient
in order to perform excitation, saturation, refocusing or inversion of magnetization
with a specific spatial and spectral profile. These pulses were first designed for selec-
tive 1H imaging of water and fat [168], and the rapid acquisition of lipid-free imaging
data remains the predominant application in clinical MRI (e.g. for blood oxygenation
level dependent imaging). The flexibility in chemically selective excitation provided
by spectral-spatial pulses has led to their use in 1H [169] and 13C [159] spectroscopic
imaging. Compared to 1H spectroscopy applications, design of spectral-spatial pulses
for HP 13C imaging is often easier due to the sparsity of chemical spectra and the lack
of a significant macromolecular baseline. However, the creation of spectral-spatial
pulses for 13C imaging is still a challenging problem, particularly for HP preparations
that probe multiple biochemical pathways in vivo [90] and for HP imaging on MRI
systems with high magnetic fields and low gradient slew rate limits.
The first step of any spectral spatial pulse design problem is the selection of a bal-
anced oscillating gradient shape. Although any shape may be employed, trapezoidal
gradients are most often used with RF subpulses applied only during the constant
amplitude gradient plateaus. In this case, the RF subpulse bandwidth and gradient
amplitude specify the slice profile as in traditional slice selection. Similar to spatial
image encoding, the gradient determines the excitation k-space trajectory. However,
the slice gradient integral is evaluated inversely in time from the end of the slice
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This equation describes the temporal phase evolution of isochromats due to their spa-
tial position. Phase evolution due to chemical shift offset occurs linearly in time, and
by periodic application of RF subpulses centered at kz = 0 the spectral k-space is sam-
pled. If the chemical shift dependent phase evolution is slow relative to the positional
phase accumulation in each subpulse, the RF subpulses approximate discrete samples
of spectral k-space. In this case, the individual subpulse amplitudes define a finite im-
pulse response (FIR) filter that determines the spectral profile of the spectral-spatial
pulse [170]. Given the desired frequency response, there are many methods for design-
ing an optimal FIR filter. In this work, a publicly available MATLAB toolbox [171] for
spectral-spatial pulse design was used that includes a specialized convex optimiza-
tion FIR filter design algorithm [159]. The FIR filter design approach only provides
an approximation of the pulse frequency response for the purpose of determining the
individual RF subpulse amplitudes. Once these subpulse amplitudes are found, the
spatial and spectral response of entire pulse can be evaluated more accurately via
Bloch simulation.
The FIR filter can be visualized in the time domain as a broad RF envelope that
modulates the amplitude of each subpulse, as shown for the Gaussian envelope in fig-
ure 5.8. The total time duration of this envelope (τ2) is inversely proportional to the
width of frequency passbands in the FIR filter frequency response. This frequency re-
sponse is periodic with passband replicates occurring at the rate of subpulse sampling
(1/τ1). More rapid subpulse sampling rates and greater total pulse durations are desir-
able for spectral-spatial pulses designed for selective imaging of individual chemical
shifts, since these result in narrower and more isolated frequency passbands. How-
ever, the slew rate of the gradient system and the duration of individual RF subpulses
needed to attain the desired spatial profile limit the minimum subpulse time separa-
tion. Additionally, the overall duration of spectral-spatial excitation pulses is limited
in practice due to the finite lifetime of the signal it produces, as determined by the
rate of spin-spin relaxation. Creation of spectral-spatial RF pulses is therefore a com-
plicated design problem that must balance many competing effects to derive usable
B1 and gradient waveforms that impart acceptable magnetization response profiles in
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Figure 5.8: The relationship between spectral-spatial RF pulse frequency response
and timing are demonstrated in this pulse designed for HP pyruvate imaging at 3
T. The RF and gradient waveforms (left) can be characterized by the time elapsed be-
tween subpulses (τ1) and the total pulse duration (τ2). The primary passbands possess
a spatial profile determined by the subpulse shape and gradient amplitude, and a fre-
quency profile determined by the envelope of the RF pulse. The passband frequency
width is inversely proportional to the overall pulse duration. For the Gaussian enve-
lope chosen for this pulse (dashed line), the spectral FWHM is 2/τ2. The periodicity in
time of the RF subpulses and gradient result in passband replicates occurring in the
pulse frequency response with a separation of 1/τ1.
Figure reprinted from Angus Z. Lau, et al. Spectral-spatial excitation for rapid imag-
ing of DNP compounds. NMR Biomed 2011; 24: 988-996. doi:10.1002/nbm.1743. with
permission from John Wiley and Sons (License Number 4873230896286).
space and frequency.
The spectral-spatial RF pulse used in this work was designed for selective HP imag-
ing of [1-13C]pyruvate and lactate at 7 T using the spectral spatial RF pulse design
MATLAB package written by Adam Kerr and Peder Larson [159, 171, 172]. A flyback
trapezoidal gradient was chosen with RF subpulses applied only during the unipolar
gradient plateaus. This configuration entails a greater minimum subpulse separa-
tion than symmetric oscillating gradients (e.g. figure 5.8), however flyback gradients
are less sensitive both to deviations in kz from timing errors and eddy currents [35],
and to uncompensated phase accumulation of moving isochromats [173]. The RF sub-
pulses excite a 1 cm slice with a time-bandwidth factor of 3.5. For HP 13C imaging
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Figure 5.9: The spectral-spatial pulse used in this work was designed for selec-
tive imaging of pyruvate and lactate at 7 T with a 1 cm slice thickness and fly-
back gradient using a publicly available spectral spatial RF pulse design package
(https://github.com/LarsonLab/Spectral-Spatial-RF-Pulse-Design) [171]. The RF
excitation waveform (A) consists of 9 subpulses and has a total duration of 6.6 ms.
The real RF B1 magnitude shown corresponds to a 90 degree excitation, and may be
scaled down to achieve lower excitation angles in HP experiments. A 420 Hz passband
and 930 Hz stopband allow selective imaging of pyruvate and lactate at 7 T (B). 13C
urea at -1680 Hz (arrow) falls within a passband replicate when the MRI center fre-
quency is set to lactate, but can be pre-saturated when using this pulse for dynamic
imaging. Bloch simulation of the transverse magnetization response to this pulse (C)
agrees with measurement in a relaxed water phantom (D).
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the excitation of empty spectral regions may be permitted, however for this design
we chose to specify a desired frequency response with sufficiently wide passband sep-
aration to minimize excitation of other chemical shifts when imaging pyruvate and
lactate. The FIR design specifications included a single passband of at least 1 ppm
width (75.5 Hz) separated from its frequency replicates by at least 12.3 ppm (930 Hz).
With these specifications, a flyback gradient with a period of 0.74 ms was used, re-
sulting in a passband replicate spacing of approximately 1350 Hz. As illustrated in
figure 5.9, this spectral response allows selective imaging of pyruvate without signif-
icant excitation of the remaining chemical shifts listed in table 5.1. However, when
the primary passband is centered on lactate significant excitation of 13C urea occurs.
For our purposes this urea signal is present in a thermally polarized phantom placed
in the imaging volume for calibration of 13C center frequency and RF transmit power,
and the urea can be saturated using a separate spectrally selective RF pulse shortly
before spectral-spatial excitation of lactate. The spatial and frequency response of
this spectral-spatial RF pulse was validated by measuring one-dimensional spatial
readouts along the slice direction in a gadolinium-doped water phantom with vary-
ing offsets between transmission and reception frequency. The spatial axis in this 1H
measured spectral-spatial profile was corrected by multiplying it by the ratio of 1H to
13C gyromagnetic ratios for comparison with the 13C design Bloch simulation.
The spectral-spatial RF pulse used throughout this chapter was designed with a
nominal excitation angle of 90 degrees, and the RF and gradient waveforms are ex-
ported to a plain text format that allows them to be imported into our custom pulse
sequence (as described below). This sequence scales the B1 waveform to provide any
specified excitation angle <90 degrees. In order to realize spatial slice shifts, the B1
phase of a spectral-spatial pulse must be modulated as a function of kz [35].
B1(t,∆z) = e
i2πkz(t)∆zB1(t,∆z = 0) (5.6)
It is not possible to apply this non-linear phase modulation to our spectral-spatial RF
waveforms directly on our MRI system. Instead, fixed spatial offsets (e.g. for multislice
imaging) are realized by applying the phase modulation described in equation 5.6 to
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the B1 waveform before exporting it from MATLAB. The spectral-spatial pulse used
in this chapter had no spatial shift, and great care was taken to position the imaging
subject at the MRI system isocenter.
5.4 Sequence Design and Implementation
The vendor gradient-echo (FLASH) imaging method from ParaVision 6.0.1 was mod-
ified to permit gradient waveforms of arbitrary shape defined in plain text files to be
played out during three sequence segments for excitation, preparation and readout.
Gradient waveforms are stored in plain-text files with amplitude in units of mT/m
and the dwell time of each point determined by the gradient timing resolution of the
system (8 µs). The use of these custom gradient waveforms permit the use of spectral-
spatial pulses (which are otherwise unavailable on this imaging platform), as well as
more time-efficient imaging readouts.
Tools for single-shot flyback and symmetric EPI waveform design and image recon-
struction were written in MATLAB R2017a. The EPI waveforms designed with our
method are fully rewound and traverse in minimum time the k-space trajectory deter-
mined by the requested FOV, image matrix and readout bandwidth for the specified
gyromagnetic ratio and gradient specifications (timing resolution, maximum ampli-
tude and slew rate). Apart from the EPI encoding simulations described in the follow-
ing subsection, all image data presented in this chapter were acquired or simulated
using the flyback EPI trajectory shown in figure 5.10.
For selective imaging of individual chemical shifts, both the excitation angle and
center frequency of each excitation can be set individually. The acquisition duration
may also optionally be extended beyond the length of the single-shot imaging readout.
As illustrated in figure 5.11, this extended readout can allow the measurement of a
residual FID if T ∗2 is sufficiently long. When the residual FID SNR is sufficiently high
and represents a single chemical resonance, it is used to inform the reconstruction
of the preceding imaging readout by correcting for the k-space data for the observed
off-resonance chemical shift. Since the resonant frequencies of HP signals can be esti-
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Figure 5.10: This single shot flyback EPI trajectory is used throughout this chapter,
including in comparisons of spectral encoding strategies for imaging of [1-13C]pyruvate
and associated metabolites. This readout is designed for a 16 x 16 matrix, 4 cm field
of view and 20.833 kHz readout bandwidth (48 µs dwell time). The center of k-space
is sampled 9.984 ms into the gradient waveform, which has a total duration of 18.76
ms and an echo spacing of 1.152 ms (868 Hz phase bandwidth).
mated but not precisely known before their measurement, this off-resonance correction
addresses the common issue of slight frequency offsets in HP imaging with spectrally
selective imaging of individual chemical shifts. An alternative method available in
our pulse sequence uses separate slice-selective broadband excitations (green pulses
in figure 5.12) prior to each set of imaging acquisitions to measure the chemical shift
offsets [22, 174]. However, unlike the residual FID measurement shown in figure 5.11,
the acquisition of independent slice spectra entails additional RF depletion of the HP
magnetization. These slice-selective broadband spectra are therefore used mainly for
determination of precise HP chemical shift offsets in IDEAL experiments.
An optional variable TE delay between excitation and readout allows this sequence
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Figure 5.11: Single-shot imaging trajectories used in this work are fully rewound,
permitting acquisition of a residual FID after image readout. If this residual FID is
detectable following an imaging readout of a single chemical shift (e.g. when using
a spectrally selective RF excitation), it may be used as a navigator to correct any off-
resonance shift in the preceding k-space data prior to reconstruction.
to be used for IDEAL encoding [22]. In order to permit IDEAL image acquisition
with flexible echo delays, each snapshot imaging readout follows a separate excitation
pulse. As in selective excitation mode, the excitation angle of each individual pulse
may be specified independently. The inter-pulse delay may be minimized to limit HP
signal evolution within a single set of IDEAL echoes, and the delay between subse-
quent sets of IDEAL echoes may be set separately to control dynamic sampling of HP
signal evolution.
All code for the imaging method, experiment design and image reconstruction are
publicly available online (https://github.com/mda-mrsl/PV6-HPMR). Images are recon-
structed from EPI data by 2D iDFT of plateau-sampled points. In IDEAL image re-
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Figure 5.12: Simplified pulse sequence diagrams are shown here for a single time
point in dynamic experiments using spectrally selective RF pulses (top) and multi-
excitation IDEAL (bottom) for HP imaging of pyruvate and lactate. In both imaging
techniques, a slice-selective spectrum may optionally be acquired before 13C imaging
at each timepoint using a broadband excitation (green pulse). For spectrally selective
imaging, a saturation pulse (purple) may be applied to urea (or any other frequency)
to prevent this signal from appearing in the HP images.
construction, 2D iDFT is preceded by multiplication of raw k-space data with the pseu-
doinverse of the coefficient matrix of phases accumulated by the decomposed chemical
shifts at the specified TEs (equation 5.3), with off-resonance correction [22, 175]. All
6 chemical shifts listed in table 5.1 are modeled as individual discrete peaks in this
decomposition. All multi-excitation IDEAL experiments were conducted with short
inter-pulse delays to minimize T1 recovery or decay.
Numerical Simulation of EPI Encoding
Numerical simulations were conducted to evaluate the performance of snapshot 13C
EPI encoding strategies. The relative SNR of flyback and symmetric EPI readouts for










These numerical simulations were conducted for gradient system limitations corre-
sponding both to the preclinical 7 T MRI used throughout this work (maximum am-
plitude of 660 mT/m, maximum slew rate of 4570 T/m/s, gradient timing resolution
of 8 µs) and to a clinical 3 T MRI (Discovery MR750, GE Healthcare, Waukesha, WI;
maximum amplitude of 50 mT/m, maximum slew rate of 200 T/m/s, gradient timing
5.4. Sequence Design and Implementation 129
resolution of 4 µs). While the pulse sequence described above is not available on this
clinical MRI system, a very similar sequence allows these snapshot EPI trajectories
to be used on that scanner when multi-nuclear imaging capabilities are available. For
the preclinical 7 T system, a single FOV and matrix size of 4 cm and 16 x 16 was used
in these simulations, since these are typical for mouse imaging. For the clinical 3 T
MRI, a typical human brain imaging FOV and matrix size of 24 cm and 24 x 24 was
used [78, 97, 107, 176]. For each dwell time and T ∗2 value simulated, a Shepp-Logan
phantom was also digitally reconstructed with signal apodization and the normalized
root mean square error (NRMSE) of the resulting image was calculated to quantify T ∗2
blurring effects.
The results of these simulations are shown in figure 5.13 for trajectories represen-
tative of murine imaging at 7 T and in figure 5.14 for human head imaging at 3 T.
These contour plots demonstrate that the choice of readout bandwidth must always
balance SNR performance and error introduced by T ∗2 decay during the encoding time.
As illustrated in the point spread function shown in figure 5.15, this error imparted by
signal apodization arises primarily from image blurring along the direction encoded
more slowly with blipped gradient pulses (ky). Compared to the results for our preclin-
ical 7 T MRI, the same general trends in relative SNR and NRMSE are evident for the
clinical 3 T system. However, the less powerful gradients and larger encoded matrix
necessary for imaging of the human head result in a steeper decrease in SNR and in-
crease in NRMSE with increasing readout dwell time. For a given dwell time and T ∗2
value on either MRI system, symmetric EPI always utilizes the encoding time more
efficiently than flyback EPI. Therefore the relative SNR is always higher and NRMSE
is always lower for a symmetric trajectory than for a flyback trajectory designed with
the same parameters. For the 3 T MRI, a greater benefit in the theoretical SNR is
evident for symmetric EPI trajectories than on the preclinical system. This is a result
of the lower gradient slew rate limit on the clinical system, which necessitates longer
flyback gradient pulses. For well-shimmed small animal imaging at 7 T, we have typi-
cally observed a T ∗2 value of around 20 ms. The results in figure 5.13 show that at this
T ∗2 value, a symmetric trajectory with 48 µs dwell time provides a 13.8% increase in
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Figure 5.13: Numerical simulations demonstrate the relative SNR and NRMSE per-
formance of single-shot EPI trajectories with flyback and symmetric readout gradients
for 13C imaging on a 7 T preclinical MRI system using a 4 cm FOV and 16 x 16 matrix.
Minimum error occurs at short readout dwell times (maximum sampling bandwidth)
due to reduced T ∗2 decay during image encoding. However, the choice of dwell time
represents a compromise between image accuracy and SNR.
SNR and 20.4% decrease in NRMSE compared to the equivalent flyback readout.
It should be noted, however, that these simulations account only for the effects of
T ∗2 decay and readout bandwidth. Despite the theoretical benefit shown for symmetric
EPI, we chose to utilize the flyback EPI trajectory illustrated in figure 5.10 through-
out this chapter due to the relative ease and simplicity flyback trajectories provide in
reconstruction of artifact-free images. In particular, symmetric EPI often suffers from
phase inconsistencies between readouts on the positive and negative lobes of the bipo-
lar gradient, resulting in characteristic N/2 ghosts. A variety of methods are used to
correct these phase inconsistencies and minimize or eliminate these ghosts, but most
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Figure 5.14: Numerical simulations demonstrate the relative SNR and NRMSE per-
formance of single-shot EPI trajectories with flyback and symmetric readout gradients
for 13C imaging on a 3 T clinical MRI system using a 24 cm FOV and 24 x 24 matrix.
These EPI trajectories were not implemented on the clinical MRI system for this work,
but are presented to demonstrate the impact of larger matrix sizes and less powerful
gradients.
often this is done through the acquisition of a separate reference scan that measures
the signal phase evolution during the symmetric readout gradient without gradient
blips applied in the orthogonal direction [177]. In HP imaging, the use of such ref-
erence scans is problematic as it must either use up a portion of the finite HP mag-
netization during its limited lifetime or be estimated from 1H data acquired with an
identical gradient trajectory [178]. For reconstruction of symmetrically encoded 13C
EPI data in our sequence, we have included an automated implementation of Buono-
core’s phase correction algorithm for N/2 ghost correction, which does not require a
reference scan [179]. This algorithm estimates phase correction coefficients directly
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Figure 5.15: The point-spread function of the flyback EPI trajectory shown in figure
5.10 depicts image blurring predominantly in the blipped (ky) direction due to T ∗2 decay.
This point-spread function was generated for a T ∗2 of 20 ms, which corresponds to a
well-shimmed in vivo experiment at 7 T. Note that color is scaled logarithmically to
illustrate the much less significant blurring effect along the readout (kx) direction.
from the image data and has been applied to HP 13C imaging previously [180]. As
an example, the rat liver HP 13C urea images shown in section 4.4 were encoded with
symmetric EPI readouts and reconstructed using this referenceless ghost correction
algorithm.
5.5 Comparison of Spectral Excitation and IDEAL Encoding
The two methods for dynamic chemical shift encoding enabled in our imaging se-
quence, single-band spectral-spatial excitation [20] and IDEAL encoding [21], were
both applied to HP pyruvate imaging within a few years of the initial reports demon-
strating the ability of this agent to resolve metabolism in vivo [68–70]. To this day, both
methods are still among the most widely used imaging strategies for time-resolved HP
imaging of pyruvate and other metabolic agents. Although there are significantly dif-
ferent considerations in implementing these two chemical shift encoding methods for
a particular HP experiment on a specific MRI system, they are both unique among
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HP MRSI strategies in that they perform chemical shift encoding in a manner that is
decoupled from the method of spatial encoding. It is therefore notable that to date —
despite multiple studies comparing acquisition strategies for metabolic HP MRI [106,
163] — a direct quantitative comparison of spectral-spatial excitation and IDEAL en-
coding that fully accounts for the different HP magnetization usage between these
methods has not been reported in the literature.
In this section, we will compare the single-band spectral-spatial excitation and
IDEAL imaging methods designed for preclinical imaging of HP pyruvate and lac-
tate at 7 T in terms their SNR performance in numerical simulations and phantom
experiments. A fair comparison of HP image SNR for these two methods must prop-
erly account for the fraction of longitudinal magnetization depleted by each method.
If proper RF calibration can be assumed and slice profile imperfections are neglected,
a spectrally selective excitation simply reduces the longitudinal magnetization for the
excited chemical shift by a factor of cos θ. However, the multiple broadband excitations
applied in quick succession for IDEAL encoding will each experience a progressively
smaller longitudinal magnetic moment due to the effects of preceeding excitations.
Therefore, we devised a variable excitation angle scheme for multi-excitation IDEAL
experiments to provide a constant signal amplitude across echoes and deplete the lon-
gitudinal magnetization to a fraction specified by the desired effective excitation an-
gle, neglecting T1 effects [181]. Individual excitation angles (θi) were calculated from















In this equation, Mz denotes the relative longitudinal magnetization present after
each pulse, normalized to an initial value of 1 prior to the first pulse (θj=0 = 0).
This effective excitation angle describes the overall effect of the series of eight exci-
tations used for IDEAL imaging in a single value that is comparable to the excitation
angle of an individual single-band spectral-spatial pulse. It is very important to note
that the variable excitation angle scheme described here is different from the vari-
able excitation angle strategies typically used in HP MRI. Most often, these strategies
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modulate the excitation angles over the imaging time points of a dynamic experiment
to attempt to more reliably observe products of metabolism, accounting for RF losses,
T1 decay, perfusion and metabolic conversion [160, 161]. The variable excitation angle
scheme outlined in equation 5.8 accounts only for the effects of prior RF losses within
a train of pulses applied so rapidly that other effects are negligible.
Numerical Simulation of Chemical Shift Encoding
In numerical simulations comparing spectral-spatial pulses and multi-excitation IDEAL
encoding, raw k-space data for a field strength of 7 T were synthesized for a numerical
phantom consisting of 13C urea and the five chemical shifts most commonly observed
for in vivo imaging of [1-13C]pyruvate (table 5.1). The layout of this numerical phantom
is shown in figure 5.16 (center row), with each shift having a real magnitude of 1. For
spectrally-selective excitations, a perfect single-band excitation profile was assumed
for the target metabolite. IDEAL data were synthesized by summation of complex
k-space data for all metabolites at eight echo times with the echo spacing chosen to
optimize the performance of this method for these chemical shifts at 7 T (0.52 ms). The
precise TEs for each spectral encoding technique matched those used in the phantom
experiments described below. Simulations were conducted for a range of effective ex-
citation angles and T ∗2 time constants, and repeated 100 times for each variance of
complex zero-mean Gaussian noise in k-space.
Thermal Phantom Simulation of Chemical Shift Encoding
13C urea doped with gadolinium was imaged using both chemical shift encoding strate-
gies with various effective excitation angles. A single 10 mm NMR tube containing
the urea solution was imaged in the center of the 4 x 4 cm2 FOV using the flyback
EPI trajectory shown in figure 5.10 for spatial 13C encoding (16 x 16 matrix, 20.833
kHz readout bandwidth, 868 Hz phase bandwidth). To simulate chemical shift encod-
ing, either the 1 cm flyback spectral-spatial RF pulse designed for selective imaging
of pyruvate and lactate was used (figure 5.9), or IDEAL imaging was performed by
acquiring eight time-shifted readouts (figure 5.5). In the IDEAL scans a 1.6 ms (5000
5.5. Comparison of Spectral Excitation and IDEAL Encoding 135
Hz) Shinnar Le-Roux (SLR) calculated RF excitation with 1 cm slice width was used.
The first TE for IDEAL imaging was 11.5 ms and the TE for spectral-spatial excita-
tion images was 14 ms, with each of these TEs corresponding to the minimum possible
value. In both experiments, imaging data were collected for effective excitation angles
ranging from 10 to 90 degrees in 10 degree increments. At each effective excitation
angle, data acquisition was repeated eight times with a 10 second repetition time to
allow full spin-lattice recovery of the 13C signal. (For this phantom, the 13C urea T1
was measured to be approximately 1.6 s in a saturation recovery experiment.)
The results of both numerical and phantom simulations are summarized in figure
5.16. Nearly identical theoretical SNR performance is seen with these two chemical
shift encoding strategies for HP imaging. At very large T ∗2 values spectrally selec-
tive excitations provide a slight improvement in SNR over IDEAL as measured by the
mean SNR in simulation, however at no set of simulation parameters were the SNRs
of these two chemical shift encoding methods separated by more than one standard
deviation about their respective means. Under the conditions of a typical preclinical
HP imaging experiment, which is often conducted through dynamic imaging at low
excitation angles to observe substrate uptake and metabolic conversion, no significant
difference in SNR performance between spectrally selective excitations and IDEAL
decomposition was observed in numerical simulations.
Images of the thermally polarized 13C urea phantom are shown in the bottom row
of figure 5.16, with the mean phantom SNR plotted as a function of effective excitation
angle alongside numerical simulation data in the top left plot. These phantom images
showed 13C signal only for the on-resonance decomposed IDEAL chemical shift offset.
Both chemical shift encoding methods show the expected sinusoidal trend in image
SNR with increasing excitation angle, and these phantom data are congruent with
the numerical simulation results for a T ∗2 of 20 ms and k-space noise variance of 0.09.
At an effective excitation angle of 20 degrees, the 13C images shown in the bottom row
of figure 5.16 exhibit SNRs of 8.6 ± 0.47 and 8.7 ± 0.50 (mean ± standard deviation)
for spectral-spatial excitation and multi-excitation IDEAL encoding, respectively.
At each effective excitation angle used in phantom experiments, the eight measured
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Figure 5.16: Single-band spectral-spatial excitation and multi-excitation IDEAL imag-
ing provide equivalent SNR performance for HP pyruvate and lactate imaging at 7 T.
The mean output SNRs for a single metabolite is summarized as a function of nu-
merical simulation parameters in the plots in the upper row, with lines and shaded
regions denoting one standard deviation about the mean. Vertical dashed lines indi-
cate the value of each parameter used when plotting other parameters and displaying
representative images of the numerical phantom (center row). Images from a ther-
mal 13C phantom corresponding to 20 degree effective excitations are shown in the
bottom row, alone and as overlays on 1H images. SNR values were measured in eight
repetitions of this phantom imaging experiment at various effective excitation angles,
and are plotted with numerical simulation results in the upper left. Phantom data
show a significantly lower SNR for IDEAL at effective excitation angles ≥70 degrees
(* p<0.05, two-sample t-test), however the effect size is minuscule and not practically
meaningful.
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SNR values for each encoding method were compared using the two-sided two-sample
t-test assuming equal variances. At a significance level of 5%, this analysis demon-
strates that the SNR obtained through multi-excitation IDEAL imaging is lower than
that of spectral-spatial imaging for effective excitation angles of 70 degrees or greater.
This result could be attributed to multiple causes, including slight errors in RF power
calibration or RF saturation effects that vary along the slice profile [182]. In any case,
this effect is very unlikely to impact the decision of whether to use IDEAL for HP imag-
ing in practice. Since a SNR difference is only observed at large effective excitation
angles that are rarely used in HP imaging, and since the magnitude of this difference
is quite small (<5%), we conclude that both numerical and phantom simulation re-
sults demonstrate that the SNR performance of spectral-spatial and IDEAL imaging
are effectively equivalent for HP pyruvate and lactate imaging on our preclinical MRI
system.
5.6 Validation of HP Imaging Methods
The suitability of both chemical shift encoding methods for imaging of HP pyruvate
and lactate were evaluated in a LDH enzyme phantom and in vivo imaging of the
murine kidney. The LDH phantom provides a controlled environment in which the lo-
calization of HP signals can be predicted a priori, while mouse kidney imaging entails
the greater complexities of HP imaging in a living system.
LDH Phantom Experiment
The spatial fidelity of IDEAL and single-band spectral spatial excitations was tested in
phantom experiments using lactate dehydrogenase (LDH) to catalyze the conversion
of pyruvate to lactate [183]. The phantom consisted of a 50 mL conical tube containing
doped water into which two 2 mL cryovials were inserted. One cryovial was prefilled
with 1 mL of a solution containing 40 U/mL LDH (Worthington Biochemical, Lake-
wood, NJ) and 10 mM NADH (Sigma Aldrich, St. Louis, MO) dissolved in 0.2 M pH
7.6 TRIS buffer (Sigma Aldrich, St. Louis, MO). The other cryovial was prefilled with
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1 mL of the TRIS buffer solution. 1 mL of 20 mM HP pyruvate produced using an Hy-
perSense Polarizer (Oxford Instruments, Abingdon, England) was injected manually
into both cryovials simultaneously after the start of each dynamic acquisition, result-
ing in a final concentration of 20 U/mL LDH, 5 mM NADH and 10 mM pyruvate in
the vial containing LDH solution.
A 5 mm NMR tube containing concentrated doped 13C urea was placed adjacent to
the LDH phantom for calibrating the 13C frequency and RF transmit power. Because
of the strong HP 13C signal observable with this phantom, the 72 mm 1H/13C volume
resonator was used for both 13C signal excitation and reception. HP images were ac-
quired for 90 repetitions with a 2 second TR to sample dynamics of pyruvate delivery
and conversion to lactate. At the start of each repetition, a 5 degree excitation was ap-
plied using the same RF pulse shape and slice gradient as IDEAL imaging to acquire a
FID (1.6 ms, 5 kHz SLR calculated pulse). These slice spectra were averaged over time
to determine the precise frequencies of pyruvate, lactate, pyruvate-hydrate and urea
in IDEAL decomposition and for off-resonance correction of imaging data. Neglecting
these 5 degree FID excitations, the effective excitation angle on pyruvate and lactate
for both encoding methods was 20 degrees. For spectral-spatial excitations, a Gaus-
sian saturation pulse (6.58 ms, 417 Hz) was applied at the urea frequency without slice
localization just before lactate imaging. A 1H RARE image was acquired after the HP
13C scan with the same FOV and slice position to demonstrate the spatial context of
13C images. HP 13C imaging experiments were conducted once for each chemical shift
encoding method, cleaning and replacing the LDH phantom inbetween experiments.
Images from this LDH phantom study demonstrate that both chemical shift imag-
ing strategies evaluated in this work can be used for selective imaging the HP pyru-
vate and lactate. As shown in figure 5.17, similar HP imaging signal trends are seen
in images acquired with spatial-spectral excitations and multi-excitation IDEAL. In
these experiments, strong HP pyruvate signal is evident in both vials of our phantom,
with lactate production observed only in the vial preloaded with the LDH enzyme
and NADH cofactor. While the absolute SNR of LDH phantom images acquired with
spectral-spatial excitations is greater than in IDEAL images, it would not be appro-
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Figure 5.17: The spatial fidelity of both chemical shift imaging methods used in this
work was evaluated in LDH enzyme phantom experiments. In these experiments only
the vials seen on the left side of these images were preloaded with LDH and NADH,
which catalyzed production of lactate when HP pyruvate was injected simultaneously
into both vials. HP signal is plotted over time for a voxel at the center of each vial,
showing similar substrate delivery and conversion trends for spectrally selective exci-
tations and multi-excitation IDEAL imaging, with lactate signal confined to the vial
containing LDH.
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priate to attempt a quantitative comparison of these data (N = 1). Variations in the
absolute pyruvate polarization fraction between dissolutions and in both the rate and
precise amount of pyruvate delivery by manual injection preclude the conclusion that
there is any difference in SNR for these two encoding methods in equivalent HP ex-
periments. Nonetheless, these results demonstrate that both chemical shift imaging
methods provide spatial fidelity appropriate for small animal imaging when used with
the single-shot flyback EPI trajectory used in this work.
Mouse Kidney Experiment
Two healthy BALB/c mice were imaged using identical sequence methods to those de-
scribed above for the LDH phantom experiment, with additional higher-order shim-
ming applied to the isocentric 1 cm slice prior to HP imaging. The 20 mm 13C receive
surface coil was placed carefully over the left kidney on the posterior side of the ani-
mal and its positioning relative to internal anatomy and magnet isocenter was verified
through 1H imaging. The dynamic HP imaging sequences were initiated at the mo-
ment of dissolution, acquiring HP pyruvate and lactate images for the full lifetime of
the HP signals in vivo following manual injection of 200 µL of 80 mM HP pyruvate via
tail vein catheter. Each animal’s respiration was monitored continuously and anes-
thesia was effected and maintained using 2-4% isoflurane delivered via nose cone.
Figure 5.18 depicts the slice positions, time-averaged HP pyruvate and lactate im-
ages, and HP signal time courses for selective voxels from each experiment. As ex-
pected, images from both encoding strategies show a very intense pyruvate signal
from the voxel containing large blood vessels in the center of the abdominal cavity
such as the inferior vena cava and abdominal aorta. Weaker HP pyruvate signal is
observed for the voxel containing kidney parenchyma. The delay and dispersion of
the pyruvate bolus as it passes through smaller blood vessels cause the signal from
this voxel to reach a peak at later time points and persist longer than pyruvate within
the vascular voxel. HP lactate signal is seen primarily within the kidneys, following
delivery of pyruvate to this tissue.
In contrast to the LDH phantom imaging shown in figure 5.17, IDEAL imaging
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Figure 5.18: Renal pyruvate uptake and metabolism were imaged in healthy BALB/c
mice using spectral-spatial excitation (upper panels) and multi-excitation IDEAL
(lower panels). HP images in the central panel are bilinearly interpolated to the res-
olution of the axial proton images (lower left) and summed over time, with native
resolution voxels containing a large blood vessel and kidney parenchyma outlined in
green and purple, respectively. The HP signals for these vascular and renal voxels are
plotted over time on the right, and the shaded portion of these plots indicate the time
points summed in the HP images. All images depict a 4 x 4 cm2 FOV.
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provides greater SNR than spectral-spatial excitation in these animal experiments.
However, no definitive conclusions can be drawn from these data (N = 1) on the relative
performance of the two encoding methods, for all of the reasons described above in the
context of the LDH phantom experiment as well as the additional variability inherent
to metabolic HP imaging in living systems. While this mouse study lacks statistical
power, it clearly demonstrates the capacity of our imaging methods to resolve real-time
metabolism in vivo.
5.7 Conclusion
We have developed an imaging method for preclinical HP 13C imaging and quanti-
tatively compared the imaging approaches enabled in this pulse program. In com-
paring the two spectral encoding strategies written into this imaging method, multi-
excitation IDEAL and spectrally selective excitations, we found in numerical simula-
tions that both provide equivalent performance for HP imaging when the same amount
of longitudinal magnetization is depleted. In phantom experiments we demonstrate
the spatial fidelity of the image encoding strategies enabled by our method in a system
that recreates the primary enzymatic reactions this imaging technique seeks to quan-
tify in vivo. We further demonstrate the suitability of our specific methods to imaging
HP pyruvate and lactate in small animals through experiments demonstrating uptake
and metabolism in the murine kidney.
MRI scan parameters must be set carefully to provide optimal performance for a
given experiment. This is particularly important for HP MRI due to the non-renewable
nature of the imaging signal and the relatively low amplitude of signals produced via
metabolic conversion in vivo. Quantitative evaluation of methods for encoding posi-
tion and chemical shift is therefore critical for HP MRI. Previous work by Durst, et
al. compared various chemical shift readout methods for HP 13C imaging on a clinical
3 T system in extensive simulation, phantom and animal experiments [106]. While
this study included a thorough comparison of traditional CSI, EPSI and IDEAL imag-
ing using spiral readouts, spectrally selective excitations were not considered as an
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option for encoding chemical shift nor was EPI used for spatial encoding. A separate
study by Schulte, et al. focused on the evaluation of spectral-spatial excitation imaging
at 3 T with a 15 degree excitation angle on pyruvate and saturation of downstream
metabolites [136]. This study included a SNR comparison of this specific spectral-
spatial imaging strategy to IDEAL encoding with seven 10 degree excitations in a rat
tumor model. For the four animals imaged, greater mean peak SNR was observed for
pyruvate using IDEAL compared to spectral-spatial imaging. The opposite result was
seen for lactate and other downstream metabolites, where 90 degree spectral-spatial
excitations provided superior SNR than IDEAL imaging. These results are consistent
with ours, since the effective excitation angle for all metabolites in their method of
IDEAL imaging (≈26 degrees) is greater than the 15 degree spectral-spatial excita-
tion angle applied to pyruvate, but much lower than the 90 degree spectral-spatial
excitation angle applied to downstream metabolites. Additionally, due to differences
in physiology, HP sample polarization and magnetization usage, these data provide
only a very limited comparison of IDEAL and spectral-spatial imaging. Our results
provide a robust quantitative evaluation of these alternative encoding techniques for
preclinical imaging at 7 T.
The simulation and phantom experiments presented here demonstrate the relative
performance of these imaging techniques on our preclinical 7 T MRI system. Different
results could be expected if the same imaging methods were evaluated on a system
operating at another field strength, or with different gradient capabilities and RF
coils. Due to the variety of imaging applications possible with HP 13C agents, we can
make no general recommendations for use a specific imaging technique. The methods
presented here can be adapted to evaluate the 13C imaging techniques available in a
given experiment to compare their performance on the specific hardware that is to be
used.
In comparing single-band spectral-spatial excitations to multi-excitation IDEAL for
spectral encoding, there are several practical distinctions that are worth noting. The
longer total chemical shift encoding time required in IDEAL increases the chance of ar-
tifacts from physiological motion in these images. Depending on the organ of interest,
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these motion effects can be mitigated by physiological gating of the image acquisition
[184], however this gating can place strict limitations on the ability to dynamically
measure HP signal evolution. For spectral-spatial imaging, reliable signal excitation
depends on proper setting of the frequency offset so that the chemical shift of interest
falls in the passband of the pulse’s frequency response. If set incorrectly, the chemical
shift may occur at the edge of the passband and experience a reduced excitation angle,
or outside of the passband and not be detectable. This can be particularly problematic
for HP imaging with narrowband pulses since this frequency offset must be set before
the signals of interest are present. For IDEAL encoding, the wide bandwidth of the
RF pulse used is typically sufficient to consistently excite all chemical shifts present,
however the constant excitation gradient will impart positional shifts in the slice di-
rection that vary across chemical shift offsets [185]. This effect can become significant
when using IDEAL with thick slices [107] and when decomposing images for chemical
shifts separated by large frequency offsets. Lastly, it should also be noted that the two
chemical shift encoding strategies used here are not mutually exclusive. Multi-band
excitation pulses can easily be used to control the chemical content of signals encoded
with IDEAL [184] or other spectroscopic readouts such as EPSI [159]. This combina-
tion of chemical shift encoding in both excitation and readout provides methodological
flexibility that is very useful in studies of novel HP preparations [90].
In conclusion, our imaging method provides flexibility in the choice of encoding
methods for position and chemical shift and is readily adaptable for use in various
hyperpolarized imaging experiments. We have made the source code for this method
and for the reconstruction of images acquired with the techniques presented in this
work available online (https://github.com/mda-mrsl/PV6-HPMR). Readers who conduct
hyperpolarized and other specialized imaging experiments on Bruker MRI systems are
invited to adapt this method for their needs.
Chapter 6
Hyperpolarized [2-13C]Dihydroxyacetone
[2-13C]Dihydroxyacetone (DHA) is a relatively new HP agent that has been applied
primarily in studies of hepatic metabolism. As discussed briefly in section 3.2, ex vivo
studies of perfused mouse livers [91] and in vivo measurements of hepatic activity in
rats [92] have demonstrated that many of the products of HP DHA metabolism are
sensitive to acute changes in nutritional state. When introduced to the liver through
the blood, HP DHA is quickly taken up by hepatocytes and can provide non-invasive
measurements of chemical flux through glyceroneogenic, glycolytic and gluconeogenic
metabolism. In addition to these previously reported biochemical products, a chemical
signal produced from HP DHA in vivo was preliminarily identified as a product of
ketogenic metabolism in the course of the experiments outlined in this chapter.
In this chapter we will review the rationale for measuring the hepatic metabolism
of HP DHA in the context of liver disease and present our studies investigating DHA
metabolism in the healthy rat liver via MR spectroscopy and imaging.
6.1 Metabolic Liver Disease
The liver is arguably the most biochemically complex organ in the mammalian body.
Apart from the liver’s many vital roles in synthesizing bile, cholesterol, and albumin;
in storing vitamins and minerals; and in breaking down drugs and alcohol, this organ
also performs irreplaceable functions in the systemic metabolism of proteins, carbo-
6.1. Metabolic Liver Disease 146
hydrates and lipids [71].
In the fed state, hepatocytes take up glucose and other monosaccharides and con-
vert them into glycogen for storage or into fatty acids. Within hepatocytes these fatty
acids, which are also derived partly from uptake of dietary lipids, have three main
biochemical fates [186]. They may be oxidized to produce acetyl-CoA that provides
cellular fuel via the TCA cycle, or combined with glycerol to form triglycerides that
are subsequently either condensed into intracellular lipid droplets or packaged into
specific lipoproteins for export and delivery to peripheral tissues. Notably, hepato-
cytes are the primary site of de novo synthesis of lipids and fatty acids in the mam-
malian body. Adipose tissue can also generate lipids from carbohydrate sources, but
additionally uptakes fatty acids from circulating lipoproteins.
In the fasted state, hepatocytes alter their metabolism of carbohydrates and lipids
to support systemic metabolic requirements. Glycogen stores are broken down and
glucose is exported. As glycogen stores become depleted, the liver and most other or-
gans (apart from the brain) rely less on the oxidation of carbohydrates and more on
fatty acids to meet their energetic needs. These fatty acids are supplied primarily
by break down and mobilization of triglycerides stored in adipose tissue, but hepato-
cytes may also utilize the triglycerides stored within intracellular lipid droplets for
their metabolic fuel. The glycerol liberated from the breakdown of triglycerides in
adipocytes and hepatocytes is used in the liver for gluconeogenesis, yielding glucose
that is exported.
Hepatocytes also utilize several other carbon sources to support gluconeogensis,
including circulating pyruvate, lactate, and alanine, all of which must be converted to
the TCA cycle metabolite oxaloacetate for gluconeogenesis. In prolonged fasts and un-
controlled metabolic diseases, the gluconeogenic depletion of oxaloacetate in hepato-
cytes prevents the acetyl-CoA produced by fatty acid oxidation from entering the TCA
cycle and providing cellular fuel. The resulting accumulation of acetyl residues in hep-
atocytes is handled by condensing them in a series of reactions to form acetoacetate,
which frees the CoA needed to oxidize fatty acids. Acetoacetate may spontaneously
form acetone by non-enzymatic decarboxylation, and also rapidly interconverts en-
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zymatically with β-hydroxybutyrate (βHB). These three metabolites are the primary
products of ketogenic metabolism and are known collectively as ketone bodies.
The conversion of acetoacetate to βHB occurs via the reaction catalyzed by the en-
zyme βHB dehydrogenase, which restores NAD+ from NADH as in the reaction cat-
alyzed by LDH. Ketone bodies are highly mobile in tissue, and the mitochondria in
hepatocytes do not contain enzymes necessary for ketolysis, the process of utilizing
these metabolites as cellular fuel [187]. These ketone bodies are therefore exported by
the liver, primarily under fasted conditions in which they are a vital cellular fuel source
for the brain, which cannot utilize circulating fatty acids due to their inability to cross
the blood-brain barrier. However, even in the liver of healthy fed mammals, ketogenic
flux is essential in providing substrates for anabolic pathways such as cholesterol syn-
thesis, and plays a very important role in preventing the build-up of reactive oxygen
species from oxidative metabolism [188].
Hepatic metabolism through glycolytic, gluconeogenic, glyceroneogenic and keto-
genic pathways is dysregulated in many common diseases. Recent studies have shown
that hepatocellular carcinomas can gain the capacity to utilize ketone bodies as cellu-
lar fuel, and this re-activation of ketolysis correlates with higher rates of mortality in
patients [189]. Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic
disorder associated with obesity and diabetes. By some estimates, as much as 40% of
adults in the United States have NAFLD, with a yearly economic burden greater than
$100 billion [190]. Most individuals with NAFLD are asymptomatic and exhibit only
hepatic steatosis, the accumulation of triglyceride droplets in hepatocytes that does
not impair liver function. However, in a some individuals this condition progresses to
non-alcoholic steatohepatitis (NASH), in which inflammation and fibrosis of the liver
progressively diminish hepatic function. NASH can further lead to cirrhosis and the
development of hepatocellular carcinoma. NASH is predicted to become more preva-
lent in coming years, supplanting viral hepatitis as the leading indication for liver
transplant [191].
The metabolic mechanisms underlying the progression of NAFLD are currently
not well understood. While comorbidities such as obesity and diabetes are associated
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with progression and worse outcomes, the biochemical etiology of NAFLD is complex
and variable in different individuals [192]. Recent work has demonstrated that dis-
ruption of glycerol metabolism [193] and of mitochondrial ketogenesis [194, 195] are
important in the development and progression of NAFLD in patients. However, the
lack of methods for directly assessing these metabolic processes non-invasively is a sig-
nificant barrier to the formulation of treatments that target the biochemical origins
of NAFLD development and progression. Currently, no pharmacological treatment
exists for managing NAFLD and therapies typically seek to manage comorbidities
through lifestyle changes (i.e. diet and exercise) [196]. The gold-standard method for
diagnosis and staging of NAFLD is liver biopsy, however this is a very invasive surgical
procedure that is not suitable for monitoring disease progression [197]. Non-invasive
imaging can quantify hepatic fat content via MRI or tissue stiffness via elastographic
MRI or ultrasound, but these methods are sensitive to the outcomes of NAFLD pro-
gression (steatosis and fibrosis) and not the underlying biochemical causes.
In this context, the simultaneous measurement of flux through glycolytic, gluco-
neogenic and glyceroneogenic metabolism that HP DHA has been shown to provide
has tremendous potential to elucidate the mechanisms of NAFLD progression, which
would be instrumental in devising improved methods for non-invasively staging and
for therapeutically managing this very common disease.
6.2 Hyperpolarized [2-13C]Dihydroxyacetone Spectroscopy
Previously identified metabolic products of HP DHA are shown in figure 6.1. DHA is
rapidly taken up from circulation by hepatocytes, however the precise cellular trans-
porters responsible for bringing DHA into the cytosol are not known. Once in the cell,
DHA is phosphorylated to dihydroxyacetone phosphate (DHAP), which is an important
glycolytic intermediate that is rapidly and reversibly isomerized into glyceraldehyde-
3-phosphate (GA3P) by the enzyme triose phosphate isomerase. DHAP may also be
reduced to form glycerol-3-phosphate (G3P) in an enzymatic reaction in which NADH
is oxidized. Conversion of DHAP to GA3P introduces the 13C label to glycolytic and
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Figure 6.1: Previously reported chemical endpoints observed following HP DHA infu-
sion in the isolated mouse liver are shown in this diagram. Colored circles indicate
sites of 13C enrichment, and the DHA precursor is highlighted by a red box. DHA un-
dergoes rapid cellular uptake and phosphorylation to form DHAP, which then quickly
enters glyceroneogenic, gluconeogenic and glycolytic pathways. The real-time and si-
multaneous measurement of chemical flux through multiple biochemical pathways
provides broad insight into the metabolic state of the liver.
Figure adapted with permission from Alexander Kirpich, et al. Kinetic Analysis of
Hepatic Metabolism Using Hyperpolarized Dihydroxyacetone. J Chem Inf Model
2019; 59(1): 605-14. doi:10.1021/acs.jcim.8b00745. Copyright © 2019 American
Chemical Society.
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gluconeogenic pathways, while reduction to G3P probes the pathway responsible for
glycerol synthesis.
While the many chemical endpoints of HP DHA illustrated in figure 6.1 are observ-
able ex vivo in perfused livers scanned on high-resolution NMR systems, relatively few
of these signals are measurable in vivo. In particular, the products of the initial chem-
ical transformations of HP DHA in the cell are observable, but are unfortunately not
very well-resolved through in vivo MR spectroscopy. The 13C chemical shift of DHAP
is not distinguishable from the HP DHA precursor [91]. Without heteronuclear de-
coupling, the GA3P and G3P signals occur as overlapping doublets due to covalent
bonding of the HP 13C nuclide to 1H. While proton decoupling can be used to improve
the separability and detectability of G3P and GA3P [198], we did not have the capabil-
ity to utilize this method on our preclinical MRI system for the experiments presented
in this chapter. The only chemical end points previously reported from HP DHA in
vivo are G3P, GA3P and phosphoenolpyruvate (PEP). In contrast to G3P and GA3P,
PEP appears as a well-resolved singlet signal. In the very limited reports of in vivo
HP DHA metabolism currently published, PEP and G3P were shown to be produced
with greater intensity in liver tissue than in the kidneys [90]. In a separate study,
both PEP and G3P signals were demonstrated to decrease by approximately 50% in
the liver ten minutes following infusion of fructose, and this effect was attributed to
depletion of ATP and changes in the overall concentration of these glycolytic interme-
diates in hepatocytes [92].
DHA Preparation and Dissolution
In all of the experiments discussed in this chapter, the dDNP solution was prepared
by dissolving [2-13C]dihydroxyacetone dimer (99% isotopic enrichment, Sigma Aldrich
Isotec, Miamisburg, OH) at a concentration of 8 M in a 2:1 (by volume) solution of
water:DMSO, with the addition of OX063 trityl radical (Oxford Instruments, Abing-
don, UK) at a concentration of 15 mM and gadoteridol (ProHance, Bracco Diagnostics,
Monroe Township, NJ) at a concentration of 1 mM. HP samples were produced by in-
serting 40 µL of this solution in a HyperSense system and polarizing for at least 60
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Figure 6.2: Time-averaged dynamic spectroscopy of a syringe containing the HP DHA
dissolution depicts several unidentified trace 13C chemical signals. The labeled reso-
nances correspond to HP DHA (212.7 ppm), DHA hydrate (95.7 ppm) and an external
urea phantom (164 ppm, inverted peak). Apart from DHA hydrate, signals in the fre-
quency range from 92 to 114 ppm represent unidentified 13C chemical environments,
and were observed at similar SNR as products of DHA metabolism in vivo 6.4.
minutes prior to dissolution with 4 mL of phosphate buffered saline, resulting in a 80
mM HP DHA solution.
Figure 6.2 depicts the 13C spectrum of a syringe containing this HP DHA solu-
tion, acquired using the same dynamic spectroscopy method that is described below
for rat experiments. The labeled signals in this figure correspond to HP DHA, DHA
hydrate and a thermally polarized 13C urea phantom signal that was used to calibrate
the MRI system center frequency and 13C transmit power. Several signals are present
in the 92 to 114 ppm frequency range that correspond to unidentified 13C chemical
environments. One putative source of these unidentified signals is the intermedi-
ate forms present in the self-dimerization reaction that DHA can undergo in solution
[199], however they could also correspond to trace 13C impurities present in the DHA
sample from the manufacturing process. Chemical assignment of these signals by
NMR is difficult since they are not readily detectable in thermally polarized samples,
and their precise identification is beyond the scope of this work. In the 13C spectra
of the bare DHA dissolution, these unidentified peaks occur with amplitudes around
1% of the HP DHA peak. In the in vivo spectra shown in the following subsection,
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they appear with approximately the same amplitude relative to DHA as the products
of cellular metabolism.
In Vivo HP DHA Spectroscopy
In vivo spectroscopy and imaging of HP DHA have to date been performed only in a
few small animal experiments on clinical 3 T MRI systems. In the first use of this
agent at 7 T, we collected dynamic spectroscopic data from the rat liver to identify the
chemical signals that presented sufficient signal for imaging on our preclinical MRI
system. Three healthy fed female Sprague-Dawley rats (approximately 14 weeks old,
260 g) were scanned using dynamic pulse-acquire 13C spectroscopy during intravenous
infusion of HP DHA. Animals were anesthetized using 2-4% isoflurane delivered via
nose cone and imaged on the same setup described in section 5.1. By placing the 20
mm 13C receive surface coil on the rat’s upper abdomen, the effective spatial profile of
Figure 6.3: Without gradient localization of the excitation pulse, the effective spatial
sensitivity profile of 13C images and spectra in this chapter is equivalent to the sensi-
tivity profile of the reception coil. This figure displays that sensitivity profile as mea-
sured in a 13C urea phantom of much greater length than the surface coil (right). The
effective slice profile matches the position of the rat liver, as shown in a T2-weighted
sagittal image (left).
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these 13C measurements was equivalent to this coil’s receive sensitivity profile, as il-
lustrated in figure 6.3. This surface coil was positioned carefully on the upper anterior
abdomen, and its position relative to internal anatomy was verified in 1H imaging prior
to acquiring HP DHA spectra. A doped 13C urea phantom was placed on the receive
surface coil for calibration of the MRI system 13C center frequency and RF transmit
power, which was delivered via a volume resonator. Approximately 3.5 mL of 80 mM
HP DHA (≈ 98 mg/kg), produced as described above, was manually injected via tail
vein. The injection was administered rapidly to hydrodynamically enhance delivery of
the agent to the liver [200, 201]. A 13C pulse-acquire dynamic spectroscopy scan with a
TR of 3 s was initiated at the same moment as the start of the manual DHA injection.
A 30 degree, 70 µs (18.3 kHz) hard pulse was used for excitation, followed by a 18.9
kHz, 4096 point spectral readout. Spectra were reconstructed in MATLAB with 15 Hz
line broadening, using custom-written tools for phase and baseline correction.
The HP DHA spectra from each rat are shown in figure 6.4, averaged over the first
twelve time points. The unidentified resonances present in the HP DHA dissolution
itself (92-114 ppm) occur with similar amplitudes as the products of DHA metabolism
in vivo. The previously reported resonances of PEP, GA3P and G3P were observed
in each animal, along with some natural abundance 13C labeling of endogenous fatty
acids. Three previously unreported chemical signals were consistently observed at
approximately 173, 174 and 181 ppm. Through correlative 2D NMR, we have tenta-
tively identified the last of these signals as the ketone body, [1-13C]β-hydroxybutyrate.
The observation of products of ketogenic metabolism has never been reported from HP
DHA, nor from any HP agent that enters cellular metabolism as a glycolytic interme-
diate. If this observation is confirmed, it would be particularly notable that βHB was
reproducibly observed in the livers of healthy fed rats, for which ketogenic flux would
be expected to be much less significant than in the fasted state. Excluding membrane
transport, the molecule carrying the 13C label must undergo at least twelve enzymatic
reactions in the cytosol and mitochondrion for HP βHB to be produced from DHA,
so its observation within seconds in these dynamic HP DHA experiments would be
remarkable.
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Figure 6.4: Time-averaged spectra of in vivo HP DHA metabolism in three normal fed
rats demonstrate reproducible hepatic flux of the HP label into PEP, G3P, GA3P and
a chemical environment preliminary identified as βHB. Apart from these metabolites
and the DHA, hydrate, external urea and impurity signals shown in figure 6.2, HP
labeling was apparent in two relatively weak peaks at approximately 173 and 174 ppm.
These signals have not yet been definitively assigned. Other very weak HP signals
observed in some cases correspond to [2-13C]lactate (69 ppm) and [2-13C]pyruvate (206
ppm), however they are not illustrated in this figure. Thermally polarized 13C signal
from natural abundance fatty acids (NA-FA) is detectable in multiple broad peaks
around 130 ppm.
The time intensity curves of HP DHA metabolites are shown for a single rat in
figure 6.5, along with simple precursor-product ratiometric quantifications of each
metabolite in all three rats. With this very limited sample size, no definitive con-
clusions may be drawn from these data. However, it is notable that the two metabo-
lites produced through the fewest enzymatic reactions of the DHA precursor molecule
reach a maximum intensity prior to the peak of the HP DHA bolus, which could in-
dicate saturation of rate-limiting transporters or enzymes. The putative βHB signal
persists after its peak longer than the other metabolites, which is consistent with the
inability of the hepatocyte to catabolize the ketone bodies it produces and with the
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Figure 6.5: HP DHA metabolite time intensity curves and product / precursor ratios
demonstrate rapid hepatic uptake and metabolism. The shaded region of the time in-
tensity plot denotes the time points that were summed in calculation of the product /
DHA ratios (and in the time-averaged spectra shown in figure 6.4). Note that quan-
tifications of GA3P and G3P in this figure correspond to integrals of one peak of these
doublet signals, and were multiplied by 2 for the data shown in this figure.
very high mobility of these molecules in tissue. The ratiometric quantification of each
metabolite shown in figure 6.5 illustrate fairly good reproducibility between animals.
Relative to one another, the roughly 1:2 amplitude ratio of PEP and GA3P signals in
these in vivo data are in agreement with previous reports of HP DHA metabolism ex
vivo in perfused rodent livers [91].
6.3 Hyperpolarized [2-13C]Dihydroxyacetone Imaging
Imaging of the metabolic products of HP DHA is difficult due in part to the wide spec-
tral range of these signals, which spans more than 150 ppm (>11 kHz at 7 T). Slice
selection and spectroscopic readout encoding of chemical shifts with such a wide range
of frequencies is extraordinarily challenging. Using the non-localized broadband ex-
citation method and receiving 13C signal from liver tissue through the precisely posi-
tioned surface coil as described in the previous subsection obviates the need for slice
selection, however the high complexity of the spectra shown in figure 6.4 makes it very
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difficult to simultaneously encode spatial and spectral information during signal read-
out. For the same spectral resolution shown in these in vivo spectra, traditional CSI
readouts of >200 ms duration are necessary, with repeated excitation to separately
encode spatial frequencies. EPSI can be used to accelerate the simultaneous encoding
of frequency and position, however this generally comes at the expense of degraded
spectral resolution.
Prior work imaging HP DHA metabolites has only demonstrated the feasibility
of doing so at 3 T, where the metabolic signals occur over a significantly narrower
frequency range. While the reduced spectral width makes broadband slice-selective
excitation and spectroscopic readout easier at 3 T, a drawback of conducting DHA ex-
periments at lower field strengths is the reduced separation of metabolites of interest
relative to one another. In particular, the GA3P signal often becomes indistinguish-
able in tissue from the larger and overlapping G3P signal at this field strength. Only
two HP DHA imaging experiments have been reported in the literature to date. In
one study, narrowband excitation and IDEAL encoding were used only for imaging of
the DHA hydrate singlet and G3P doublet in the rat liver, covering a spectral range of
roughly 20 ppm [174]. The other study utilized specialized multiband spectral-spatial
excitations designed primarily for selective excitation of PEP and G3P [90], with accel-
erated encoding of the high spectral bandwidth using compressed sensing EPSI [202].
These imaging methods would require significant revision for use on our 7 T MRI sys-
tem, and would still overlook the resonance we have identified as βHB that we were
particularly interested in imaging.
In Vivo HP DHA Imaging
In order to demonstrate the feasibility of imaging HP DHA metabolites at 7 T, we
chose to adapt the imaging sequence we developed in chapter 5 for single time point
imaging. The same hardware setup described above for in vivo DHA spectroscopy
was used, with narrowband chemically selective excitations and spatial encoding only
in the axial plane during signal readout. Without gradient localization during RF
excitation, the effective slice profile of these images in the rostral-caudal direction is
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equivalent to the spatial sensitivity profile of the 13C receive surface coil, shown in
figure 6.3. A 300 Hz (9.13 ms) Gaussian excitation pulse was used to minimize off-
resonance effects, and the center frequency of the scanner was iterated through the
resonant frequencies of DHA, DHA hydrate, G3P, PEP, βHB and an external urea
phantom. The scan was started approximately 10 seconds after injection in order to
acquire images at the moment of maximum HP signal, as determined from dynamic
13C pulse-acquire spectroscopy performed in the same animal approximately 24 hours
before the imaging experiment. For snapshot imaging of these fairly weak metabolic
signals, 90 degree excitation angles were applied to maximize image SNR and the
minimum possible time elapsing between excitations was used. The imaged chemical
shifts, and their corresponding spectral excitation frequencies, were determined based
on their observability in this prior spectroscopic measurement as depicted in figure
6.6. Using this method, selective excitation of individual chemical shifts is performed
for all imaging bands except for G3P and GA3P, which occur as overlapping doublets
in the same excitation band.
The animal preparation and injection protocol for this imaging experiment was
identical to that described above for dynamic DHA spectroscopy. A 6 x 6 cm2 flyback
EPI readout with a 24 x 24 imaging matrix was designed using the tools outlined in
chapter 5 and used for in-plane spatial encoding of each chemically selective excitation
band. This EPI trajectory sampled the center of k-space at a TE of 17.8 ms, and had a
total duration of 23.95 ms, a readout bandwidth of 31.25 kHz and an echo spacing of
0.992 ms. The raw k-space data were filtered with a 2D Hann window prior to iDFT.
For display and registration with 1H images, 13C images were bilinearly interpolated
to a 192 x 192 image matrix.
13C images for each of the six excitation bands illustrated in figure 6.6 are shown
in figure 6.7, overlaid on anatomical 1H FLASH images acquired during the same
HP imaging study. The DHA, DHA hydrate and βHB excitation frequency bands de-
pict imaging signals localized to the region of large hepatic blood vessels, illustrat-
ing the rapid uptake and metabolism of DHA in vivo. Imaging of the external 13C
urea phantom depicts the spatial fidelity of our encoding methods for singlet signals.
6.3. Hyperpolarized [2-13C]Dihydroxyacetone Imaging 158
Figure 6.6: Excitation bands used for imaging of HP DHA metabolites were deter-
mined from pulse-acquire spectroscopy acquired in the imaged rats approximately 24
hours prior to the imaging experiment. The use of a 300 Hz Gaussian pulse provides
excellent spectral isolation for selective imaging of all chemical shifts except for G3P
and GA3P, which occur as overlapping doublets within a single excitation band (right).
This excitation band frequency offset was centered on the larger G3P doublet (JCH ≈
144 Hz), and the multiple peaks in this excitation band appear in the EPI-encoded
images as signals shifted along the low-bandwidth (phase blipped) direction.
As demonstrated in dynamic DHA spectroscopy, PEP was consistently the weakest of
these metabolic signals in tissue. In this animal, the PEP signal did not have sufficient
SNR for reliable imaging. The multiple overlapping peaks of G3P and GA3P lead to
spatial shifts of these imaging signals relative to the center frequency of this excita-
tion band. For the G3P doublet (JCH ≈ 144 Hz) that was centered in this excitation
band, the low phase bandwidth of the flyback EPI readout results in two 13C signals
with a spatial shift of approximately ±7.4 mm in the anterior-posterior direction. As
shown in figure 6.6, one peak of the GA3P doublet occurs close to the center of this
Gaussian excitation band, which we believe corresponds to the third imaging signal
occurring nearer to the large hepatic blood vessels in this image. Future work will
address the misregistration of imaging signals in this excitation band, which could be
corrected with slight modification of our imaging sequence through IDEAL encoding.
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Figure 6.7: In vivo images of HP DHA metabolites in the rat liver are shown overlaid
on an anatomical 1H FLASH image. PEP signal in this animal was too weak to reliably
image, however the DHA, hydrate and putative βHB signals demonstrate localization
to regions of large hepatic blood vessels. Due to the multiple overlapping G3P and
GA3P signals, spatial misregistrations are apparent in this imaging band. Imaging
of the external urea phantom illustrates the spatial fidelity of our encoding method in
the absence of these peak splitting effects.
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6.4 Conclusion
In this chapter, we have demonstrated the feasibility of in vivo spectroscopy and imag-
ing of HP DHA at 7 T. In contrast to prior in vivo studies using this agent at 3 T,
our spectra depict more reliable measurement of GA3P, with quantifications of this
metabolite that are in agreement with ex vivo high-resolution NMR experiments. Ad-
ditionally, in the course of these experiments a previously unreported chemical signal
was preliminary identified as a product of ketogenic metabolism, which would be a
very significant result. Together with the non-invasive measurement of glycolytic,
gluconeogenic and glycerol metabolism HP DHA provides, our experiments illustrate
the tremendous potential of this agent to elucidate the mechanisms underlying the
development and progression of very common metabolic diseases with great personal
and societal impact.
The imaging results presented in this chapter constitute the first ever images of
HP DHA at 7T, and the first ever imaging of the signal we have identified as βHB.
The imaging method we have developed illustrates the adaptability of the HP imaging
pulse sequence described in chapter 5, and with appropriate excitation bandwidths can
easily encoding individual DHA metabolite chemical shift images at any field strength.
In future work, we will refine this imaging method by adding 1H decoupling and ex-
panded chemical shift encoding capabilities to better resolve G3P and GA3P imaging
signals. Further work will also be needed to determine the optimal methods for quan-
tification of HP DHA data. In these our results, simple ratiometric analyses are em-
ployed, however it may be necessary in some cases to account for vascular delivery and
variable rates of chemical exchange and T1 relaxation in more complex pharmacoki-
netic modeling methods [203]. Lastly, studies measuring the metabolism of HP DHA
in preclinical models of metabolic liver disease are needed to definitively demonstrate
the direct impact this agent can have on our understanding of these conditions. In the
context of these preclincal experiments, some independent verification of the isotopic
enrichment of the biochemical endpoints of interest — for example via ex vivo NMR or
mass spectrometry — may be necessary to validate these imaging measurements.
Chapter 7
Conclusion and Future Work
Hyperpolarized 13C spectroscopy and imaging permits measurements of metabolic and
physiological processes in living systems in ways not possible through conventional
imaging methods. This technology is poised to make a more direct impact on clinical
practice in coming years, with research trials assessing the value of this emerging
molecular imaging modality in human diseases currently underway [9, 10].
The work presented in this dissertation reflects an investigation of several issues
that are of profound importance in HP MRI. The development of specialized imaging
protocols, such as the methods created for our preclinical MRI system in chapter 5,
is a crucial step that must precede any successful HP MRI study. The acquisition
strategy realized by a given imaging protocol should be evaluated carefully to ensure
it utilizes the non-renewable HP magnetization efficiently and provides the greatest
possible opportunity of observing and quantifying the physiological processes of in-
terest. As demonstrated in the numerical simulations presented in chapter 4, this
evaluation should consider in a holistic way the effects of the acquisition strategy on
the anticipated physiological evolution of the HP signal in living systems. Lastly, we
have shown in chapter 6 that novel HP agents hold tremendous value, allowing direct




Several significant findings and advancements have been presented throughout this
dissertation.
We have demonstrated in section 3.3 that measurement of HP [1-13C]pyruvate
metabolism detects the effects of pharmacological treatment in a mouse model of glioma.
Notably, HP pyruvate spectroscopy resolves these metabolic effects within 30 minutes
of animals receiving an orally administered therapy. The observation of treatment ef-
fects in vivo on this short of a time frame has — to our knowledge — never before been
made with HP MRI. This study therefore evinces the tremendous value HP MRI can
provide in evaluating therapeutic efficacy, which is of profound consequence for the
individualized management of cancer and many other diseases.
Quantification of HP MRI data can be very challenging due to the transient nature
of the imaging signal. In the brief lifetime of HP signals in a typical imaging experi-
ment, a large but not directly quantifiable fraction of these signals arises from blood
vessels rather than the tissue spaces that are of primary interest. Optimal methods
for analyzing HP imaging data that account for these vascular delivery effects have
not yet been established. In chapter 4, we presented methods for quantifying these
signals that account for the effects of HP agent delivery in vivo. Through numerical
simulation, we demonstrated the benefits of innovative imaging strategies designed
to provide added insight into the compartmentalization of HP agents in tissue. One
such approach to dynamic HP imaging utilizes preparatory gradients to sensitize the
HP signal to motion in vivo, yielding measurements more specific to the extravascular
signals that are typically of primary interest. The feasibility of this imaging strategy
was illustrated through HP experiments in rodents.
Even without the utilization of new encoding strategies, imaging of HP agents is an
extraordinarily difficult task that requires very specialized pulse sequences. In chap-
ter 5, we presented the pulse sequence we have created for preclinical imaging of HP
agents, which provides a high degree of flexibility in the dynamic encoding of chem-
ical shift images. We have made this sequence available to the scientific community
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to help alleviate the challenges of utilizing HP MRI in preclinical experimentation.
Through phantom measurements and numerical simulations, we quantitatively com-
pared the SNR performance of two chemical shift encoding strategies enabled by our
sequence, spectral-spatial RF pulses and multi-excitation IDEAL imaging, in the con-
text of a typical HP [1-13C]pyruvate experiment at 7 T. This comparison, which had
to our knowledge never before been made, demonstrated the conditions under which
consistent SNR performance can be attained and highlighted the relative advantages
and drawbacks of each chemical shift encoding method.
The full potential of HP imaging and spectroscopy encompasses chemical agents
that have not yet been developed or are just starting to be investigated in living sys-
tems. In chapter 6, we investigated the activity of one such novel HP agent, [2-
13C]dihydroxyacetone, via in vivo spectroscopy and imaging of the rat liver. Through
our collaborative work on DHA, a previously unreported chemical signal was prelimi-
narily identified as a product of ketogenic metabolism. The application of HP DHA in
vivo presents considerable technical challenges, and imaging of the diverse metabolic
signals DHA produces has been shown only through proof of concept rodent studies at
3 T. By adapting the imaging sequence introduced in chapter 5, we have demonstrated
a new method for DHA imaging that can more easily encode individual images of the
many biochemical endpoints at any field strength. The direct measurement of dis-
parate metabolic fluxes HP DHA provides offers rare insight into hepatic metabolism
that can greatly improve our fundamental understanding of disorders with signifi-
cant societal and personal impact such as diabetes, non-alcoholic fatty liver disease
and cancer.
7.2 Future Work
The background discussions and new studies presented in this dissertation must nec-
essarily represent a limited picture of a rapidly evolving new imaging modality. Sig-
nificant advancements will continue to be made in the application of HP agents for
imaging and spectroscopy of living systems. Currently, HP MRI in the clinic is per-
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formed only in the context of clinical trials without direct impact on patient care. Im-
provements in accuracy and reproducibility of quantitative biomarkers derived from
HP imaging data will be vital in establishing the value of HP MRI for clinical use. For
this purpose, continued refinement of imaging hardware, pulse sequences and data
analysis methods will be necessary.
Quantitative evaluation of HP imaging performance must account for signal varia-
tions due to agent delivery, relaxation and utilization by the imaging method itself to
derive values that are meaningful in a specific biological context. Further evaluation of
methods for quantifying HP MRI data that account for the specific biological and tech-
nical factors in preclinical and clinical imaging studies is needed to define the value
of this emerging molecular imaging technology. The new method for sensitizing HP
imaging signals to diffusive motion that we have shown to be feasible in rodent imag-
ing will need further evaluation to confirm the benefit of this imaging strategy in other
situations. Additionally, the quantitative measures of vascular delivery provided by
this HP imaging strategy should be compared more directly to other more established
techniques for measuring these effects, such as 1H DCE and IVIM imaging. All HP
imaging in this work was modeled and acquired with spoiled gradient-echo imaging,
for which the effects of RF excitation on finite HP magnetization is relatively simple to
model. For use on clinical MRI hardware, many of the imaging techniques developed
here will need to be adapted to use more complex spin-echo imaging methods which
will require both significant revision of the pulse sequence and of the methods for data
analysis.
The development and application of new HP agents brings both novel biological
insights and additional technical challenges for HP MRI. Through adaptation of our
preclinical imaging method, we have demonstrated that imaging of HP DHA can pro-
vide broad insight into hepatic metabolism non-invasively. Further application of our
spectroscopic and imaging methods for this agent in preclinical studies assessing nor-
mal and abnormal metabolism will be needed to demonstrate the capacity of HP DHA
to provide the direct measurements of biochemical processes underlying the develop-
ment and progression of specific metabolic diseases.
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In the foreseeable future, we plan to build upon the many compelling results out-
lined in this document. Through refinement of the pharmacokinetic modeling and
data acquisition infrastructure we have developed, optimal methods of HP data ac-
quisition and analysis will be identified. This process must be done in a holistic and
synergistic fashion, with full consideration of the specific biology of interest and the
imaging methods available for a given study. By expanding the capabilities of HP MRI
sequences, new analysis methods are made possible that can fulfill the tremendous po-
tential of HP MRI for clinical and research applications.
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